PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
18176318-12	2008	Tenofovir DF-containing regimens should be considered for PEP to enhance adherence and regimen completion.	Tenofovir	0-12	progestagen associated endometrial protein	Homo sapiens	58-61
18215977-9	2008	Subjects who received stavudine (median 6.6 years) and switched to tenofovir demonstrated significant improvements in total cholesterol (p = .009), triglycerides (p = .023), apolipoprotein C-III (p < .001 ), adiponectin (p = .008), fasting insulin (p = .04), and leptin (p = .03).	Tenofovir	67-76	apolipoprotein C3	Homo sapiens	174-194
18572746-1	2008	BACKGROUND: The efficacy of long-term hepatitis B virus (HBV) treatment with tenofovir (TDF) in relation to lamivudine (LMV) resistance in HIV patients failing on LMV deserves further investigations.	Tenofovir	77-86	sex determining region Y	Homo sapiens	88-91
18215977-9	2008	Subjects who received stavudine (median 6.6 years) and switched to tenofovir demonstrated significant improvements in total cholesterol (p = .009), triglycerides (p = .023), apolipoprotein C-III (p < .001 ), adiponectin (p = .008), fasting insulin (p = .04), and leptin (p = .03).	Tenofovir	67-76	adiponectin, C1Q and collagen domain containing	Homo sapiens	211-222
18215977-9	2008	Subjects who received stavudine (median 6.6 years) and switched to tenofovir demonstrated significant improvements in total cholesterol (p = .009), triglycerides (p = .023), apolipoprotein C-III (p < .001 ), adiponectin (p = .008), fasting insulin (p = .04), and leptin (p = .03).	Tenofovir	67-76	insulin	Homo sapiens	243-250
17949244-9	2008	In conclusion, repeated administration of tenofovir in higher doses led to significant decrease of the relative proportion of active liver microsomal CYPs accompanied by a conversion of these enzymes to the inactive form (CYP420) maintaining the sum of CYP proteins unchanged.	Tenofovir	42-51	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	150-153
18924648-1	2008	OBJECTIVE: To assess effectiveness and safety of a generic fixed-dose combination of tenofovir (TDF)/emtricitabine (FTC)/efavirenz (EFV) among HIV-1-infected patients in Western India.	Tenofovir	85-94	sex determining region Y	Homo sapiens	96-99
17434879-1	2007	BACKGROUND: Tenofovir with full-dose didanosine has been associated with paradoxical CD4 + T cell decrease despite virological suppression.	Tenofovir	12-21	CD4 molecule	Homo sapiens	85-88
17664327-9	2007	Analogous to hepatic cytochrome P450-mediated drug interactions, we propose that the relative differences in perturbations in TFV plasma levels when TDF is coadministered with PIs are based in part on the net effect of inhibition and induction of intestinal Pgp by PIs.	Tenofovir	149-152	PGP	Canis lupus familiaris	258-261
17667331-1	2007	OBJECTIVE: Efavirenz (EFV; 600 mg), emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg) are preferred agents for treatment of HIV-1 infection in adults.	Tenofovir	68-97	sex determining region Y	Homo sapiens	99-102
18771054-1	2008	BACKGROUND: Characteristics and factors influencing viral decay under tenofovir (TDF) and adefovir (ADV) need to be determined in HIV-HBV-coinfected patients.	Tenofovir	70-79	sex determining region Y	Homo sapiens	81-84
17901802-0	2007	Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir.	Tenofovir	116-125	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	10-16
17901802-1	2007	A single-center cross sectional evaluation of beta-2 micro-globinuria as a marker of proximal renal tubule damage in 92 HIV-infected children showed that tenofovir treatment was significantly associated with very high abnormal values.	Tenofovir	154-163	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	46-52
17503669-1	2007	BACKGROUND: Active renal secretion of tenofovir (TFV) across proximal tubules occurs via uptake by human organic anion transporters 1 and 3 (hOAT1 and hOAT3) coupled with efflux by multidrug resistance protein 4 (MRP4).	Tenofovir	38-47	solute carrier family 22 member 6	Homo sapiens	105-139
17502723-16	2007	Short-term data indicate that replacing stavudine and PI with tenofovir and efavirenz restores the RANKL/osteoprotegerin equilibrium, and may thus lead to a reduction in the bone resorption rate.	Tenofovir	62-71	TNF superfamily member 11	Homo sapiens	99-104
17502723-16	2007	Short-term data indicate that replacing stavudine and PI with tenofovir and efavirenz restores the RANKL/osteoprotegerin equilibrium, and may thus lead to a reduction in the bone resorption rate.	Tenofovir	62-71	TNF receptor superfamily member 11b	Homo sapiens	105-120
17328866-7	2007	In the calcein assay, all PIs, all NNRTIs, abacavir, and tenofovir disoproxil fumarate acted as P-gp inhibitors with largely differing potencies between compounds.	Tenofovir	57-86	phosphoglycolate phosphatase	Mus musculus	96-100
17461718-1	2007	Regimens containing abacavir (ABC), tenofovir (TDF), and lamivudine (3TC) have recently been demonstrated to have high failure rates.	Tenofovir	36-45	sex determining region Y	Homo sapiens	47-50
17372702-9	2007	CONCLUSION: These results indicate that adefovir, cidofovir and tenofovir are substrates of hOAT3 as well as hOAT1, but that quantitatively hOAT1 is the major renal transporter for these drugs.	Tenofovir	64-73	solute carrier family 22 member 8	Homo sapiens	92-97
17372702-9	2007	CONCLUSION: These results indicate that adefovir, cidofovir and tenofovir are substrates of hOAT3 as well as hOAT1, but that quantitatively hOAT1 is the major renal transporter for these drugs.	Tenofovir	64-73	solute carrier family 22 member 6	Homo sapiens	109-114
17341536-6	2007	DISCUSSION: Paradoxical declines in CD4+ cell counts have been reported in HIV-infected patients virally suppressed on tenofovir/didanosine regimens, presumably via inhibition of purine nucleoside phosphorylase (PNP) by tenofovir and enhancement of didanosine toxicity.	Tenofovir	119-128	CD4 molecule	Homo sapiens	36-39
17341536-6	2007	DISCUSSION: Paradoxical declines in CD4+ cell counts have been reported in HIV-infected patients virally suppressed on tenofovir/didanosine regimens, presumably via inhibition of purine nucleoside phosphorylase (PNP) by tenofovir and enhancement of didanosine toxicity.	Tenofovir	220-229	CD4 molecule	Homo sapiens	36-39
17372702-0	2007	Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).	Tenofovir	44-53	solute carrier family 22 member 6	Homo sapiens	80-85
17372702-0	2007	Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).	Tenofovir	44-53	solute carrier family 22 member 2	Homo sapiens	98-103
17372702-5	2007	RESULTS: The uptake of adefovir, cidofovir and tenofovir in monolayers stably expressing hOAT3 increased time-dependently, compared with control.	Tenofovir	47-56	solute carrier family 22 member 8	Homo sapiens	89-94
17177308-9	2007	After 4 weeks of treatment with tenofovir 600 mg, the median decrease in the viral load was -0.61 log(10) (range -0.05; -0.88) and the median gain of CD4 was +109/mm(3).	Tenofovir	32-41	CD4 molecule	Homo sapiens	150-153
17110501-0	2007	Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.	Tenofovir	142-151	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	69-73
17110501-0	2007	Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.	Tenofovir	142-151	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	74-79
17110501-3	2007	ATP-dependent uptake of adefovir and tenofovir but not cidofovir was observed only in the membrane vesicles expressing MRP4.	Tenofovir	37-46	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	119-123
17110501-4	2007	The ATP-dependent uptake of adefovir and tenofovir by MRP4 was not saturated at 1 mM.	Tenofovir	41-50	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	54-58
17110501-8	2007	The kidney accumulation of adefovir and tenofovir was significantly greater in Mrp4 knockout mice (130 versus 66 and 191 versus 87 pmol/g tissue, respectively); thus, the renal luminal efflux clearance was estimated to be 37 and 46%, respectively, of the control.	Tenofovir	40-49	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	79-83
17110501-12	2007	Our results suggest that MRP4 is involved in the luminal efflux of both adefovir and tenofovir, but it makes only a limited contribution to the urinary excretion of cidofovir.	Tenofovir	85-94	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	25-29
17713153-5	2007	More promising data were obtained when AZT, 3TC and ABC were intensified with tenofovir (TDF), resulting in a quadruple nucleoside therapy.	Tenofovir	78-87	sex determining region Y	Homo sapiens	89-92
17926643-8	2007	Patients on tenofovir showed significantly lower CD4+ T-cell increases compared with stavudine.	Tenofovir	12-21	CD4 molecule	Homo sapiens	49-52
17926643-9	2007	CONCLUSIONS: In our observational study, long-term CD4+ T-cell increase in drug-naive patients with suppressed VL was higher in regimens without tenofovir.	Tenofovir	145-154	CD4 molecule	Homo sapiens	51-54
17503669-1	2007	BACKGROUND: Active renal secretion of tenofovir (TFV) across proximal tubules occurs via uptake by human organic anion transporters 1 and 3 (hOAT1 and hOAT3) coupled with efflux by multidrug resistance protein 4 (MRP4).	Tenofovir	38-47	solute carrier family 22 member 6	Homo sapiens	141-146
17503669-1	2007	BACKGROUND: Active renal secretion of tenofovir (TFV) across proximal tubules occurs via uptake by human organic anion transporters 1 and 3 (hOAT1 and hOAT3) coupled with efflux by multidrug resistance protein 4 (MRP4).	Tenofovir	38-47	solute carrier family 22 member 8	Homo sapiens	151-156
17503669-1	2007	BACKGROUND: Active renal secretion of tenofovir (TFV) across proximal tubules occurs via uptake by human organic anion transporters 1 and 3 (hOAT1 and hOAT3) coupled with efflux by multidrug resistance protein 4 (MRP4).	Tenofovir	38-47	ATP binding cassette subfamily C member 4	Homo sapiens	181-211
17503669-1	2007	BACKGROUND: Active renal secretion of tenofovir (TFV) across proximal tubules occurs via uptake by human organic anion transporters 1 and 3 (hOAT1 and hOAT3) coupled with efflux by multidrug resistance protein 4 (MRP4).	Tenofovir	38-47	ATP binding cassette subfamily C member 4	Homo sapiens	213-217
17503669-1	2007	BACKGROUND: Active renal secretion of tenofovir (TFV) across proximal tubules occurs via uptake by human organic anion transporters 1 and 3 (hOAT1 and hOAT3) coupled with efflux by multidrug resistance protein 4 (MRP4).	Tenofovir	49-52	solute carrier family 22 member 6	Homo sapiens	105-139
17503669-1	2007	BACKGROUND: Active renal secretion of tenofovir (TFV) across proximal tubules occurs via uptake by human organic anion transporters 1 and 3 (hOAT1 and hOAT3) coupled with efflux by multidrug resistance protein 4 (MRP4).	Tenofovir	49-52	solute carrier family 22 member 6	Homo sapiens	141-146
17503669-1	2007	BACKGROUND: Active renal secretion of tenofovir (TFV) across proximal tubules occurs via uptake by human organic anion transporters 1 and 3 (hOAT1 and hOAT3) coupled with efflux by multidrug resistance protein 4 (MRP4).	Tenofovir	49-52	solute carrier family 22 member 8	Homo sapiens	151-156
17503669-1	2007	BACKGROUND: Active renal secretion of tenofovir (TFV) across proximal tubules occurs via uptake by human organic anion transporters 1 and 3 (hOAT1 and hOAT3) coupled with efflux by multidrug resistance protein 4 (MRP4).	Tenofovir	49-52	ATP binding cassette subfamily C member 4	Homo sapiens	181-211
17503669-1	2007	BACKGROUND: Active renal secretion of tenofovir (TFV) across proximal tubules occurs via uptake by human organic anion transporters 1 and 3 (hOAT1 and hOAT3) coupled with efflux by multidrug resistance protein 4 (MRP4).	Tenofovir	49-52	ATP binding cassette subfamily C member 4	Homo sapiens	213-217
17503755-5	2007	However, under conditions of limited EFV metabolism, that is, the group of 23 individuals carrying two copies of CYP2B6 loss/diminished-function alleles, plasma AUC values were highest among individuals receiving TFV (n=5, 353,031 ng*h/ml), compared with those not receiving TFV (n=18, 180,689 ng*h/ml).	Tenofovir	213-216	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	113-119
17503755-5	2007	However, under conditions of limited EFV metabolism, that is, the group of 23 individuals carrying two copies of CYP2B6 loss/diminished-function alleles, plasma AUC values were highest among individuals receiving TFV (n=5, 353,031 ng*h/ml), compared with those not receiving TFV (n=18, 180,689 ng*h/ml).	Tenofovir	275-278	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	113-119
16940060-8	2006	The effects of ddI, but not those of AZT, on mtDNA and COII mRNA were further enhanced in the presence of TFV, a finding consistent with the inhibition of ddI clearance by TFV.	Tenofovir	106-109	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	55-59
17083032-0	2006	Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.	Tenofovir	46-55	ATP binding cassette subfamily C member 2	Homo sapiens	20-25
17083032-1	2006	BACKGROUND: Tenofovir disoproxil fumarate (TDF) may induce renal proximal tubulopathy (rPT).	Tenofovir	12-41	magnesium transporter MRS2	Rattus norvegicus	87-90
17083032-1	2006	BACKGROUND: Tenofovir disoproxil fumarate (TDF) may induce renal proximal tubulopathy (rPT).	Tenofovir	43-46	magnesium transporter MRS2	Rattus norvegicus	87-90
17083032-3	2006	METHODS: Mutational screening of the genes for MRP2 (ABCC2) and MRP4 (ABCC4) was performed using genomic DNA from 13 human immunodeficiency virus type 1 (HIV-1)-infected patients (group 1) presenting with TDF-induced rPT.	Tenofovir	205-208	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
17159773-3	2006	RESULTS: Activity of FMO3 was inhibited by PMPA and bisPOC-PMPA even at low levels of these drugs (below 100 microM).	Tenofovir	43-47	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	21-25
17159773-6	2006	CONCLUSIONS: PMPA and bisPOC-PMPA are able to inhibit FMO3 activity at relatively low levels (10-100 microM) indicating a relatively specific interaction.	Tenofovir	13-17	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	54-58
17159773-9	2006	As the inhibitor concentration in the systemic circulation does not exceed 2 microM, the probability of a significant in vivo effect of adefovir, tenofovir and the respective prodrugs on the microsomal system of cytochromes P450 and FMO3 is relatively low.	Tenofovir	146-155	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	233-237
17162464-6	2006	Tenofovir and tenofovir disoproxil influenced the activity of CYP2C9, and competitive inhibition was found with Ki = 580 and 395 microM, respectively.	Tenofovir	0-9	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	62-68
17162464-6	2006	Tenofovir and tenofovir disoproxil influenced the activity of CYP2C9, and competitive inhibition was found with Ki = 580 and 395 microM, respectively.	Tenofovir	14-34	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	62-68
17162464-7	2006	Tenofovir disoproxil was shown to inhibit microsomal CYP2E1 activities by a mixed-type inhibition with Ki values at about 140 microM.	Tenofovir	0-20	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	53-59
16940060-9	2006	The addition of TFV to ddI or AZT appeared to slightly increase the COII mRNA/mtDNA ratio relative to that in cells treated with ddI or AZT alone.	Tenofovir	16-19	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	68-72
17005808-5	2006	In contrast to Pgp and MRP2, TFV was observed to be a substrate for MRP4.	Tenofovir	29-32	ATP binding cassette subfamily C member 4	Homo sapiens	68-72
17005808-6	2006	TFV accumulated to fivefold lower levels in MRP4-overexpressing cells, and its accumulation could be increased by an MRP inhibitor.	Tenofovir	0-3	ATP binding cassette subfamily C member 4	Homo sapiens	44-48
17005808-6	2006	TFV accumulated to fivefold lower levels in MRP4-overexpressing cells, and its accumulation could be increased by an MRP inhibitor.	Tenofovir	0-3	ATP binding cassette subfamily C member 1	Homo sapiens	44-47
17005808-7	2006	Furthermore, MRP4-overexpressing cells were found to be 2.0- to 2.5-fold less susceptible to cytotoxicity caused by TFV.	Tenofovir	116-119	ATP binding cassette subfamily C member 4	Homo sapiens	13-17
17005808-8	2006	ATP-dependent uptake of TFV was observed in membrane vesicles containing MRP4 but not in vesicles lacking the transporter.	Tenofovir	24-27	ATP binding cassette subfamily C member 4	Homo sapiens	73-77
17005808-9	2006	On the basis of these and previous results, the molecular transport pathway for the active tubular secretion of TFV through renal proximal-tubule cells involves uptake from the blood mediated by human organic anion transporters 1 and 3 and efflux into urine by MRP4.	Tenofovir	112-115	solute carrier family 22 member 6	Homo sapiens	201-235
17005808-9	2006	On the basis of these and previous results, the molecular transport pathway for the active tubular secretion of TFV through renal proximal-tubule cells involves uptake from the blood mediated by human organic anion transporters 1 and 3 and efflux into urine by MRP4.	Tenofovir	112-115	ATP binding cassette subfamily C member 4	Homo sapiens	261-265
16691065-6	2006	Comparing two drug nucleoside backbones, there was a lower annual change in CD4 cell count for zidovudine/lamivudine (n = 13038; -15.4/microl; P = 0.012) and for those on tenofovir (n = 1809; -27.3/microl; P = 0.029) compared to lamivudine/stavudine (n = 7339).	Tenofovir	171-180	CD4 molecule	Homo sapiens	76-79
17127826-3	2006	Patients with low CD4 cell count, low body weight and with concomitant diseases such as arterial hypertension and diabetes or co-infections with HCV, HBV or Treponema pallidum seem at higher risk of tenofovir-related nephrotoxicity.	Tenofovir	199-208	CD4 molecule	Homo sapiens	18-21
16910829-0	2006	Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate.	Tenofovir	86-115	beta-2-microglobulin	Homo sapiens	8-27
16910829-1	2006	Tenofovir disoproxil fumarate (TDF) is renally excreted by a combination of glomerular filtration and active tubular secretion, and its renal safety profiles have been reported based on a limited increase of serum creatinine (sCr) levels.	Tenofovir	0-29	sex determining region Y	Homo sapiens	31-34
16956530-9	2006	In patients treated with TDF + 3TC, CD4 count increased by 160 cel/microl (95% CI, 53-266) more than in patients treated with TDF + ddI; and in patients receiving ddI + 3TC, CD4+ count increased by 138 cel/microl (95% CI, 25-266) more than in patients receiving TDF + ddI.	Tenofovir	25-28	CD4 molecule	Homo sapiens	36-39
16956530-9	2006	In patients treated with TDF + 3TC, CD4 count increased by 160 cel/microl (95% CI, 53-266) more than in patients treated with TDF + ddI; and in patients receiving ddI + 3TC, CD4+ count increased by 138 cel/microl (95% CI, 25-266) more than in patients receiving TDF + ddI.	Tenofovir	25-28	CD4 molecule	Homo sapiens	174-177
17009933-2	2006	TDF (the bioavailable prodrug of tenofovir) is hydrolyzed to tenofovir intracellularly and phosphorylated to the active metabolite, tenofovir diphosphate.	Tenofovir	33-42	sex determining region Y	Homo sapiens	0-3
17009933-2	2006	TDF (the bioavailable prodrug of tenofovir) is hydrolyzed to tenofovir intracellularly and phosphorylated to the active metabolite, tenofovir diphosphate.	Tenofovir	61-70	sex determining region Y	Homo sapiens	0-3
16717052-0	2006	Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.	Tenofovir	84-93	CD4 molecule	Homo sapiens	23-26
16531427-0	2006	Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.	Tenofovir	72-81	CD4 molecule	Homo sapiens	11-14
16531427-4	2006	As an example, the combination of didanosine and tenofovir has recently been associated with a paradoxical depletion of CD4+ T cells in the face of complete viral suppression.	Tenofovir	49-58	CD4 molecule	Homo sapiens	120-123
16691065-8	2006	CONCLUSIONS: A nucleoside backbone of zidovudine/lamivudine or any tenofovir-based backbone was associated with significantly poorer increases in CD4 cell count compared to a nucleoside backbone of stavudine/lamivudine, as was an abacavir-based triple nucleoside regimen compared to a boosted protease inhibitor regimen.	Tenofovir	67-76	CD4 molecule	Homo sapiens	146-149
16184059-0	2005	Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens.	Tenofovir	139-148	CD4 molecule	Homo sapiens	104-107
16623622-1	2006	Coadministration of didanosine (ddI) and tenofovir (TDF) results in increased ddI serum concentrations, which may lead to increased risk of ddI-associated toxicities.	Tenofovir	41-50	sex determining region Y	Homo sapiens	52-55
16390539-2	2006	This study was undertaken to understand PMPA distribution to the virus sanctuary sites located in the brain, CSF and choroid plexuses and to clarify its possible role in reducing the neurological problems associated with HIV infection.	Tenofovir	40-44	colony stimulating factor 2	Homo sapiens	109-112
16390539-7	2006	However, [3H]PMPA accumulation was significantly higher than that of D-[14C]mannitol in the choroid plexus and CSF.	Tenofovir	13-17	colony stimulating factor 2	Homo sapiens	111-114
16640107-1	2006	The combination of tenofovir (TDF) and efavirenz (EFV) has not been associated with any pharmakokinetic interaction or with enhancement of neuropsychiatric disturbances.	Tenofovir	19-28	sex determining region Y	Homo sapiens	30-33
16260911-2	2005	Twelve weeks after initiating a tenofovir-containing HAART regimen, a high urine-beta 2 microglobulin level was observed in 12 out of 17 patients, the percentage of tubular reabsorption of phosphate decreased from 96.0 to 91.1% and alkaline phosphatase increased from 294 to 365 U/l, whereas serum creatinine and phosphorus remained largely unchanged.	Tenofovir	32-41	beta-2-microglobulin	Homo sapiens	81-101
16393861-1	2005	The role of multidrug resistance-associated protein 2 (MRP2) on the intestinal disposition and hepatobiliary elimination of tenofovir disoproxil fumarate (DF) and its metabolites [tenofovir (mono)ester and tenofovir] was studied in the Caco-2 system, Ussing chambers and rat in-situ efflux experiments.	Tenofovir	124-153	ATP binding cassette subfamily C member 2	Rattus norvegicus	12-53
16393861-1	2005	The role of multidrug resistance-associated protein 2 (MRP2) on the intestinal disposition and hepatobiliary elimination of tenofovir disoproxil fumarate (DF) and its metabolites [tenofovir (mono)ester and tenofovir] was studied in the Caco-2 system, Ussing chambers and rat in-situ efflux experiments.	Tenofovir	124-153	ATP binding cassette subfamily C member 2	Rattus norvegicus	55-59
16393861-4	2005	After intravenous administration of tenofovir DF, the excretion of tenofovir [(mono)ester] in bile was significantly decreased in MRP2-deficient rats and in rats treated with probenecid.	Tenofovir	36-48	ATP binding cassette subfamily C member 2	Rattus norvegicus	130-134
16393861-4	2005	After intravenous administration of tenofovir DF, the excretion of tenofovir [(mono)ester] in bile was significantly decreased in MRP2-deficient rats and in rats treated with probenecid.	Tenofovir	36-45	ATP binding cassette subfamily C member 2	Rattus norvegicus	130-134
16107993-1	2005	The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials).	Tenofovir	44-53	CD4 molecule	Homo sapiens	95-98
16306034-1	2005	The liver safety of tenofovir (TDF) was investigated in 142 HIV+ patients exposed to the drug for longer than 12 months.	Tenofovir	20-29	sex determining region Y	Homo sapiens	31-34
15622326-0	2004	CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.	Tenofovir	37-46	CD4 molecule	Homo sapiens	0-3
15802975-0	2005	Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.	Tenofovir	96-105	CD4 molecule	Homo sapiens	12-15
15627039-2	2005	Patients on tenofovir showed a lower mean glomerular filtration rate estimated by creatinine clearance or cystatin C clearance compared with control patients.	Tenofovir	12-21	cystatin C	Homo sapiens	106-116
16218172-1	2005	BACKGROUND: Tenofovir (TDF) is an adenosine nucleotide analogue that has been approved for the treatment of HIV-1 infection.	Tenofovir	12-21	sex determining region Y	Homo sapiens	23-26
15914676-8	2005	Interestingly, the K(m) for the nucleoside phosphonate analogs adefovir, cidofovir, and tenofovir seemed to be decreased in the R50H-hOAT1 variant compared with the wild type, whereas the kinetics of K525I-hOAT1 remained unchanged.	Tenofovir	88-97	solute carrier family 22 member 6	Homo sapiens	133-138
15914676-8	2005	Interestingly, the K(m) for the nucleoside phosphonate analogs adefovir, cidofovir, and tenofovir seemed to be decreased in the R50H-hOAT1 variant compared with the wild type, whereas the kinetics of K525I-hOAT1 remained unchanged.	Tenofovir	88-97	solute carrier family 22 member 6	Homo sapiens	206-211
15958845-0	2005	Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen.	Tenofovir	60-69	CD4 molecule	Homo sapiens	17-20
15958845-1	2005	In this study, the dynamics of CD4 cell depletion during tenofovir/didanosine co-administration were analysed.	Tenofovir	57-66	CD4 molecule	Homo sapiens	31-34
15918336-1	2005	OBJECTIVE: An anti-HIV regimen composed of the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) tenofovir (TFV) disoproxil fumarate (TDF), abacavir (ABC) and lamivudine (3TC) has performed poorly in patients.	Tenofovir	110-119	sex determining region Y	Homo sapiens	147-150
15259896-13	2004	Combination of standard doses of didanosine and tenofovir may have contributed to the CD4 cell decline observed with this QD regimen.	Tenofovir	48-57	CD4 molecule	Homo sapiens	86-89
15113912-0	2004	CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.	Tenofovir	80-89	CD8a molecule	Homo sapiens	0-3
15047506-0	2004	Role of purine nucleoside phosphorylase in interactions between 2",3"-dideoxyinosine and allopurinol, ganciclovir, or tenofovir.	Tenofovir	118-127	purine nucleoside phosphorylase	Homo sapiens	8-39
15047506-5	2004	It was further established that the mono- and diphosphate forms of tenofovir were inhibitors of PNP-dependent degradation of ddI (K(i)s, 38 nM and 1.3 microM, respectively).	Tenofovir	67-76	purine nucleoside phosphorylase	Homo sapiens	96-99
15047506-8	2004	While inhibition of the physiological function of PNP is unlikely due to the ubiquitous presence of high levels of enzymatic activity, phosphorylated metabolites of GCV and tenofovir may cause the increased level of exposure to ddI by direct inhibition of its phosphorolysis by PNP.	Tenofovir	173-182	purine nucleoside phosphorylase	Homo sapiens	50-53
15047506-8	2004	While inhibition of the physiological function of PNP is unlikely due to the ubiquitous presence of high levels of enzymatic activity, phosphorylated metabolites of GCV and tenofovir may cause the increased level of exposure to ddI by direct inhibition of its phosphorolysis by PNP.	Tenofovir	173-182	purine nucleoside phosphorylase	Homo sapiens	278-281
15090798-0	2004	Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.	Tenofovir	71-80	CD4 molecule	Homo sapiens	11-14
15090798-1	2004	BACKGROUND: We recently observed a significant CD4 cell count decline in patients receiving didanosine (ddI) 400 mg, tenofovir (TDF) and nevirapine (NVP), despite virological suppression.	Tenofovir	117-126	CD4 molecule	Homo sapiens	47-50
14588080-4	2003	Tenofovir (TDF), a recently approved drug for the treatment of HIV, is also active against hepatitis B.	Tenofovir	0-9	sex determining region Y	Homo sapiens	11-14
12943802-0	2003	Tenofovir, COX inhibitors and zileuton during cancer immunotherapies: up-regulated TNF-alpha increases antigen driven lymphocyte proliferation.	Tenofovir	0-9	tumor necrosis factor	Homo sapiens	83-92
12943802-14	2003	This paper reviews the data on TNF up-regulation by tenofovir and COX inhibitors and the consequent augmented antigen driven lymphocyte proliferation secondary to increased TNF and suggests exploration of tenofovir and COX inhibitors like indomethacin, diclofenac or ketorolac in augmentation of current cancer immunotherapy attempts.	Tenofovir	52-61	tumor necrosis factor	Homo sapiens	31-34
12943802-14	2003	This paper reviews the data on TNF up-regulation by tenofovir and COX inhibitors and the consequent augmented antigen driven lymphocyte proliferation secondary to increased TNF and suggests exploration of tenofovir and COX inhibitors like indomethacin, diclofenac or ketorolac in augmentation of current cancer immunotherapy attempts.	Tenofovir	205-214	tumor necrosis factor	Homo sapiens	31-34
10480261-7	1999	The compounds PCV, GCV, H2G and PMPA showed some activity in CD4+ T lymphocytes, but not in SupT1 cells.	Tenofovir	32-36	CD4 molecule	Homo sapiens	61-64
14498980-8	2003	In contrast to untreated infected control animals that showed substantial depletion of CD4+ T cells from gut-associated lymphoid tissues (GALT), tenofovir-treated animals showed sparing of GALT CD4+ T cells both during the treatment period and in the off treatment follow-up period.	Tenofovir	145-154	CD4 molecule	Homo sapiens	194-197
12396448-8	2002	The dideoxynucleoside RTI abacavir as well as the phosphonates (R)-PMPA and PMEA were more active in infected MO-DCs as compared with either CEM T cells or PHA/IL-2 activated CD4(+) T cells.	Tenofovir	63-71	CD4 molecule	Homo sapiens	175-178
11401985-5	2001	The major pilin, SfpA, despite its similarity to PapA, does not cluster together with known PapA alleles in a phylogenetic tree but is structurally related to the PmpA pilin of Proteus mirabilis.	Tenofovir	163-167	w0006	Escherichia coli	17-21
11137619-4	2000	Some of them, i.e. (R)-PMPA, (S)-PMPA, and PMEG, stimulate secretion of TNF-alpha and IL-10 in a concentration-dependent manner, and enhance the IFN-gamma-induced secretion of TNF-alpha.	Tenofovir	19-27	tumor necrosis factor	Mus musculus	72-81
11137619-4	2000	Some of them, i.e. (R)-PMPA, (S)-PMPA, and PMEG, stimulate secretion of TNF-alpha and IL-10 in a concentration-dependent manner, and enhance the IFN-gamma-induced secretion of TNF-alpha.	Tenofovir	19-27	interleukin 10	Mus musculus	86-91
11137619-4	2000	Some of them, i.e. (R)-PMPA, (S)-PMPA, and PMEG, stimulate secretion of TNF-alpha and IL-10 in a concentration-dependent manner, and enhance the IFN-gamma-induced secretion of TNF-alpha.	Tenofovir	19-27	interferon gamma	Mus musculus	145-154
11137619-4	2000	Some of them, i.e. (R)-PMPA, (S)-PMPA, and PMEG, stimulate secretion of TNF-alpha and IL-10 in a concentration-dependent manner, and enhance the IFN-gamma-induced secretion of TNF-alpha.	Tenofovir	19-27	tumor necrosis factor	Mus musculus	176-185
11137619-4	2000	Some of them, i.e. (R)-PMPA, (S)-PMPA, and PMEG, stimulate secretion of TNF-alpha and IL-10 in a concentration-dependent manner, and enhance the IFN-gamma-induced secretion of TNF-alpha.	Tenofovir	29-37	tumor necrosis factor	Mus musculus	72-81
11137619-4	2000	Some of them, i.e. (R)-PMPA, (S)-PMPA, and PMEG, stimulate secretion of TNF-alpha and IL-10 in a concentration-dependent manner, and enhance the IFN-gamma-induced secretion of TNF-alpha.	Tenofovir	29-37	interleukin 10	Mus musculus	86-91
11137619-4	2000	Some of them, i.e. (R)-PMPA, (S)-PMPA, and PMEG, stimulate secretion of TNF-alpha and IL-10 in a concentration-dependent manner, and enhance the IFN-gamma-induced secretion of TNF-alpha.	Tenofovir	29-37	interferon gamma	Mus musculus	145-154
11137619-4	2000	Some of them, i.e. (R)-PMPA, (S)-PMPA, and PMEG, stimulate secretion of TNF-alpha and IL-10 in a concentration-dependent manner, and enhance the IFN-gamma-induced secretion of TNF-alpha.	Tenofovir	29-37	tumor necrosis factor	Mus musculus	176-185
11137619-9	2000	Although less effectively, PMEG and (R)-PMPA also increase production of TNF-alpha and NO by the IFN-gamma- but not LPS-co-stimulated macrophages from C3H/HeJ mice, which are otherwise hypo-responsive to major immune stimuli provided by IFN-gamma and LPS.	Tenofovir	36-44	tumor necrosis factor	Mus musculus	73-82
11137619-9	2000	Although less effectively, PMEG and (R)-PMPA also increase production of TNF-alpha and NO by the IFN-gamma- but not LPS-co-stimulated macrophages from C3H/HeJ mice, which are otherwise hypo-responsive to major immune stimuli provided by IFN-gamma and LPS.	Tenofovir	36-44	interferon gamma	Mus musculus	97-106
11137619-9	2000	Although less effectively, PMEG and (R)-PMPA also increase production of TNF-alpha and NO by the IFN-gamma- but not LPS-co-stimulated macrophages from C3H/HeJ mice, which are otherwise hypo-responsive to major immune stimuli provided by IFN-gamma and LPS.	Tenofovir	36-44	interferon gamma	Mus musculus	237-246
11137619-9	2000	Although less effectively, PMEG and (R)-PMPA also increase production of TNF-alpha and NO by the IFN-gamma- but not LPS-co-stimulated macrophages from C3H/HeJ mice, which are otherwise hypo-responsive to major immune stimuli provided by IFN-gamma and LPS.	Tenofovir	36-44	toll-like receptor 4	Mus musculus	251-254
12124311-5	2002	As tenofovir DF is a substrate for P-glycoprotein (P-gp)-related efflux carriers in the Caco-2 model, the modulatory effect of the ester mixtures was studied on the functionality of P-gp using cyclosporin A (CsA) as a model substrate.	Tenofovir	3-15	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	35-49
12124311-5	2002	As tenofovir DF is a substrate for P-glycoprotein (P-gp)-related efflux carriers in the Caco-2 model, the modulatory effect of the ester mixtures was studied on the functionality of P-gp using cyclosporin A (CsA) as a model substrate.	Tenofovir	3-15	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	51-55
12124311-5	2002	As tenofovir DF is a substrate for P-glycoprotein (P-gp)-related efflux carriers in the Caco-2 model, the modulatory effect of the ester mixtures was studied on the functionality of P-gp using cyclosporin A (CsA) as a model substrate.	Tenofovir	3-15	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	182-186
11145893-7	2001	On the contrary, the animals that received PMPA showed transient loss of CD4(+) T cells that recovered during the treatment period.	Tenofovir	43-47	CD4 molecule	Homo sapiens	73-76
10440094-9	1999	Under the same conditions PMEA inhibits, while PMPA slightly stimulates, secretion of RANTES.	Tenofovir	47-51	C-C motif chemokine ligand 5	Rattus norvegicus	86-92
10400763-4	1999	Phosphonate 9-[2-(phosphomethoxypropyl]adenine (PMPA) treatment led to a moderate suppression of intestinal viral loads and repopulation of intestinal mucosa by predominantly activated memory CD4(+) T-helper cells.	Tenofovir	48-52	CD4 molecule	Homo sapiens	192-195
10400763-6	1999	Compared to preinfection values, the frequency of naive CD4(+) T cells increased following PMPA therapy, suggesting that new CD4(+) T cells were repopulating the intestinal mucosa.	Tenofovir	91-95	CD4 molecule	Homo sapiens	56-59
10400763-6	1999	Compared to preinfection values, the frequency of naive CD4(+) T cells increased following PMPA therapy, suggesting that new CD4(+) T cells were repopulating the intestinal mucosa.	Tenofovir	91-95	CD4 molecule	Homo sapiens	125-128
10400763-8	1999	The majority of CD4(+) T cells repopulating the intestinal mucosa following PMPA therapy were CD29(hi) and CD11ahi.	Tenofovir	76-80	CD4 molecule	Homo sapiens	16-19
10400763-8	1999	The majority of CD4(+) T cells repopulating the intestinal mucosa following PMPA therapy were CD29(hi) and CD11ahi.	Tenofovir	76-80	integrin subunit beta 1	Homo sapiens	94-98
9637359-4	1997	PMEG, (R)-PMPA, and (S)-PMPA greatly enhanced the secretion of both tumour necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10), (R)-PMPDAP stimulated only TNF-alpha, other test compounds were ineffective.	Tenofovir	6-14	tumor necrosis factor	Homo sapiens	98-107
9637359-4	1997	PMEG, (R)-PMPA, and (S)-PMPA greatly enhanced the secretion of both tumour necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10), (R)-PMPDAP stimulated only TNF-alpha, other test compounds were ineffective.	Tenofovir	6-14	interleukin 10	Homo sapiens	113-127
9637359-4	1997	PMEG, (R)-PMPA, and (S)-PMPA greatly enhanced the secretion of both tumour necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10), (R)-PMPDAP stimulated only TNF-alpha, other test compounds were ineffective.	Tenofovir	6-14	interleukin 10	Homo sapiens	129-134
9637359-4	1997	PMEG, (R)-PMPA, and (S)-PMPA greatly enhanced the secretion of both tumour necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10), (R)-PMPDAP stimulated only TNF-alpha, other test compounds were ineffective.	Tenofovir	20-28	tumor necrosis factor	Homo sapiens	98-107
9637359-4	1997	PMEG, (R)-PMPA, and (S)-PMPA greatly enhanced the secretion of both tumour necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10), (R)-PMPDAP stimulated only TNF-alpha, other test compounds were ineffective.	Tenofovir	20-28	interleukin 10	Homo sapiens	113-127
9637359-4	1997	PMEG, (R)-PMPA, and (S)-PMPA greatly enhanced the secretion of both tumour necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10), (R)-PMPDAP stimulated only TNF-alpha, other test compounds were ineffective.	Tenofovir	20-28	interleukin 10	Homo sapiens	129-134
9637359-6	1997	Both TNF-alpha and IL-10 have been found to be major factors determining enhancing effects of PMEG, (R)-PMPA, and (S)-PMPA on production of NO generated by exogenous IFN-gamma.	Tenofovir	100-108	tumor necrosis factor	Homo sapiens	5-14
9637359-6	1997	Both TNF-alpha and IL-10 have been found to be major factors determining enhancing effects of PMEG, (R)-PMPA, and (S)-PMPA on production of NO generated by exogenous IFN-gamma.	Tenofovir	100-108	interleukin 10	Homo sapiens	19-24
9637359-6	1997	Both TNF-alpha and IL-10 have been found to be major factors determining enhancing effects of PMEG, (R)-PMPA, and (S)-PMPA on production of NO generated by exogenous IFN-gamma.	Tenofovir	100-108	interferon gamma	Homo sapiens	166-175
9637359-6	1997	Both TNF-alpha and IL-10 have been found to be major factors determining enhancing effects of PMEG, (R)-PMPA, and (S)-PMPA on production of NO generated by exogenous IFN-gamma.	Tenofovir	114-122	tumor necrosis factor	Homo sapiens	5-14
9637359-6	1997	Both TNF-alpha and IL-10 have been found to be major factors determining enhancing effects of PMEG, (R)-PMPA, and (S)-PMPA on production of NO generated by exogenous IFN-gamma.	Tenofovir	114-122	interleukin 10	Homo sapiens	19-24
9637359-6	1997	Both TNF-alpha and IL-10 have been found to be major factors determining enhancing effects of PMEG, (R)-PMPA, and (S)-PMPA on production of NO generated by exogenous IFN-gamma.	Tenofovir	114-122	interferon gamma	Homo sapiens	166-175
33587439-4	2021	METHODS: Virologically suppressed adults receiving efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF), or its components, with ongoing EFV-associated CNS toxicity Grade 2 or higher (DAIDS Criteria) were switched to doravirine/lamivudine/tenofovir (DOR/3TC/TDF) on Day 1 (immediate switch group [ISG]) or after 12 weeks (deferred switch group [DSG]).	Tenofovir	75-84	sex determining region Y	Homo sapiens	94-97
34946974-0	2021	Effects of Genetic Polymorphisms of Cathepsin A on Metabolism of Tenofovir Alafenamide.	Tenofovir	65-74	cathepsin A	Homo sapiens	36-47
34879114-0	2021	Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway.	Tenofovir	0-29	thymoma viral proto-oncogene 1	Mus musculus	137-140
34561299-11	2021	Significance Statement Muscle-type creatine kinase (CKM) is important to the activation of tenofovir, a key component of HIV prophylaxis.	Tenofovir	91-100	creatine kinase, M-type	Homo sapiens	52-55
34879114-0	2021	Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway.	Tenofovir	0-29	mechanistic target of rapamycin kinase	Mus musculus	141-145
34829768-10	2021	In conclusion, by conducting a glycoproteome-wide search for GalNAc-T14 substrates, we unexpectedly found that tenofovir was a major negative regulator of GalNAc-T14 substrates and an unfavorable anti-hepatitis B drug in HCC patients receiving sorafenib.	Tenofovir	111-120	polypeptide N-acetylgalactosaminyltransferase 14	Homo sapiens	61-71
34829768-10	2021	In conclusion, by conducting a glycoproteome-wide search for GalNAc-T14 substrates, we unexpectedly found that tenofovir was a major negative regulator of GalNAc-T14 substrates and an unfavorable anti-hepatitis B drug in HCC patients receiving sorafenib.	Tenofovir	111-120	polypeptide N-acetylgalactosaminyltransferase 14	Homo sapiens	155-165
34704355-2	2022	METHODS: In the Monitoring Early Treatment Adherence study, adherence was monitored electronically in real time among adult, treatment-naive PWH in Uganda and South Africa who initiated tenofovir disoproxil fumarate/emtricitabine/efavirenz during early-stage (CD4 > 350 cells/microL) or late-stage (CD4 < 200 cells/microL) disease.	Tenofovir	186-215	CD4 molecule	Homo sapiens	260-263
34768920-0	2021	Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor.	Tenofovir	0-9	sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D	Mus musculus	20-33
34768920-0	2021	Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor.	Tenofovir	0-9	adenosine A2a receptor	Mus musculus	122-144
34768920-3	2021	Therefore, tenofovir might activate Sema4D signaling to alter bone turnover.	Tenofovir	11-20	sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D	Mus musculus	36-42
34768920-6	2021	In vivo tenofovir showed an increased expression of Sema4D when compared to control mice, and dipyridamole reverted the expression in an A2A-dependent manner.	Tenofovir	8-17	sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D	Mus musculus	52-58
34768920-7	2021	In vitro, tenofovir increases Sema4D expression and secretion in osteoclast precursors, and pre-treatment with dipyridamole reverted this effect.	Tenofovir	10-19	sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D	Mus musculus	30-36
34768920-8	2021	pRhoA and ROCK1 activation were increased and IRS1/IGF1R expression was diminished by tenofovir in the Vav3/ARHGAP18 mechanism in osteoblast precursors and reverted by dipyridamole in an A2A-dependent manner.	Tenofovir	86-95	Rho-associated coiled-coil containing protein kinase 1	Mus musculus	10-15
34768920-8	2021	pRhoA and ROCK1 activation were increased and IRS1/IGF1R expression was diminished by tenofovir in the Vav3/ARHGAP18 mechanism in osteoblast precursors and reverted by dipyridamole in an A2A-dependent manner.	Tenofovir	86-95	insulin receptor substrate 1	Mus musculus	46-50
34768920-8	2021	pRhoA and ROCK1 activation were increased and IRS1/IGF1R expression was diminished by tenofovir in the Vav3/ARHGAP18 mechanism in osteoblast precursors and reverted by dipyridamole in an A2A-dependent manner.	Tenofovir	86-95	insulin-like growth factor I receptor	Mus musculus	51-56
34768920-8	2021	pRhoA and ROCK1 activation were increased and IRS1/IGF1R expression was diminished by tenofovir in the Vav3/ARHGAP18 mechanism in osteoblast precursors and reverted by dipyridamole in an A2A-dependent manner.	Tenofovir	86-95	vav 3 oncogene	Mus musculus	103-107
34768920-8	2021	pRhoA and ROCK1 activation were increased and IRS1/IGF1R expression was diminished by tenofovir in the Vav3/ARHGAP18 mechanism in osteoblast precursors and reverted by dipyridamole in an A2A-dependent manner.	Tenofovir	86-95	Rho GTPase activating protein 18	Mus musculus	108-116
34768920-9	2021	This suggests that tenofovir increases bone loss by activation of Sema4D/PlexinB1 signaling, which inhibits osteoblast differentiation.	Tenofovir	19-28	sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D	Mus musculus	66-72
34768920-9	2021	This suggests that tenofovir increases bone loss by activation of Sema4D/PlexinB1 signaling, which inhibits osteoblast differentiation.	Tenofovir	19-28	plexin B1	Mus musculus	73-81
34703277-11	2021	Furthermore, there was a trend of higher TAF AUC and shorter tenofovir t1/2 for the rs2032582 (ABCB1) T allele and rs3742106 (ABCC4) CC variant, respectively, although not statistically significant in the multiple linear regression analysis.	Tenofovir	61-70	ATP binding cassette subfamily B member 1	Homo sapiens	95-100
34703277-11	2021	Furthermore, there was a trend of higher TAF AUC and shorter tenofovir t1/2 for the rs2032582 (ABCB1) T allele and rs3742106 (ABCC4) CC variant, respectively, although not statistically significant in the multiple linear regression analysis.	Tenofovir	61-70	ATP binding cassette subfamily C member 4	Homo sapiens	126-131
34458919-1	2021	OBJECTIVES: To determine the extent of hepatitis B virus (HBV) suppression and its association with seroclearance of hepatitis "e" antigen (HBeAg) and hepatitis B surface antigen (HBsAg) in HIV/HBV-coinfected patients undergoing long-term tenofovir-based antiretroviral therapy (ART).	Tenofovir	239-248	capsid protein;pre-capsid protein	Hepatitis B virus	140-145
34222849-1	2021	Background: Tenofovir and emtricitabine interfere with the SARS CoV-2 ribonucleic acid (RNA)-dependent RNA polymerase (RdRp).	Tenofovir	12-21	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	119-123
34558270-0	2021	Concentration of LDLR, degree of hepatic fibrosis and hepatic steatosis in patients with chronic hepatitis B infection treated with tenofovir disoproxil fumarate.	Tenofovir	132-161	low density lipoprotein receptor	Homo sapiens	17-21
34558270-4	2021	OBJECTIVE: The aim of the study was to investigate the LDLR concentration and degree of hepatic fibrosis and hepatic steatosis in patients with chronic hepatitis B infection during tenofovir disoproxil fumarate therapy.	Tenofovir	181-210	low density lipoprotein receptor	Homo sapiens	55-59
34571970-0	2021	Combination Treatment with the Vimentin-Targeting Antibody hzVSF and Tenofovir Suppresses Woodchuck Hepatitis Virus Infection in Woodchucks.	Tenofovir	69-78	vimentin	Homo sapiens	31-39
34432302-7	2022	RESULTS: PAS inhibited OAT1- and OAT3-mediated tenofovir uptake in vitro.	Tenofovir	47-56	solute carrier family 22 member 6	Homo sapiens	23-27
34432302-7	2022	RESULTS: PAS inhibited OAT1- and OAT3-mediated tenofovir uptake in vitro.	Tenofovir	47-56	solute carrier family 22 member 8	Homo sapiens	33-37
35631648-6	2022	Placental mitochondrial DNA content, as well as placental expression of cytochrome c-oxidase subunit-II, DNA polymerase gamma, and citrate synthase, was higher in tenofovir/emtricitabine-treated mice compared to other groups.	Tenofovir	163-172	cytochrome c oxidase II, mitochondrial	Mus musculus	72-103
34197574-1	2022	BACKGROUND: In individuals co-infected with HIV and hepatitis B virus (HBV), widespread tenofovir (TDF)-containing antiretroviral therapy (ART) has led to substantial decreases in HBV-DNA and HIV-RNA detection.	Tenofovir	88-97	sex determining region Y	Homo sapiens	99-102
34107578-0	2021	(Effect of tenofovir disoproxil fumarate antiviral therapy on virus-specific CD8+T Cells function in patients with chronic hepatitis B).	Tenofovir	11-40	CD8a molecule	Homo sapiens	77-80
34107578-1	2021	Objective: To observe the effect of tenofovir disoproxil fumarate (TDF) antiviral therapy on HBV-specific CD8(+)T cell function in peripheral blood of patients with HBeAg-positive chronic hepatitis B, and to assess its correlation with HBeAg sero-negativeness.	Tenofovir	36-65	CD8a molecule	Homo sapiens	106-109
34107578-1	2021	Objective: To observe the effect of tenofovir disoproxil fumarate (TDF) antiviral therapy on HBV-specific CD8(+)T cell function in peripheral blood of patients with HBeAg-positive chronic hepatitis B, and to assess its correlation with HBeAg sero-negativeness.	Tenofovir	67-70	CD8a molecule	Homo sapiens	106-109
34130467-9	2021	Ribavirin and tenofovir showed significant binding energy above -8 kcal/mol with seven HB interactions with the main protease and also spike protein.	Tenofovir	14-23	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	135-140
34814505-9	2021	When compared with corresponding control groups, age <35 years at ART, female, education of middle school or above, sexual transmission, no opportunistic infection, CD4 >=200 cells/mul, baseline regimen with tenofovir (TDF) and time from HIV diagnosis to ART <1 year were the related factors facilitating the higher CD4 subgroups.	Tenofovir	208-217	CD4 molecule	Homo sapiens	316-319
33633036-0	2021	Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.	Tenofovir	35-44	sex determining region Y	Homo sapiens	66-77
33633036-1	2021	BACKGROUND: In the primary analysis of the DRIVE-SHIFT trial, switching to doravirine/lamivudine/ tenofovir disoproxil fumarate (DOR/3TC/TDF) maintained suppression of HIV-1 through Week 48.	Tenofovir	98-107	sex determining region Y	Homo sapiens	129-140
34235009-0	2021	Antiretroviral Tenofovir Induces Senescence-Associated beta-Galactosidase Activity in Primary Human Brain Vascular Cells in Multi-Layer Three-Dimensional Co-Culture.	Tenofovir	15-24	galactosidase beta 1	Homo sapiens	55-73
34235009-3	2021	Here we assessed the effects of FTC and TFV exposure on senescence-associated beta-galactosidase (SA-beta-Gal) activity, a marker of cellular senescence, in human brain vascular cells.	Tenofovir	40-43	galactosidase beta 1	Homo sapiens	78-96
34093527-4	2021	Dolutegravir (DTG) and emtricitabine (FTC) combination, together with tenofovir (TAF or TDF), is one of the recommended first line treatments for HIV.	Tenofovir	70-79	TATA-box binding protein associated factor 8	Homo sapiens	81-84
35618038-0	2022	Tenofovir disoproxil fumarate-mediated gamma-globin induction is correlated with the suppression of trans-acting factors in CD34+ progenitor cells: A role in the reactivation of fetal hemoglobin.	Tenofovir	0-29	hemoglobin subunit gamma 1	Homo sapiens	39-51
35618038-0	2022	Tenofovir disoproxil fumarate-mediated gamma-globin induction is correlated with the suppression of trans-acting factors in CD34+ progenitor cells: A role in the reactivation of fetal hemoglobin.	Tenofovir	0-29	CD34 molecule	Homo sapiens	124-128
35306280-0	2022	Downregulation of the long non-coding RNA MALAT1 in tenofovir-treated pregnant women with hepatitis B virus infection promotes immune recovery of natural killer cells via the has-miR-155-5p/HIF-1alpha axis.	Tenofovir	52-61	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	42-48
35306280-0	2022	Downregulation of the long non-coding RNA MALAT1 in tenofovir-treated pregnant women with hepatitis B virus infection promotes immune recovery of natural killer cells via the has-miR-155-5p/HIF-1alpha axis.	Tenofovir	52-61	microRNA 155	Homo sapiens	179-186
35306280-0	2022	Downregulation of the long non-coding RNA MALAT1 in tenofovir-treated pregnant women with hepatitis B virus infection promotes immune recovery of natural killer cells via the has-miR-155-5p/HIF-1alpha axis.	Tenofovir	52-61	hypoxia inducible factor 1 subunit alpha	Homo sapiens	190-200
35631648-6	2022	Placental mitochondrial DNA content, as well as placental expression of cytochrome c-oxidase subunit-II, DNA polymerase gamma, and citrate synthase, was higher in tenofovir/emtricitabine-treated mice compared to other groups.	Tenofovir	163-172	citrate synthase	Mus musculus	131-147
35631648-7	2022	Zidovudine/lamivudine-treated mice had elevated malondialdehyde levels (oxidative stress marker) compared to other groups and lower mRNA levels of manganese superoxide dismutase and peroxisome proliferator-activated receptor gamma coactivator 1-alpha in the placenta compared to tenofovir/emtricitabine-treated mice.	Tenofovir	279-288	superoxide dismutase 2, mitochondrial	Mus musculus	147-177
35631648-7	2022	Zidovudine/lamivudine-treated mice had elevated malondialdehyde levels (oxidative stress marker) compared to other groups and lower mRNA levels of manganese superoxide dismutase and peroxisome proliferator-activated receptor gamma coactivator 1-alpha in the placenta compared to tenofovir/emtricitabine-treated mice.	Tenofovir	279-288	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	182-250
35631624-7	2022	A significant increase in caspase 3 and ROS/RNS level but a decrease in total ATP were observed in USC treated with ddC, TFV, RAL, and RTNN.	Tenofovir	121-124	caspase 3	Homo sapiens	26-35
35631624-7	2022	A significant increase in caspase 3 and ROS/RNS level but a decrease in total ATP were observed in USC treated with ddC, TFV, RAL, and RTNN.	Tenofovir	121-124	FAM20C golgi associated secretory pathway kinase	Homo sapiens	44-47
35045162-3	2022	RESULTS: In an adjusted analysis, participants treated with tenofovir for at least 4 years had shorter TL in CD8+ T cells (P = 0.04) and lower telomerase activity in CD4+ (P = 0.012) and CD8+ T cells (P = 0.023).	Tenofovir	60-69	CD8a molecule	Homo sapiens	109-112
35185356-8	2022	The availability of FDA-approved anti-RdRp drugs (Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir) as potent drugs against SARS-CoV-2 that tightly bind to its RdRp may aid in the treatment of patients and reduce the risk of the mysterious new form of COVID-19 viral infection.	Tenofovir	102-111	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	38-42
35185356-8	2022	The availability of FDA-approved anti-RdRp drugs (Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir) as potent drugs against SARS-CoV-2 that tightly bind to its RdRp may aid in the treatment of patients and reduce the risk of the mysterious new form of COVID-19 viral infection.	Tenofovir	102-111	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	173-177
35045162-3	2022	RESULTS: In an adjusted analysis, participants treated with tenofovir for at least 4 years had shorter TL in CD8+ T cells (P = 0.04) and lower telomerase activity in CD4+ (P = 0.012) and CD8+ T cells (P = 0.023).	Tenofovir	60-69	CD4 molecule	Homo sapiens	166-169
35045162-3	2022	RESULTS: In an adjusted analysis, participants treated with tenofovir for at least 4 years had shorter TL in CD8+ T cells (P = 0.04) and lower telomerase activity in CD4+ (P = 0.012) and CD8+ T cells (P = 0.023).	Tenofovir	60-69	CD8a molecule	Homo sapiens	187-190
35045162-4	2022	Tenofovir treatment was also associated with lower proportions of recent thymic emigrant (RTE) CD4+ cells (P = 0.031) and PD1 marker expression (P = 0.013).	Tenofovir	0-9	CD4-1 molecule	Oncorhynchus mykiss	95-98
35045162-5	2022	CONCLUSIONS: In long-term aviraemic HIV adults, the inhibition of telomerase by tenofovir could explain telomere shortening in CD8+ T cells.	Tenofovir	80-89	CD8a molecule	Homo sapiens	127-130
35319375-8	2022	Being under a tenofovir disoproxil- containing treatment in both years was the only explanatory variable significantly associated with inadequately low levels of PTH in the presence of hypocalcemia in both years (OR 4.3 (CI95: 1.4; 16.0)).	Tenofovir	14-34	parathyroid hormone	Homo sapiens	162-165
33880839-0	2021	Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.	Tenofovir	64-93	glutamic--pyruvic transaminase	Homo sapiens	11-35
32338164-6	2021	The results show the effectiveness of Sofosbuvir, Ribavirin, Galidesivir, Remdesivir, Favipiravir, Cefuroxime, Tenofovir, and Hydroxychloroquine, in binding to SARS-CoV-2 RdRp.	Tenofovir	111-120	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	171-175
33524314-0	2021	Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial.	Tenofovir	11-40	glutamic--pyruvic transaminase	Homo sapiens	125-149
34016716-6	2021	Soluble programmed cell death protein 1 and sTIM-3 both positively correlated with hepatitis B virus (HBV) DNA level and increased in entecavir or tenofovir used group.	Tenofovir	147-156	programmed cell death 1	Homo sapiens	8-39
34007475-7	2021	In linear regression models, the lowest p-value for association with the tenofovir CSF-to-plasma ratio was ABCB1 rs1989830 (p = 1.2 x 10-3) and for emtricitabine, it was ABCC5 rs11921035 (p = 1.4 x 10-3).	Tenofovir	73-82	ATP binding cassette subfamily B member 1	Homo sapiens	107-112
34007475-7	2021	In linear regression models, the lowest p-value for association with the tenofovir CSF-to-plasma ratio was ABCB1 rs1989830 (p = 1.2 x 10-3) and for emtricitabine, it was ABCC5 rs11921035 (p = 1.4 x 10-3).	Tenofovir	73-82	ATP binding cassette subfamily C member 5	Homo sapiens	170-175
33894278-6	2021	By testing seven commonly used nucleotide analog viral polymerase inhibitors, Remdesivir, Molnupiravir, Ribavirin, Favipiravir, Penciclovir, Entecavir and Tenofovir, we found that both Molnupiravir and Remdesivir showed the strong inhibition of SARS-CoV-2 RdRp, with EC50 value of 0.22 muM and 0.67 muM, respectively.	Tenofovir	155-164	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	256-260
33998950-7	2021	Tenofovir, an antiretroviral for HIV-proteases and Terlipressin, a vasoconstrictor show stable RMSD, RMSF, better MM/GBSA with good cross correlation as compared to the Apo and O6K.	Tenofovir	0-9	aminopeptidase O (putative)	Homo sapiens	169-172
32729019-0	2021	Marketing of Tenofovir Disoproxil Fumarate (TDF) Lawsuits and Social Media Misinformation Campaigns" Impact on PrEP Uptake Among Gender and Sexual Minority Individuals.	Tenofovir	13-42	prolyl endopeptidase	Homo sapiens	111-115
32729019-0	2021	Marketing of Tenofovir Disoproxil Fumarate (TDF) Lawsuits and Social Media Misinformation Campaigns" Impact on PrEP Uptake Among Gender and Sexual Minority Individuals.	Tenofovir	44-47	prolyl endopeptidase	Homo sapiens	111-115
32729019-1	2021	There has been an influx of ads on social media seeking plaintiffs in lawsuits for harms/side-effects caused by tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC, Truvada) for PrEP.	Tenofovir	112-141	prolyl endopeptidase	Homo sapiens	179-183
33880839-0	2021	Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.	Tenofovir	95-98	glutamic--pyruvic transaminase	Homo sapiens	11-35
33850298-0	2021	ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment.	Tenofovir	52-81	ATP binding cassette subfamily C member 4	Homo sapiens	0-5
33850298-3	2021	We have retrospectively investigated, in 179 HIV positive patients treated with TDF, the association between the main variants in ABCC2, ABCC4, and ABCC10 genes and four safety endpoints, three clinically relevant as renal outcomes and a higher tenofovir plasma concentration.	Tenofovir	245-254	ATP binding cassette subfamily C member 2	Homo sapiens	130-135
33637048-6	2021	RESULTS: ZOL treatment significantly suppressed the expression of CTx and osteocalcin in HIV patients treated with tenofovir.	Tenofovir	115-124	bone gamma-carboxyglutamate protein	Homo sapiens	74-85
33850298-3	2021	We have retrospectively investigated, in 179 HIV positive patients treated with TDF, the association between the main variants in ABCC2, ABCC4, and ABCC10 genes and four safety endpoints, three clinically relevant as renal outcomes and a higher tenofovir plasma concentration.	Tenofovir	245-254	ATP binding cassette subfamily C member 10	Homo sapiens	148-154
33850298-7	2021	The stronger associations were found between the tenofovir accumulation and ABCC4 c.*38T>G and c.3348G>A: the percentage of these patients was higher in the TG + GG (p = 0.011) and in the AA (p = 0.004) genotype, respectively.	Tenofovir	49-58	ATP binding cassette subfamily C member 4	Homo sapiens	76-81
33850298-10	2021	Our results show a major role for a combined determination of ABCC4/ABCC10 variants as an indicator of tenofovir toxicity in the clinical practice.	Tenofovir	103-112	ATP binding cassette subfamily C member 4	Homo sapiens	62-67
33850298-10	2021	Our results show a major role for a combined determination of ABCC4/ABCC10 variants as an indicator of tenofovir toxicity in the clinical practice.	Tenofovir	103-112	ATP binding cassette subfamily C member 10	Homo sapiens	68-74
33637048-6	2021	RESULTS: ZOL treatment significantly suppressed the expression of CTx and osteocalcin in HIV patients treated with tenofovir.	Tenofovir	115-124	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	66-69
33405910-1	2021	Vaginal films featuring the pH-dependent release of tenofovir (TFV) were developed for the prevention of sexual transmission of human immunodeficiency syndrome (HIV).	Tenofovir	52-61	phenylalanine hydroxylase	Homo sapiens	28-30
33405910-1	2021	Vaginal films featuring the pH-dependent release of tenofovir (TFV) were developed for the prevention of sexual transmission of human immunodeficiency syndrome (HIV).	Tenofovir	63-66	phenylalanine hydroxylase	Homo sapiens	28-30
33055571-9	2021	In multivariable models, an unsuppressed VL in late pregnancy was associated with 80% lower adjusted mean peripartum TFV concentrations than pregnancies with viral suppression (95% CI: -90% to -59%, p < 0.001).	Tenofovir	117-120	modulator of VRAC current 1	Homo sapiens	41-43
33535672-6	2021	Here, we reviewed previous reports regarding the effects of combination therapy of entecavir or tenofovir with Peg-IFNalpha, focusing on long-term reduction in HBsAg levels.	Tenofovir	96-105	interferon alpha 1	Homo sapiens	115-123
33829539-8	2021	Tenofovir-25 failed to attenuate DMH/HFD-induced cell proliferation whereas tenofovir-50 significantly decreased cell proliferation revealed by the decreased PCNA expression.	Tenofovir	76-85	proliferating cell nuclear antigen	Rattus norvegicus	158-162
33829539-10	2021	Moreover, tenofovir-50 decreased Bcl-2 and cyclin D1 expressions in colon tissues compared to DMH/HFD group.	Tenofovir	10-19	BCL2, apoptosis regulator	Rattus norvegicus	33-38
33829539-10	2021	Moreover, tenofovir-50 decreased Bcl-2 and cyclin D1 expressions in colon tissues compared to DMH/HFD group.	Tenofovir	10-19	cyclin D1	Rattus norvegicus	43-52
33526487-9	2021	In-vivo pharmacokinetic (PK) study of BIC, TAF and respective drug metabolite in female BALB/c mice after single subcutaneous BIC+TAF NPs demonstrated plasma drug concentrations of BIC and tenofovir (TFV) above intracellular IC50 level during the entire 30-day study period, and prolonged persistence of both active drugs in the HIV target organs including vagina, colon, spleen, and lymph nodes.	Tenofovir	189-198	TATA-box binding protein associated factor 8	Homo sapiens	130-133
33734021-8	2021	The ARVs predicted to bind the catalytic site of the RdRp included Nucleoside Reverse Transcriptase Inhibitors, abacavir, emtricitabine, zidovudine, and tenofovir.	Tenofovir	153-162	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	53-57
33567990-8	2022	MPA and P4 at concentrations above 0.1 microM, as well as IL-1beta and IL-8 at concentrations above 10 ng/mL significantly decreased HIV-1BaL inhibition in PM1 cells when 1 microM TFV was added.	Tenofovir	180-183	interleukin 1 alpha	Homo sapiens	58-66
33567990-8	2022	MPA and P4 at concentrations above 0.1 microM, as well as IL-1beta and IL-8 at concentrations above 10 ng/mL significantly decreased HIV-1BaL inhibition in PM1 cells when 1 microM TFV was added.	Tenofovir	180-183	C-X-C motif chemokine ligand 8	Homo sapiens	71-75
33507010-0	2021	Differences in tenofovir trough concentrations between branded and generic formulations in people taking PrEP.	Tenofovir	15-24	prolyl endopeptidase	Homo sapiens	105-109
33755983-7	2021	Furthermore, we evidenced the ability of remdesivir, tenofovir, emtricitabine, and lamivudine to be incorporated in SARS-CoV-2 RdRp in the same protein pocket where poses the corresponding natural nucleoside substrates with comparable Ki and activating similar interactions.	Tenofovir	53-62	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	127-131
33663172-6	2021	There were 87.4% co-infected patients treated with two anti-HBV drugs, including lamivudine (3TC) and tenofovir (TDF).	Tenofovir	102-111	sex determining region Y	Homo sapiens	113-116
33625064-8	2021	In target gene analyses, the lowest P-values for the dolutegravir and tenofovir groups were ABCG2 rs4148149 (P = 7.0x10-4) and ABCC10 rs67861980 (P = 1.0x10-2), respectively, which were not significant after correction for multiple testing.	Tenofovir	70-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	92-97
33625064-8	2021	In target gene analyses, the lowest P-values for the dolutegravir and tenofovir groups were ABCG2 rs4148149 (P = 7.0x10-4) and ABCC10 rs67861980 (P = 1.0x10-2), respectively, which were not significant after correction for multiple testing.	Tenofovir	70-79	ATP binding cassette subfamily C member 10	Homo sapiens	127-133
33614029-1	2021	Treatment with entecavir (ETV), tenofovir disoproxil (TDF) and the later released tenofovir alafenamide (TAF) is highly effective at controlling hepatitis B virus (HBV) infection and, in the vast majority of patients, is well tolerated.	Tenofovir	32-52	sex determining region Y	Homo sapiens	54-57
33185325-3	2021	We analyzed data of a prospective treatment trial where 120 HDV-RNA positive patients were randomized to receive PEG-IFNalpha-2a plus tenofovir-disoproxil-fumarate (PEG-IFNalpha/TDF, n=59) or placebo (PEG-IFNalpha/PBO; n=61) for 96 weeks.	Tenofovir	134-163	interferon alpha 1	Homo sapiens	169-177
33637048-12	2021	Furthermore, down-regulated expression of RANKL by ZOL treatment alleviated osteoporosis in HIV-positive subjects treated with tenofovir.	Tenofovir	127-136	TNF superfamily member 11	Homo sapiens	42-47
33045968-0	2021	In vitro anti-HIV-1 activity of the recombinant HIV-1 TAT protein along with Tenofovir drug.	Tenofovir	77-86	tyrosine aminotransferase	Homo sapiens	54-57
33045968-9	2021	In addition, the recombinant TAT protein at a certain dose with low toxicity could suppress Scr-HIV replication in the infected HeLa cells (~30%) that was comparable with a low toxic dose of Tenofovir drug (~40%).	Tenofovir	191-200	tyrosine aminotransferase	Homo sapiens	29-32
33045968-10	2021	It was interesting that the recombinant TAT protein could enhance anti-HIV potency of Tenofovir drug up to 66%.	Tenofovir	86-95	tyrosine aminotransferase	Homo sapiens	40-43
33259998-9	2021	Antiviral therapy, preferably tenofovir (TDF), is recommended for mothers with viral load >= 200,000 IU/mL2), with the neonates receiving both active and passive immunisations.	Tenofovir	30-39	sex determining region Y	Homo sapiens	41-44
33259998-9	2021	Antiviral therapy, preferably tenofovir (TDF), is recommended for mothers with viral load >= 200,000 IU/mL2), with the neonates receiving both active and passive immunisations.	Tenofovir	30-39	skull development traits QTL 2	Mus musculus	104-107
33396968-4	2020	In our study, we explored the potential of tenofovir disoproxil (TFD) adducts with block copolymers of poly(ethylene glycol) monomethyl ether and poly(ethylene phosphoric acid) (mPEG-b-PEPA) as candidates for developing a long-acting/controlled-release formulation of TFV.	Tenofovir	43-63	carnosine dipeptidase 2	Homo sapiens	185-189
33396968-4	2020	In our study, we explored the potential of tenofovir disoproxil (TFD) adducts with block copolymers of poly(ethylene glycol) monomethyl ether and poly(ethylene phosphoric acid) (mPEG-b-PEPA) as candidates for developing a long-acting/controlled-release formulation of TFV.	Tenofovir	65-68	carnosine dipeptidase 2	Homo sapiens	185-189
32852859-1	2020	We read with great interest the article titled "Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment" by Tao et al1 published in a recent issue of this journal.	Tenofovir	175-184	ephrin A5	Homo sapiens	206-209
32378496-3	2020	In the present study, we examined whether chronic exposure to the anti-HIV drugs tenofovir disoproxil fumarate and nevirapine induces lipid peroxidation thereby promoting BACE1 and beta-amyloid generation and consequently impair cognitive function in mice.	Tenofovir	81-110	beta-site APP cleaving enzyme 1	Mus musculus	171-176
33167541-6	2020	In urine samples, the limits of detection for tenofovir and creatinine were 4 microg mL-1 and 0.03 micromol mL-1, respectively.	Tenofovir	46-55	L1 cell adhesion molecule	Mus musculus	85-89
33167541-6	2020	In urine samples, the limits of detection for tenofovir and creatinine were 4 microg mL-1 and 0.03 micromol mL-1, respectively.	Tenofovir	46-55	L1 cell adhesion molecule	Mus musculus	108-112
33167541-7	2020	In plasma samples, the limits of detection were 0.15 microg mL-1 for tenofovir and 0.0003 micromol mL-1 for creatinine.	Tenofovir	69-78	L1 cell adhesion molecule	Mus musculus	60-64
33136729-2	2021	The current study aimed to assess urinary beta2-M as a reliable marker for early prediction of tenofovir disoproxil fumarate (TDF)-related nephrotoxicity among hepatitis B virus (HBV) patients.	Tenofovir	95-124	alpha-2-macroglobulin	Homo sapiens	42-49
33136729-11	2021	Therefore, the suitability of urinary beta2-M as a screening tool for tenofovir induced tubular dysfunction should be further.	Tenofovir	70-79	alpha-2-macroglobulin	Homo sapiens	38-45
32222463-0	2020	Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.	Tenofovir	52-61	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	111-115
32766890-1	2021	BACKGROUND: Pilot studies showed lower tenofovir plasma concentrations during PrEP use among transgender women (TGW) using feminizing hormones compared with cisgender men (CGM).	Tenofovir	39-48	prolyl endopeptidase	Homo sapiens	78-82
32502129-1	2020	A cross-sectional study of 358 HIV-1-infected children and adolescents living in Sub-Saharan Africa treated with tenofovir disoproxil fumarate-based regimens for a median of 1.5 interquartile range [0.6-3.1 years] showed a loss of glomerular filtration rate estimated to be 0.41 mL/min/1.73 m per month of treatment.	Tenofovir	113-142	CD59 molecule (CD59 blood group)	Homo sapiens	282-287
32180249-1	2020	BACKGROUND: Studies had shown that tenofovir (TDF) and entecavir (ETV) are widely used as the first-line therapy to inhibit hepatitis B virus (HBV) replication, which can reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients, but it was unclear which nucleos(t)ide analogue (NA) was most effective.	Tenofovir	35-44	sex determining region Y	Homo sapiens	46-49
32829410-10	2021	In the clinical trials cohort (N=462), CYP2B6 slow metabolizers had lesser weight gain at week 48 among participants receiving efavirenz with tenofovir disoproxil fumarate (p=0.001) but not those receiving efavirenz with abacavir (p=0.65).	Tenofovir	142-171	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	39-45
32222463-6	2020	KEY FINDINGS: The results suggest the effectiveness of Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir as potent drugs against SARS-CoV-2 since they tightly bind to its RdRp.	Tenofovir	107-116	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	183-187
31529730-4	2020	However, our recent findings that only acyclic nucleoside phosphonates (ANPs; adefovir dipivoxil and tenofovir disoproxil fumarate) had an additional effect of inducing interferon (IFN)-lambda3 in the gastrointestinal tract suggests that ANPs are not only distinct in their structures but also in their functions from nucleoside analogs (lamivudine and entecavir).	Tenofovir	101-130	interferon lambda 3	Homo sapiens	169-193
32733445-7	2020	GT gp41- and p24-specific ADNP were significantly higher in the tenofovir than the placebo arm at 6 and 12 months respectively (p < 0.05).	Tenofovir	64-73	transmembrane p24 trafficking protein 2	Homo sapiens	13-16
32733445-7	2020	GT gp41- and p24-specific ADNP were significantly higher in the tenofovir than the placebo arm at 6 and 12 months respectively (p < 0.05).	Tenofovir	64-73	activity dependent neuroprotector homeobox	Homo sapiens	26-30
32733445-8	2020	Plasma gp120-, gp41-, and p66-specific ADNP, and GT gp41-specific ADCC increased significantly over time (p < 0.05) in the tenofovir arm.	Tenofovir	123-132	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	7-12
32733445-8	2020	Plasma gp120-, gp41-, and p66-specific ADNP, and GT gp41-specific ADCC increased significantly over time (p < 0.05) in the tenofovir arm.	Tenofovir	123-132	DNA polymerase delta 3, accessory subunit	Homo sapiens	26-29
32733445-8	2020	Plasma gp120-, gp41-, and p66-specific ADNP, and GT gp41-specific ADCC increased significantly over time (p < 0.05) in the tenofovir arm.	Tenofovir	123-132	activity dependent neuroprotector homeobox	Homo sapiens	39-43
32733445-9	2020	In the tenofovir arm only, significant inverse correlations were observed between gp120-specific ADCC and gp120-antibody titres (r = -0.54; p = 0.009), and gp41-specific ADNP and gp41-specific antibody titres at 6 months post-infection (r = -0.50; p = 0.015).	Tenofovir	7-16	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	82-87
32733445-9	2020	In the tenofovir arm only, significant inverse correlations were observed between gp120-specific ADCC and gp120-antibody titres (r = -0.54; p = 0.009), and gp41-specific ADNP and gp41-specific antibody titres at 6 months post-infection (r = -0.50; p = 0.015).	Tenofovir	7-16	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	106-111
32733445-9	2020	In the tenofovir arm only, significant inverse correlations were observed between gp120-specific ADCC and gp120-antibody titres (r = -0.54; p = 0.009), and gp41-specific ADNP and gp41-specific antibody titres at 6 months post-infection (r = -0.50; p = 0.015).	Tenofovir	7-16	activity dependent neuroprotector homeobox	Homo sapiens	170-174
32624702-0	2020	The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNalpha-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNalpha-2b treatment alone.	Tenofovir	28-57	interferon alpha 2	Homo sapiens	192-203
32438744-0	2020	Adenosine Deaminase as a Biomarker of Tenofovir Mediated Inflammation in Naive HIV Patients.	Tenofovir	38-47	adenosine deaminase	Homo sapiens	0-19
32596332-1	2020	Aims: Tenofovir (TDF) is an antiviral drug with potential risk of kidney injury.	Tenofovir	6-15	sex determining region Y	Homo sapiens	17-20
32455152-11	2020	The positive association between sclerostin and BMD among seropositive women remained statistically significant after adjusting for ART or tenofovir disoproxil fumarate (TDF) use.	Tenofovir	139-168	sclerostin	Homo sapiens	33-43
32455152-11	2020	The positive association between sclerostin and BMD among seropositive women remained statistically significant after adjusting for ART or tenofovir disoproxil fumarate (TDF) use.	Tenofovir	170-173	sclerostin	Homo sapiens	33-43
31960918-1	2020	BACKGROUND: To describe the kinetics of hepatitis B core-related antigen (qHBcrAg) and anti-hepatitis B core antibody (qAnti-HBc) during tenofovir (TDF)-treatment and assess their ability to predict HBeAg-seroclearance in patients co-infected with HIV and hepatitis B virus (HBV).	Tenofovir	137-146	keratin 88, pseudogene	Homo sapiens	75-78
32363985-4	2020	He received radiofrequency ablation and tenofovir disoproxil anti-HBV therapy and his serum AFP and globulin levels were significantly reduced.	Tenofovir	40-60	alpha fetoprotein	Homo sapiens	92-95
31597561-11	2019	Patients with normal BMI compared to underweight, (HR: 0.79, CI 0.69-0.91), with CD4 counts 200-350 cells/microL compared to < 200 cells/microL (HR: 0.81- CI 0.71-0.93), and started on zidovudine (HR: 0.51 CI 0.44-0.59) and tenofovir (HR: 0.16, CI 0.14-0.22) compared to stavudine were less likely to have ART modification due to toxicity.	Tenofovir	224-233	CD4 molecule	Homo sapiens	81-84
32041580-9	2020	In the HIV group, TBS was negatively correlated with the duration of tenofovir disoproxil fumarate(TDF) exposure (p = 0.04).	Tenofovir	69-98	sex determining region Y	Homo sapiens	99-102
32238341-0	2020	Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial.	Tenofovir	20-29	BCL2 binding component 3	Homo sapiens	127-131
32562524-4	2020	METHODS: The antiviral activity of tenofovir disoproxil fumarate, lamivudine and ACC007 alone or in combination against different HIV-1 strains were determined by detection of HIV-1 p24 level through enzyme-linked immunosorbent assay.	Tenofovir	35-64	transmembrane p24 trafficking protein 2	Homo sapiens	182-185
31335591-0	2019	Brief Report: Relationship Between ABCC4 SNPs and Hepatitis B Virus Suppression During Tenofovir-Containing Antiretroviral Therapy in Patients With HIV/HBV Coinfection.	Tenofovir	87-96	ATP binding cassette subfamily C member 4	Homo sapiens	35-40
30985556-0	2019	Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.	Tenofovir	35-64	sex determining region Y	Homo sapiens	74-77
31339677-16	2019	CONCLUSIONS: Treatment with DTG combined with either of two tenofovir prodrugs (TAF and TDF) showed noninferior efficacy to treatment with the standard-care regimen.	Tenofovir	60-69	TATA-box binding protein associated factor 8	Homo sapiens	80-83
31430318-1	2019	INTRODUCTION: Efficacy of daily emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for PrEP is strongly dependent on the adherence.	Tenofovir	46-75	prolyl endopeptidase	Homo sapiens	90-94
31331325-4	2019	Because of the similarity of fibrotic diseases, we hypothesized that tenofovir alafenamide fumarate (TAF), the prodrug of tenofovir, and NS5ATP9, is related to and plays a role in the suppression of pulmonary fibrosis.	Tenofovir	69-78	PCNA clamp associated factor	Homo sapiens	137-144
31258661-1	2019	The aim of the present study was to analyze the efficacy and safety of tenofovir (TDF) treatment for up to 5 years in nucleos(t)ide-naive chronic hepatitis B (CHB) patients, particularly those with a high viral load, a in real-life scenario.	Tenofovir	71-80	sex determining region Y	Homo sapiens	82-85
30388308-7	2019	A significantly negative influence in all the lipid profile parameters in experienced patients and total cholesterol (TC), and LDL-C in naive patients were observed after 48 weeks of treatment with EVG/c/FTC/TAF, while these parameters remained stable in the EVG/c/FTC/TDF group.	Tenofovir	269-272	TATA-box binding protein associated factor 8	Homo sapiens	208-211
31183158-0	2019	Utility of urinary liver-type fatty acid-binding protein as a predictor of renal dysfunction in Japanese patients with HIV receiving tenofovir disoproxil fumarate with low urinary beta2 microglobulin levels: a retrospective observational study.	Tenofovir	133-162	fatty acid binding protein 1	Homo sapiens	19-56
31183158-0	2019	Utility of urinary liver-type fatty acid-binding protein as a predictor of renal dysfunction in Japanese patients with HIV receiving tenofovir disoproxil fumarate with low urinary beta2 microglobulin levels: a retrospective observational study.	Tenofovir	133-162	beta-2-microglobulin	Homo sapiens	180-199
30922593-2	2019	Tenofovir plasma exposure has been associated with a polymorphism in SLC28A2 gene (encoding the concentrative nucleoside transporter 2, CNT2): particularly, SLC28A2 124 CT/TT genotype patients show higher plasma tenofovir concentrations, compared to CC group.	Tenofovir	0-9	solute carrier family 28 member 2	Homo sapiens	69-76
30922593-2	2019	Tenofovir plasma exposure has been associated with a polymorphism in SLC28A2 gene (encoding the concentrative nucleoside transporter 2, CNT2): particularly, SLC28A2 124 CT/TT genotype patients show higher plasma tenofovir concentrations, compared to CC group.	Tenofovir	0-9	solute carrier family 28 member 2	Homo sapiens	96-134
30922593-2	2019	Tenofovir plasma exposure has been associated with a polymorphism in SLC28A2 gene (encoding the concentrative nucleoside transporter 2, CNT2): particularly, SLC28A2 124 CT/TT genotype patients show higher plasma tenofovir concentrations, compared to CC group.	Tenofovir	0-9	solute carrier family 28 member 2	Homo sapiens	136-140
30922593-2	2019	Tenofovir plasma exposure has been associated with a polymorphism in SLC28A2 gene (encoding the concentrative nucleoside transporter 2, CNT2): particularly, SLC28A2 124 CT/TT genotype patients show higher plasma tenofovir concentrations, compared to CC group.	Tenofovir	0-9	solute carrier family 28 member 2	Homo sapiens	157-164
30922593-2	2019	Tenofovir plasma exposure has been associated with a polymorphism in SLC28A2 gene (encoding the concentrative nucleoside transporter 2, CNT2): particularly, SLC28A2 124 CT/TT genotype patients show higher plasma tenofovir concentrations, compared to CC group.	Tenofovir	212-221	solute carrier family 28 member 2	Homo sapiens	69-76
30922593-2	2019	Tenofovir plasma exposure has been associated with a polymorphism in SLC28A2 gene (encoding the concentrative nucleoside transporter 2, CNT2): particularly, SLC28A2 124 CT/TT genotype patients show higher plasma tenofovir concentrations, compared to CC group.	Tenofovir	212-221	solute carrier family 28 member 2	Homo sapiens	96-134
30922593-2	2019	Tenofovir plasma exposure has been associated with a polymorphism in SLC28A2 gene (encoding the concentrative nucleoside transporter 2, CNT2): particularly, SLC28A2 124 CT/TT genotype patients show higher plasma tenofovir concentrations, compared to CC group.	Tenofovir	212-221	solute carrier family 28 member 2	Homo sapiens	136-140
30922593-2	2019	Tenofovir plasma exposure has been associated with a polymorphism in SLC28A2 gene (encoding the concentrative nucleoside transporter 2, CNT2): particularly, SLC28A2 124 CT/TT genotype patients show higher plasma tenofovir concentrations, compared to CC group.	Tenofovir	212-221	solute carrier family 28 member 2	Homo sapiens	157-164
30922593-3	2019	In literature, substrate studies are lacking; for this reason, our aim was to understand if tenofovir and tenofovir-alafenamide are CNT2 substrates.	Tenofovir	92-101	solute carrier family 28 member 2	Homo sapiens	132-136
31147594-9	2019	Particularly, tenofovir (TDF) resistance was observed in one patient undergoing TDF monotherapy and experienced several NA treatment before.	Tenofovir	14-23	sex determining region Y	Homo sapiens	25-28
31147594-9	2019	Particularly, tenofovir (TDF) resistance was observed in one patient undergoing TDF monotherapy and experienced several NA treatment before.	Tenofovir	14-23	sex determining region Y	Homo sapiens	80-83
30645771-11	2019	Tenofovir increased cathepsin K and NFATc1 mRNA levels and dipyridamole reversed the effect.	Tenofovir	0-9	cathepsin K	Mus musculus	20-31
30645771-11	2019	Tenofovir increased cathepsin K and NFATc1 mRNA levels and dipyridamole reversed the effect.	Tenofovir	0-9	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	36-42
30645771-17	2019	RANKL-positive cells were increased in tenofovir-treated mice, whereas osteoprotegerin-positive cells were decreased; both effects were reversed by dipyridamole.	Tenofovir	39-48	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	0-5
31114265-1	2019	Background and aim: We aimed to evaluate the effectiveness of pegylated interferon (Peg-IFN) monotherapy (IFN group) and combination therapy with tenofovir (TDF) and Peg-IFN (IFN+TDF group) in chronic hepatitis B (CHB) patients.	Tenofovir	146-155	sex determining region Y	Homo sapiens	157-160
31142283-2	2019	However, the difference of effectiveness in reducing HCC occurrence between tenofovir (TDF) and enticavir (ETV), two first-line NAs drugs, is still little known.	Tenofovir	76-85	HCC	Homo sapiens	53-56
31142283-2	2019	However, the difference of effectiveness in reducing HCC occurrence between tenofovir (TDF) and enticavir (ETV), two first-line NAs drugs, is still little known.	Tenofovir	76-85	sex determining region Y	Homo sapiens	87-90
31142283-3	2019	This meta analysis aims to assess the efficacy in reducing incidence of HCC comparing tenofovir monotherapy with entecavir monotherapy among chronic hepatitis B (CHB) patients by analyzing their long-term clinical outcomes.	Tenofovir	86-95	HCC	Homo sapiens	72-75
31142283-9	2019	CONCLUSION: There is a better effect of tenofovir in reducing HCC incidence than entecavir, which indicates tenofovir should be used more widely while treating chronic hepatitis B patients.	Tenofovir	40-49	HCC	Homo sapiens	62-65
31142283-9	2019	CONCLUSION: There is a better effect of tenofovir in reducing HCC incidence than entecavir, which indicates tenofovir should be used more widely while treating chronic hepatitis B patients.	Tenofovir	108-117	HCC	Homo sapiens	62-65
31223460-3	2019	The most active compound 11 (IC50: 0.71 muM), a bis(l-valine) ester prodrug of TFV, was found to have obviously greater AUC0- , C max, and F% than tenofovir disoproxil fumarate (TDF), and potent in vivo efficacy which is not inferior to TDF in a duck HBV (DHBV) model and a HBV DNA hydrodynamic mouse model, and it may serve as a promising lead compound for further anti-HBV drug discovery.	Tenofovir	79-82	latexin	Homo sapiens	40-43
31223460-3	2019	The most active compound 11 (IC50: 0.71 muM), a bis(l-valine) ester prodrug of TFV, was found to have obviously greater AUC0- , C max, and F% than tenofovir disoproxil fumarate (TDF), and potent in vivo efficacy which is not inferior to TDF in a duck HBV (DHBV) model and a HBV DNA hydrodynamic mouse model, and it may serve as a promising lead compound for further anti-HBV drug discovery.	Tenofovir	147-176	latexin	Homo sapiens	40-43
30326737-4	2019	We hypothesized that mitochondrial pathway of apoptosis, poly [ADP-ribose] polymerase (PARP) overactivation and neutrophil infiltration may contribute to tenofovir-induced renal damage.	Tenofovir	154-163	poly (ADP-ribose) polymerase 1	Rattus norvegicus	57-85
30259350-6	2019	In 10 patients, the possible tenofovir (TDF) resistance (3.14%) was found.	Tenofovir	29-38	sex determining region Y	Homo sapiens	40-43
30336207-7	2018	Our results showed that administration of Tenofovir disoproxil fumarate and Nevirapine induced astrogliosis and up-regulated IL-1beta and TNF-alpha.	Tenofovir	42-71	interleukin 1 beta	Mus musculus	125-133
29971734-2	2019	Tenofovir-based PrEP is effective in preventing HIV transmission in MSM.	Tenofovir	0-9	prolyl endopeptidase	Homo sapiens	16-20
27753647-0	2019	Value of Cystatin C-Based e-GFR Measurements to Predict Long-Term Tenofovir Nephrotoxicity in Patients With Hepatitis B.	Tenofovir	66-75	cystatin C	Homo sapiens	9-19
27753647-11	2019	CONCLUSIONS: Long-term tenofovir disoproxil fumarate nephrotoxicity can be predicted by serum cystatin C plus creatinine-based e-GFR measured before treatment.	Tenofovir	23-52	cystatin C	Homo sapiens	94-104
31143861-8	2019	The mean increase in CD4 count (57.16%) after 6 months was statistically significant (P &lt; 0.05) with tenofovir + lamivudine + atazanavir/ritonavir regimen in forty patients.	Tenofovir	104-113	CD4 molecule	Homo sapiens	21-24
30267080-3	2019	Objective: To compare entecavir and tenofovir in terms of the risk of HCC and death or liver transplant in patients with CHB infection.	Tenofovir	36-45	HCC	Homo sapiens	70-73
30267080-10	2019	In the population cohort, the annual incidence rate of HCC was significantly lower in the tenofovir group (0.64 per 100 person-years [PY]) than in the entecavir group (1.06 per 100 PY).	Tenofovir	90-99	HCC	Homo sapiens	55-58
30267080-11	2019	By multivariable-adjusted analysis, tenofovir therapy was associated with a significantly lower risk of HCC (hazard ratio [HR], 0.61; 95% CI, 0.54-0.70) and all-cause mortality or transplant (HR, 0.77; 95% CI, 0.65-0.92) compared with entecavir.	Tenofovir	36-45	HCC	Homo sapiens	104-107
30267080-12	2019	The tenofovir group also showed a significantly lower risk of HCC in the 10 923-pair propensity score-matched population cohort (HR, 0.62; 95% CI, 0.54-0.70) and 869-pair propensity score-matched hospital cohort (HR, 0.68; 95% CI, 0.46-0.99) compared with the entecavir group.	Tenofovir	4-13	HCC	Homo sapiens	62-65
30267080-13	2019	Conclusions and Relevance: This study suggests that tenofovir treatment was associated with a significantly lower risk of HCC compared with entecavir treatment in a population-based cohort of adults with CHB; these findings were validated in a hospital cohort.	Tenofovir	52-61	HCC	Homo sapiens	122-125
30755713-1	2019	Tenofovir (TFV) treatment of female reproductive tract (FRT) cells results in differential accumulation of intracellular Tenofovir diphosphate (TFV-DP) in different cell types, with greater concentrations in epithelial cells (100-fold) and fibroblasts (10-fold) than in CD4+ T cells.	Tenofovir	0-9	CD4 molecule	Homo sapiens	270-273
30755713-1	2019	Tenofovir (TFV) treatment of female reproductive tract (FRT) cells results in differential accumulation of intracellular Tenofovir diphosphate (TFV-DP) in different cell types, with greater concentrations in epithelial cells (100-fold) and fibroblasts (10-fold) than in CD4+ T cells.	Tenofovir	11-14	CD4 molecule	Homo sapiens	270-273
30525661-5	2019	Tenofovir (TFV) encapsulation and loading efficiencies in MRP were 70.1% and 16.3% w/w, respectively.	Tenofovir	0-9	ATP binding cassette subfamily C member 1	Homo sapiens	58-61
30525661-5	2019	Tenofovir (TFV) encapsulation and loading efficiencies in MRP were 70.1% and 16.3% w/w, respectively.	Tenofovir	11-14	ATP binding cassette subfamily C member 1	Homo sapiens	58-61
30697570-0	2019	Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ss2M in the ION-4 Study Cohort.	Tenofovir	20-29	retinol binding protein 4	Homo sapiens	67-72
30697570-6	2019	Both RBP-4 and beta2M exhibited positive correlations with tenofovir AUC.	Tenofovir	59-68	retinol binding protein 4	Homo sapiens	5-10
30697570-6	2019	Both RBP-4 and beta2M exhibited positive correlations with tenofovir AUC.	Tenofovir	59-68	beta-2-microglobulin	Homo sapiens	15-21
30336207-7	2018	Our results showed that administration of Tenofovir disoproxil fumarate and Nevirapine induced astrogliosis and up-regulated IL-1beta and TNF-alpha.	Tenofovir	42-71	tumor necrosis factor	Mus musculus	138-147
30154221-8	2018	During the first year of tenofovir use, eGFR decreased on average by 9.2 (95% confidence interval, 6.5 to 11.9) ml/min per 1.73 m2 and was stable afterward (decrease of 0.62; 95% confidence interval, -0.85 to 2.1 ml/min per 1.73 m2 per year).	Tenofovir	25-34	epidermal growth factor receptor	Homo sapiens	40-44
30047286-1	2018	Adherence to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC, Truvada ) is the primary determinant of HIV pre-exposure prophylaxis (PrEP) efficacy.	Tenofovir	13-42	sex determining region Y	Homo sapiens	58-61
30154221-12	2018	CONCLUSIONS: Urinary biomarkers of kidney injury measured before and after tenofovir initiation are associated with subsequent changes in eGFR in individuals with HIV.	Tenofovir	75-84	epidermal growth factor receptor	Homo sapiens	138-142
29980578-7	2018	This was most probably attributable to specific uptake of CDDP by the organic cation transporter 2 (OCT2), TFV through organic anion transporter 1 (OAT1), and CsA competing for P-glycoprotein-mediated efflux.	Tenofovir	107-110	solute carrier family 22 member 6	Homo sapiens	119-146
29980578-7	2018	This was most probably attributable to specific uptake of CDDP by the organic cation transporter 2 (OCT2), TFV through organic anion transporter 1 (OAT1), and CsA competing for P-glycoprotein-mediated efflux.	Tenofovir	107-110	solute carrier family 22 member 6	Homo sapiens	148-152
30075765-1	2018	INTRODUCTION: Concomitant use of ledipasvir and boosted protease inhibitors (PIs) may increase the risk of tenofovir (TDF) nephrotoxicity, since both these drugs increase TDF levels.	Tenofovir	107-116	sex determining region Y	Homo sapiens	118-121
30181772-0	2018	Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis.	Tenofovir	0-29	HCC	Homo sapiens	50-53
30181772-9	2018	The cumulative probability of HCC development in TDF-contained group were significantly lower than it in non-TDF-contained group (p &lt; 0.05).	Tenofovir	49-52	HCC	Homo sapiens	30-33
30181772-9	2018	The cumulative probability of HCC development in TDF-contained group were significantly lower than it in non-TDF-contained group (p &lt; 0.05).	Tenofovir	109-112	HCC	Homo sapiens	30-33
30075765-1	2018	INTRODUCTION: Concomitant use of ledipasvir and boosted protease inhibitors (PIs) may increase the risk of tenofovir (TDF) nephrotoxicity, since both these drugs increase TDF levels.	Tenofovir	107-116	sex determining region Y	Homo sapiens	171-174
29807506-5	2018	Among biomarkers tested, kidney injury molecule 1 (Kim-1) and clusterin (CLU) clearly outperformed BUN and SCr and were the most reliable in detecting the onset and progression of tenofovir-induced tubular injury.	Tenofovir	180-189	clusterin	Canis lupus familiaris	73-76
29746295-2	2018	Most of these patients are using the combination of tenofovir (TDF), lamivudine (3TC) and efavirenz (EFV).	Tenofovir	52-61	sex determining region Y	Homo sapiens	63-66
29602711-2	2018	However, little is known regarding the renal safety of tenofovir (TDF) co-administered with LPV/r.	Tenofovir	55-64	sex determining region Y	Homo sapiens	66-69
29649076-9	2018	Coadministration with P-gp/BCRP inhibitors such as cobicistat or PI-based regimens (ATV + RTV, LPV/r, or DRV + RTV) resulted in a range of 6%-183% increases in TAF and 105%-316% increases in TFV exposure, whereas coadministration with a P-gp inducer, efavirenz, resulted in a 15%-24% decrease in TAF and TFV exposure.	Tenofovir	191-194	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
29649076-9	2018	Coadministration with P-gp/BCRP inhibitors such as cobicistat or PI-based regimens (ATV + RTV, LPV/r, or DRV + RTV) resulted in a range of 6%-183% increases in TAF and 105%-316% increases in TFV exposure, whereas coadministration with a P-gp inducer, efavirenz, resulted in a 15%-24% decrease in TAF and TFV exposure.	Tenofovir	191-194	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	27-31
29649076-9	2018	Coadministration with P-gp/BCRP inhibitors such as cobicistat or PI-based regimens (ATV + RTV, LPV/r, or DRV + RTV) resulted in a range of 6%-183% increases in TAF and 105%-316% increases in TFV exposure, whereas coadministration with a P-gp inducer, efavirenz, resulted in a 15%-24% decrease in TAF and TFV exposure.	Tenofovir	304-307	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
29649076-9	2018	Coadministration with P-gp/BCRP inhibitors such as cobicistat or PI-based regimens (ATV + RTV, LPV/r, or DRV + RTV) resulted in a range of 6%-183% increases in TAF and 105%-316% increases in TFV exposure, whereas coadministration with a P-gp inducer, efavirenz, resulted in a 15%-24% decrease in TAF and TFV exposure.	Tenofovir	304-307	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	27-31
30101439-0	2018	FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir.	Tenofovir	132-141	benign adult familial myoclonic epilepsy 1	Homo sapiens	0-4
29720497-4	2018	In OAT1 stably transfected human embryonic kidney 293 cells, the Km value of tenofovir for human OAT1 (hOAT1) was significantly lower than for OAT1 orthologs from common preclinical animals, including cynomolgus monkey, mouse, rat, and dog.	Tenofovir	77-86	solute carrier family 22 member 6	Homo sapiens	3-7
29720497-4	2018	In OAT1 stably transfected human embryonic kidney 293 cells, the Km value of tenofovir for human OAT1 (hOAT1) was significantly lower than for OAT1 orthologs from common preclinical animals, including cynomolgus monkey, mouse, rat, and dog.	Tenofovir	77-86	solute carrier family 22 member 6	Homo sapiens	97-101
29720497-4	2018	In OAT1 stably transfected human embryonic kidney 293 cells, the Km value of tenofovir for human OAT1 (hOAT1) was significantly lower than for OAT1 orthologs from common preclinical animals, including cynomolgus monkey, mouse, rat, and dog.	Tenofovir	77-86	solute carrier family 22 member 6	Homo sapiens	103-108
29720497-4	2018	In OAT1 stably transfected human embryonic kidney 293 cells, the Km value of tenofovir for human OAT1 (hOAT1) was significantly lower than for OAT1 orthologs from common preclinical animals, including cynomolgus monkey, mouse, rat, and dog.	Tenofovir	77-86	solute carrier family 22 member 6	Homo sapiens	97-101
29455571-4	2018	We previously demonstrated that adenylate kinase 2, pyruvate kinase, muscle and pyruvate kinase, liver and red blood cell phosphorylate TFV in peripheral blood mononuclear cells (PBMC).	Tenofovir	136-139	adenylate kinase 2	Homo sapiens	32-50
29940869-15	2018	CD8+ cells increased in the tenofovir-reducing group despite a viro-immunological response.	Tenofovir	28-37	CD8a molecule	Homo sapiens	0-3
29743623-5	2018	In two animals, the GCPII inhibitor PMPA (23 mg/kg BW) was added to the tracer solution.	Tenofovir	36-40	folate hydrolase 1	Rattus norvegicus	20-25
28961682-0	2018	Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.	Tenofovir	24-53	TATA-box binding protein associated factor 8	Homo sapiens	78-81
29850480-0	2018	Tenofovir-Based Highly Active Antiretroviral Therapy Is Associated with Superior CD4 T Cells Repopulation Compared to Zidovudine-Based HAART in HIV 1 Infected Adults.	Tenofovir	0-9	CD4 molecule	Homo sapiens	81-84
29850480-8	2018	After five months of the HAART, the tenofovir cohort recorded higher CD4 T cell count change from baseline compared to the zidovudine cohort (p &lt; 0.0001).	Tenofovir	36-45	CD4 molecule	Homo sapiens	69-72
29433097-1	2018	BACKGROUND: The nucleotide reverse transcriptase inhibitor tenofovir (TFV) is widely administered in a disoproxil prodrug form (tenofovir disoproxil fumarate, TDF) for HIV management and prevention.	Tenofovir	59-68	sex determining region Y	Homo sapiens	159-162
29433097-1	2018	BACKGROUND: The nucleotide reverse transcriptase inhibitor tenofovir (TFV) is widely administered in a disoproxil prodrug form (tenofovir disoproxil fumarate, TDF) for HIV management and prevention.	Tenofovir	70-73	sex determining region Y	Homo sapiens	159-162
29641561-2	2018	Adenylate kinase 2 (AK2) has been previously demonstrated to phosphorylate tenofovir to tenofovir-monophosphate, while creatine kinase, muscle (CKM), pyruvate kinase, muscle (PKM) and pyruvate kinase, liver and red blood cell (PKLR) each have been found to phosphorylate tenofovir-monophosphate to the pharmacologically active tenofovir-diphosphate.	Tenofovir	75-84	adenylate kinase 2	Homo sapiens	0-18
29641561-2	2018	Adenylate kinase 2 (AK2) has been previously demonstrated to phosphorylate tenofovir to tenofovir-monophosphate, while creatine kinase, muscle (CKM), pyruvate kinase, muscle (PKM) and pyruvate kinase, liver and red blood cell (PKLR) each have been found to phosphorylate tenofovir-monophosphate to the pharmacologically active tenofovir-diphosphate.	Tenofovir	75-84	adenylate kinase 2	Homo sapiens	20-23
29641561-5	2018	To functionally test these predictions, AK2 and AK2 variants were expressed in and purified from E. coli, followed by investigation of their activities towards tenofovir.	Tenofovir	160-169	adenylate kinase 2	Homo sapiens	40-43
29641561-5	2018	To functionally test these predictions, AK2 and AK2 variants were expressed in and purified from E. coli, followed by investigation of their activities towards tenofovir.	Tenofovir	160-169	adenylate kinase 2	Homo sapiens	48-51
29641561-6	2018	Interestingly, we found that purified AK2 had the ability to phosphorylate tenofovir-monophosphate to tenofovir-diphosphate in addition to phosphorylating tenofovir to tenofovir-monophosphate.	Tenofovir	75-84	adenylate kinase 2	Homo sapiens	38-41
29368537-1	2018	We previously demonstrated superior efficacy and safety advantages in HIV-infected, virologically suppressed adults switched to a regimen containing tenofovir alafenamide (TAF) as compared with those remaining on a tenofovir disoproxil fumarate (TDF) regimen through week 48.	Tenofovir	246-249	TATA-box binding protein associated factor 8	Homo sapiens	172-175
29938701-1	2018	The introduction of tenofovir (TFV) alafenamide (TAF) into clinical practice will be a further revolution in antiretroviral therapy.	Tenofovir	31-34	TATA-box binding protein associated factor 8	Homo sapiens	49-52
27789659-6	2018	RESULTS: Higher serum IFN-lambda3 levels were detected in the patients treated with nucleotide analogues (adefovir or tenofovir) compared with those treated with nucleoside analogues (lamivudine or entecavir).	Tenofovir	118-127	interferon lambda 3	Homo sapiens	22-33
30260797-0	2018	Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.	Tenofovir	0-29	parathyroid hormone	Homo sapiens	83-102
29136775-0	2018	High parathyroid hormone concentration in tenofovir-treated patients are due to inhibition of calcium-sensing receptor activity.	Tenofovir	42-51	parathyroid hormone	Homo sapiens	5-24
29136775-0	2018	High parathyroid hormone concentration in tenofovir-treated patients are due to inhibition of calcium-sensing receptor activity.	Tenofovir	42-51	calcium sensing receptor	Homo sapiens	94-118
29136775-2	2018	High serum parathyroid hormone (PTH) concentration in patients on antiretroviral treatment containing tenofovir disoproxil fumarate (TDF) has been reported.	Tenofovir	102-131	parathyroid hormone	Homo sapiens	11-30
29136775-2	2018	High serum parathyroid hormone (PTH) concentration in patients on antiretroviral treatment containing tenofovir disoproxil fumarate (TDF) has been reported.	Tenofovir	133-136	parathyroid hormone	Homo sapiens	11-30
29424790-10	2018	Vaginal tissue TFV concentrations were significantly positively correlated with vaginal epithelial thickness, whereas vaginal tissue TFV-DP concentrations were positively correlated with density of vaginal CD4 and CD8 immune cells.	Tenofovir	133-136	CD4 molecule	Homo sapiens	206-209
29424790-10	2018	Vaginal tissue TFV concentrations were significantly positively correlated with vaginal epithelial thickness, whereas vaginal tissue TFV-DP concentrations were positively correlated with density of vaginal CD4 and CD8 immune cells.	Tenofovir	133-136	CD8a molecule	Homo sapiens	214-217
29641561-7	2018	Further, four of the six AK2 variants predicted to result in a loss or decrease of enzyme function exhibited a &gt;=30% decrease in activity towards tenofovir in our in vitro assays.	Tenofovir	149-158	adenylate kinase 2	Homo sapiens	25-28
29707599-8	2018	Conclusions: Our study found a low prevalence of renal impairment among PLWHIV despite high usage of tenofovir and its association with age, hypertension, low CD4 count, and advanced WHO stage.	Tenofovir	101-110	CD4 molecule	Homo sapiens	159-162
29938701-1	2018	The introduction of tenofovir (TFV) alafenamide (TAF) into clinical practice will be a further revolution in antiretroviral therapy.	Tenofovir	20-29	TATA-box binding protein associated factor 8	Homo sapiens	49-52
29309806-8	2018	In conclusion, altered megalin/cubilin expression represents a distinctive feature in tenofovir-induced tubulopathy, and its severity is correlated with urine retinol binding protein loss and is associated with a poor renal prognosis.	Tenofovir	86-95	LDL receptor related protein 2	Homo sapiens	23-30
29309806-8	2018	In conclusion, altered megalin/cubilin expression represents a distinctive feature in tenofovir-induced tubulopathy, and its severity is correlated with urine retinol binding protein loss and is associated with a poor renal prognosis.	Tenofovir	86-95	cubilin	Homo sapiens	31-38
29216208-7	2017	RESULTS: Overall we showed that patients receiving tenofovir (TDF) with a ritonavir boosted protease inhibitor (rbPI) exhibited a higher risk of CKD compared with patients who received TDF with a non-nucleosidic reverse transcriptase inhibitor (NNRTI).	Tenofovir	51-60	sex determining region Y	Homo sapiens	62-65
28902074-0	2017	Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.	Tenofovir	7-16	sex determining region Y	Homo sapiens	48-51
29145453-0	2017	The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin.	Tenofovir	19-28	pannexin 1	Mus musculus	46-56
29145453-5	2017	We tested the hypothesis that tenofovir has direct antifibrotic effects in vivo by interfering with adenosine pathways of fibrosis using two distinct models of adenosine and A2AR-mediated fibrosis.	Tenofovir	30-39	adenosine A2a receptor	Mus musculus	174-178
29029138-8	2017	For both ATV and TFV, FGT:plasma was significantly lower in participant visits with high- and low-diversity mCT groups (all P &lt; .02).	Tenofovir	17-20	microcephaly, primary autosomal recessive 1	Mus musculus	108-111
29061086-4	2017	RESULTS: The estimated glomerular filtration rate calculated by the Cockcroft and Gault equation, concomitant use of lopinavir/ritonavir and ABCC4 3463A&gt;G polymorphism were associated with tenofovir apparent oral clearance (CL/F).	Tenofovir	192-201	ATP binding cassette subfamily C member 4	Homo sapiens	141-146
28335588-0	2017	Recovery of NK(CD56+CD3-) Cells after One Year of Tenofovir Therapy for Chronic Hepatitis B Infection.	Tenofovir	50-59	neural cell adhesion molecule 1	Homo sapiens	15-19
28898281-0	2017	Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.	Tenofovir	40-69	keratin 88, pseudogene	Homo sapiens	129-132
28648081-0	2017	In Silico and in Vitro Screening for P-Glycoprotein Interaction with Tenofovir, Darunavir, and Dapivirine: An Antiretroviral Drug Combination for Topical Prevention of Colorectal HIV Transmission.	Tenofovir	69-78	ATP binding cassette subfamily B member 1	Homo sapiens	37-51
28392234-2	2017	We herein report two cases of HBV-infected patients with insufficient viral suppression, despite dual antiviral therapy with entecavir (ETV) and tenofovir (TDF).	Tenofovir	145-154	sex determining region Y	Homo sapiens	156-159
28260391-12	2017	Syndecan-1 remained independently associated with serum creatinine and reduced GFR even after we forced variables related with HIV infection status, tenofovir use, treatment time, dyslipidemia, and others in a multivariate analysis.	Tenofovir	149-158	syndecan 1	Homo sapiens	0-10
28797967-5	2017	PLGA and PLCL EFs, incorporating the antiretroviral, tenofovir disoproxil fumarate (TDF), exhibited sustained-release for up to 4 weeks, and provided complete in vitro protection against HSV-2 and HIV-1 for 24h and 1 wk, respectively, based on the doses tested.	Tenofovir	53-82	phospholipase C like 1 (inactive)	Homo sapiens	9-13
28830144-1	2017	The purpose of this study was to engineer a model anti-HIV microbicide (tenofovir) drug delivery system targeting HIV-1 envelope glycoprotein gp120 (HIV-1 g120) for the prevention of HIV sexual transmission.	Tenofovir	72-81	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	142-147
28403692-9	2017	Our hypothesis is that the hypokalemia could be a result of a tenofovir-mediated tubular damage triggered by the increased vinblastine serum levels secondary to a CYP3A4 inhibition by ritonavir.	Tenofovir	62-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	163-169
28779108-6	2017	Moreover, the pmpA/crp double mutant exhibited reduced kidney adhesion comparable to that of the pmpA mutant, and mouse kidney colonization by the pmpA mutant was significantly attenuated.	Tenofovir	14-18	C-reactive protein, pentraxin-related	Mus musculus	19-22
28779108-6	2017	Moreover, the pmpA/crp double mutant exhibited reduced kidney adhesion comparable to that of the pmpA mutant, and mouse kidney colonization by the pmpA mutant was significantly attenuated.	Tenofovir	97-101	C-reactive protein, pentraxin-related	Mus musculus	19-22
28335588-3	2017	In this study, we investigated the phenotypic changes of NK(CD56+CD3-) cells in terms of their functional markers (CD16, NKG2A, NKG2D) during tenofovir therapy in CHB.	Tenofovir	142-151	neural cell adhesion molecule 1	Rattus norvegicus	60-64
28335588-4	2017	The frequency of NK(CD56+CD3-) cells in CHB patients was significantly increased after 12 months of tenofovir therapy when compared with baseline.	Tenofovir	100-109	neural cell adhesion molecule 1	Homo sapiens	20-24
28335588-5	2017	The expression levels of CD16+/CD56+CD3- and NKG2A+/CD56+CD3- cells were also affected by tenofovir treatment.	Tenofovir	90-99	Fc gamma receptor IIIa	Homo sapiens	25-29
28335588-5	2017	The expression levels of CD16+/CD56+CD3- and NKG2A+/CD56+CD3- cells were also affected by tenofovir treatment.	Tenofovir	90-99	neural cell adhesion molecule 1	Homo sapiens	31-35
28416547-1	2017	Tenofovir disoproxil fumarate (TDF), a prodrug of tenofovir, has oral bioavailability (25%) limited by intestinal transport (P-glycoprotein), and intestinal degradation (carboxylesterase).	Tenofovir	0-29	ATP binding cassette subfamily B member 1	Homo sapiens	125-139
28416547-1	2017	Tenofovir disoproxil fumarate (TDF), a prodrug of tenofovir, has oral bioavailability (25%) limited by intestinal transport (P-glycoprotein), and intestinal degradation (carboxylesterase).	Tenofovir	31-34	ATP binding cassette subfamily B member 1	Homo sapiens	125-139
28335588-5	2017	The expression levels of CD16+/CD56+CD3- and NKG2A+/CD56+CD3- cells were also affected by tenofovir treatment.	Tenofovir	90-99	killer cell lectin like receptor C1	Homo sapiens	45-50
28335588-5	2017	The expression levels of CD16+/CD56+CD3- and NKG2A+/CD56+CD3- cells were also affected by tenofovir treatment.	Tenofovir	90-99	neural cell adhesion molecule 1	Homo sapiens	52-56
28583112-1	2017	BACKGROUND: Tenofovir (TDF) is one of the most widely used antiretroviral drug.	Tenofovir	12-21	sex determining region Y	Homo sapiens	23-26
27861242-9	2017	CONCLUSIONS: Our results confirm that HIV+ older adults have higher cystatin C than HIV- older adults and further identify that cystatin C may be associated with NCI in this population, particularly if they use tenofovir.	Tenofovir	211-220	cystatin C	Homo sapiens	128-138
28397817-6	2017	Analysis of the proteins in TCA cycle showed succinate dehydrogenase subunit B (SDHB) was nearly depleted in glucose oxidative phosphorylation pathway however certain enzymes in the glycolysis and glycogen synthesis pathway had elevated expression in TFV and ADV-treated HK-2 cells.	Tenofovir	251-254	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	45-78
28397817-6	2017	Analysis of the proteins in TCA cycle showed succinate dehydrogenase subunit B (SDHB) was nearly depleted in glucose oxidative phosphorylation pathway however certain enzymes in the glycolysis and glycogen synthesis pathway had elevated expression in TFV and ADV-treated HK-2 cells.	Tenofovir	251-254	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	80-84
28257038-0	2017	Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity.	Tenofovir	57-66	hexokinase 2	Homo sapiens	17-21
28373196-6	2017	TRK-560 significantly suppressed the production of intracellular HBV replication intermediates and extracellular HBV surface antigen (HBsAg) (P &lt; 0.001 and P &lt; 0.001, respectively), and the antiviral effects of TRK-560 were enhanced in combination with nucleot(s)ide analogues, such as entecavir and tenofovir disoproxil fumarate.	Tenofovir	306-335	neurotrophic receptor tyrosine kinase 1	Homo sapiens	0-3
28397817-0	2017	Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity.	Tenofovir	0-9	TNF receptor associated protein 1	Homo sapiens	61-66
28397817-0	2017	Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity.	Tenofovir	0-9	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	71-104
28167562-0	2017	Tenofovir Disoproxil Fumarate Is a New Substrate of ATP-Binding Cassette Subfamily C Member 11.	Tenofovir	0-29	ATP binding cassette subfamily C member 11	Homo sapiens	52-94
28167562-3	2017	In this study, the ATP-binding cassette subfamily C member 11 (ABCC11; multidrug resistance protein 8 [MRP8]) transporter, which is abundant in proximal tubular cells, was demonstrated to act as an efflux transporter of tenofovir.	Tenofovir	220-229	ATP binding cassette subfamily C member 11	Homo sapiens	19-61
28167562-3	2017	In this study, the ATP-binding cassette subfamily C member 11 (ABCC11; multidrug resistance protein 8 [MRP8]) transporter, which is abundant in proximal tubular cells, was demonstrated to act as an efflux transporter of tenofovir.	Tenofovir	220-229	ATP binding cassette subfamily C member 11	Homo sapiens	63-69
28167562-3	2017	In this study, the ATP-binding cassette subfamily C member 11 (ABCC11; multidrug resistance protein 8 [MRP8]) transporter, which is abundant in proximal tubular cells, was demonstrated to act as an efflux transporter of tenofovir.	Tenofovir	220-229	ATP binding cassette subfamily C member 11	Homo sapiens	71-101
28167562-3	2017	In this study, the ATP-binding cassette subfamily C member 11 (ABCC11; multidrug resistance protein 8 [MRP8]) transporter, which is abundant in proximal tubular cells, was demonstrated to act as an efflux transporter of tenofovir.	Tenofovir	220-229	ATP binding cassette subfamily C member 11	Homo sapiens	103-107
28167562-9	2017	Transport assays also showed that the intracellular accumulation of tenofovir in MRP8-overexpressing cells was 55 times lower than that in parental cells and was partly reversed by MK-571.	Tenofovir	68-77	ATP binding cassette subfamily C member 11	Homo sapiens	81-85
28167562-10	2017	Similarly, an "inside-out" vesicular uptake assay, using Sf9 inverted membrane vesicles to allow measuring of accumulation of the substrates into the vesicles, demonstrated a higher intravesicular concentration of tenofovir in MRP8-overexpressing vesicles than in Sf9 insect control vesicles.	Tenofovir	214-223	ATP binding cassette subfamily C member 11	Homo sapiens	227-231
28167562-12	2017	In conclusion, tenofovir is a new substrate of the MRP8 transporter.	Tenofovir	15-24	ATP binding cassette subfamily C member 11	Homo sapiens	51-55
28233741-0	2017	Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism.	Tenofovir	26-35	fibroblast growth factor 23	Homo sapiens	103-108
28257038-10	2017	Caspase 3 and 9 cleavage was induced by TFV compared to vehicle at 72 h. These studies show that HK-2 cells are a sensitive model for TFV cytotoxicity and suggest that mitochondrial stress and apoptosis occur in HK-2 cells treated with TFV.	Tenofovir	40-43	hexokinase 2	Homo sapiens	97-101
28257038-10	2017	Caspase 3 and 9 cleavage was induced by TFV compared to vehicle at 72 h. These studies show that HK-2 cells are a sensitive model for TFV cytotoxicity and suggest that mitochondrial stress and apoptosis occur in HK-2 cells treated with TFV.	Tenofovir	40-43	hexokinase 2	Homo sapiens	212-216
28257038-10	2017	Caspase 3 and 9 cleavage was induced by TFV compared to vehicle at 72 h. These studies show that HK-2 cells are a sensitive model for TFV cytotoxicity and suggest that mitochondrial stress and apoptosis occur in HK-2 cells treated with TFV.	Tenofovir	134-137	hexokinase 2	Homo sapiens	97-101
28257038-10	2017	Caspase 3 and 9 cleavage was induced by TFV compared to vehicle at 72 h. These studies show that HK-2 cells are a sensitive model for TFV cytotoxicity and suggest that mitochondrial stress and apoptosis occur in HK-2 cells treated with TFV.	Tenofovir	134-137	hexokinase 2	Homo sapiens	97-101
28288232-1	2017	Tenofovir (TDF) is an inhibitor of reverse transcriptase nucleotide analogue, although it has good tolerability and high anti-retroviral activity, its effect on the kidney has been a concern.	Tenofovir	0-9	sex determining region Y	Homo sapiens	11-14
27809359-2	2017	We aimed to evaluate renal toxicity in HIV/HBV and HBV mono-infected patients on long-term therapy with tenofovir (TDF) and to explore the association of polymorphisms in ATP-binding cassette (ABCC)2, ABCC4, ABCC10 with the development of renal dysfunction.	Tenofovir	104-113	sex determining region Y	Homo sapiens	115-118
27965153-0	2017	Covalent inhibition of carboxylesterase-2 by sofosbuvir and its effect on the hydrolytic activation of tenofovir disoproxil.	Tenofovir	103-123	carboxylesterase 2	Homo sapiens	23-41
28272219-9	2017	The decline of ALT could be used to predict HBeAg seroconversion for CHB patients during TDF treatment.	Tenofovir	89-92	glutamic pyruvic transaminase, soluble	Mus musculus	15-18
27862762-1	2017	OBJECTIVE: Using data from four public sector clinics in South Africa, we sought to investigate provider- and patient-level outcomes, to understand how the 2012 tenofovir stock shortage affected the HIV care and monitoring of ART patients.	Tenofovir	161-170	artemin	Homo sapiens	226-229
28638661-1	2017	BACKGROUND: Although tenofovir (TDF)/emtricitabine (FTC)/efavirenz (EFV) and zidovudine (ZDV)/lamivudine (3TC)/efavirenz (EFV) are used as preferred first line regimen, their head-to-head comparison in terms of their efficacy and tolerability was limited.	Tenofovir	21-30	sex determining region Y	Homo sapiens	32-35
27898591-1	2017	OBJECTIVE: Tenofovir (TDF) affects bone health and is widely used in pregnancy but data are limited on the effects of TDF exposure in utero.	Tenofovir	11-20	sex determining region Y	Homo sapiens	22-25
28638661-10	2017	We found superior viral load suppression among tenofovir (TDF) arm compared to zidovudine (ZDV) arm.	Tenofovir	47-56	sex determining region Y	Homo sapiens	58-61
27553871-1	2017	BACKGROUND: Renal toxicity is a common side effect during tenofovir (TDF)-use in HIV-infected, but not necessarily HBV-infected, patients.	Tenofovir	58-67	sex determining region Y	Homo sapiens	69-72
28076335-1	2017	BACKGROUND: Tenofovir alafenamide (TAF) is a novel prodrug of the nucleotide reverse transcriptase inhibitor tenofovir (TFV) that loads lymphocytes with TFV-diphosphate more efficiently than tenofovir disoproxil fumarate (TDF).	Tenofovir	109-118	TATA-box binding protein associated factor 8	Homo sapiens	35-38
28076335-1	2017	BACKGROUND: Tenofovir alafenamide (TAF) is a novel prodrug of the nucleotide reverse transcriptase inhibitor tenofovir (TFV) that loads lymphocytes with TFV-diphosphate more efficiently than tenofovir disoproxil fumarate (TDF).	Tenofovir	109-118	sex determining region Y	Homo sapiens	222-225
28076335-1	2017	BACKGROUND: Tenofovir alafenamide (TAF) is a novel prodrug of the nucleotide reverse transcriptase inhibitor tenofovir (TFV) that loads lymphocytes with TFV-diphosphate more efficiently than tenofovir disoproxil fumarate (TDF).	Tenofovir	120-123	TATA-box binding protein associated factor 8	Homo sapiens	35-38
28076335-1	2017	BACKGROUND: Tenofovir alafenamide (TAF) is a novel prodrug of the nucleotide reverse transcriptase inhibitor tenofovir (TFV) that loads lymphocytes with TFV-diphosphate more efficiently than tenofovir disoproxil fumarate (TDF).	Tenofovir	120-123	sex determining region Y	Homo sapiens	222-225
28076335-1	2017	BACKGROUND: Tenofovir alafenamide (TAF) is a novel prodrug of the nucleotide reverse transcriptase inhibitor tenofovir (TFV) that loads lymphocytes with TFV-diphosphate more efficiently than tenofovir disoproxil fumarate (TDF).	Tenofovir	191-220	TATA-box binding protein associated factor 8	Homo sapiens	35-38
29270324-1	2017	Tenofovir disoproxil fumarate- (TDF-) related nephropathy is known to be a long-term complication of this drug, more commonly observed in HIV-infected patients, but occurring also in hepatitis B.	Tenofovir	0-29	sex determining region Y	Homo sapiens	32-35
27552152-2	2017	Median inhibition of telomerase activity by tenofovir at 0.5 and 1 muM was 29% [Interquartile range (IQR) 29%-34%, P = 0.042] and 28% (IQR 28%-41%, P = 0.042), respectively.	Tenofovir	44-53	latexin	Homo sapiens	67-70
27809711-1	2016	BACKGROUND: Tenofovir disoproxil fumarate (TDF) is a component of many combinations of antiretroviral treatment (ART) regimens.	Tenofovir	12-41	sex determining region Y	Homo sapiens	43-46
27903949-4	2017	The authors report 2 cases in which a possible drug-herb interaction may have led to virological breakthrough in patients who were maintained on the same regimen for many years, including lamivudine (3TC)/zidovudine (ZDV)/efavirenz (EFV) and emtricitabine (FTC)/tenofovir (TDF)/EFV, respectively.	Tenofovir	262-271	sex determining region Y	Homo sapiens	273-276
26781865-1	2016	Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial.	Tenofovir	36-45	prolyl endopeptidase	Homo sapiens	58-62
26781865-2	2016	Differences between unannounced and announced tenofovir levels as measures of PrEP adherence are not well understood.	Tenofovir	46-55	prolyl endopeptidase	Homo sapiens	78-82
27846073-1	2016	The World Health Organization has issued an early release revision to its antiretroviral guidelines in which PrEP (pre-exposure prophylaxis in the form of daily oral, fixed dose combination tenofovir disoproxil fumarate/emtricitabine) is recommended as a prevention option to all people at substantial risk of acquiring HIV.	Tenofovir	190-219	prolyl endopeptidase	Homo sapiens	109-113
28087953-7	2016	From multivariate analysis, the odds of developing &gt;25% decrease in eGFR with tenofovir-containing regimen was three times higher for patients with baseline moderate renal impairment (HR 3.19; 95% CI, 1.43-7.12; p=0.005) and 14 times higher for patients with baseline severe renal impairment (HR 14.2; 95% CI, 11.20-170.7; p=0.036) as compared to those without pre-existing renal insufficiency.	Tenofovir	81-90	epidermal growth factor receptor	Homo sapiens	71-75
27806064-1	2016	BACKGROUND: Pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) is a novel HIV prevention strategy.	Tenofovir	67-96	sex determining region Y	Homo sapiens	102-105
26440731-5	2016	At multivariate analysis estimated creatinine clearance, protease inhibitors co-administration and SLC28A2 CT/TT genotypes were independently associated with plasma tenofovir exposure; ABCC10 GA/AA genotypes and protease inhibitor co-administration were independently associated with the urinary to plasma tenofovir ratio.	Tenofovir	165-174	solute carrier family 28 member 2	Homo sapiens	99-106
26440731-5	2016	At multivariate analysis estimated creatinine clearance, protease inhibitors co-administration and SLC28A2 CT/TT genotypes were independently associated with plasma tenofovir exposure; ABCC10 GA/AA genotypes and protease inhibitor co-administration were independently associated with the urinary to plasma tenofovir ratio.	Tenofovir	306-315	solute carrier family 28 member 2	Homo sapiens	99-106
27067321-1	2016	Preexposure prophylaxis (PrEP) against HIV using oral regimens based on the nucleoside reverse transcriptase inhibitor tenofovir disoproxil fumarate (TDF) has been effective to various degrees in multiple clinical trials, and the CCR5 receptor antagonist maraviroc (MVC) holds potential for complementary efficacy.	Tenofovir	150-153	C-C motif chemokine receptor 5	Homo sapiens	230-234
27054757-2	2016	Herein, we report one case of abnormal liver function tests occurring in a young HLA B*5701-negative woman on a stable nevirapine-based regimen with no history of liver problems or alcohol abuse after switching to abacavir from tenofovir.	Tenofovir	228-237	major histocompatibility complex, class I, B	Homo sapiens	81-86
27704026-0	2016	Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s.	Tenofovir	90-99	insulin	Homo sapiens	11-18
30730651-11	2016	Tenofovir mainly causes renal disorders (tubulopathy, Fanconi syn- drome), bone disorders (osteoporosis, fractures, osteomalacia) and gastrointestinal disorders.	Tenofovir	0-9	synemin	Homo sapiens	62-65
26689970-1	2016	We describe HIV-1 evolutionary dynamics in the 4 participants from the TDF2-PrEP trial who became HIV-1 infected while prescribed emtricitabine and tenofovir disoproxil fumarate (FTC/TDF).	Tenofovir	148-177	sex determining region Y	Homo sapiens	71-74
27780535-2	2016	It has recently been shown that fetal exposure of nucleoside reverse transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate (TDF) and abacavir is decreased by placental ABC transporters p-glycoprotein (ABCB1) and BCRP (ABCG2).	Tenofovir	102-131	ATP binding cassette subfamily B member 1	Homo sapiens	194-208
27780535-2	2016	It has recently been shown that fetal exposure of nucleoside reverse transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate (TDF) and abacavir is decreased by placental ABC transporters p-glycoprotein (ABCB1) and BCRP (ABCG2).	Tenofovir	102-131	ATP binding cassette subfamily B member 1	Homo sapiens	210-215
27780535-2	2016	It has recently been shown that fetal exposure of nucleoside reverse transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate (TDF) and abacavir is decreased by placental ABC transporters p-glycoprotein (ABCB1) and BCRP (ABCG2).	Tenofovir	102-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	221-225
27780535-2	2016	It has recently been shown that fetal exposure of nucleoside reverse transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate (TDF) and abacavir is decreased by placental ABC transporters p-glycoprotein (ABCB1) and BCRP (ABCG2).	Tenofovir	102-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	227-232
27780535-2	2016	It has recently been shown that fetal exposure of nucleoside reverse transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate (TDF) and abacavir is decreased by placental ABC transporters p-glycoprotein (ABCB1) and BCRP (ABCG2).	Tenofovir	133-136	ATP binding cassette subfamily B member 1	Homo sapiens	194-208
27780535-2	2016	It has recently been shown that fetal exposure of nucleoside reverse transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate (TDF) and abacavir is decreased by placental ABC transporters p-glycoprotein (ABCB1) and BCRP (ABCG2).	Tenofovir	133-136	ATP binding cassette subfamily B member 1	Homo sapiens	210-215
27780535-2	2016	It has recently been shown that fetal exposure of nucleoside reverse transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate (TDF) and abacavir is decreased by placental ABC transporters p-glycoprotein (ABCB1) and BCRP (ABCG2).	Tenofovir	133-136	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	221-225
27780535-2	2016	It has recently been shown that fetal exposure of nucleoside reverse transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate (TDF) and abacavir is decreased by placental ABC transporters p-glycoprotein (ABCB1) and BCRP (ABCG2).	Tenofovir	133-136	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	227-232
27646953-5	2016	CASES PRESENTATION: A first case was a 33 years-old female newly diagnosed HIV patient with CD4 count of 4 cells/muL (0 %), normal complete blood count, liver and renal function tests was started on co-formulated tenofovir/emtricitabine/efavirenz and prophylactic cotrimoxazole.	Tenofovir	213-222	CD4 molecule	Homo sapiens	92-95
27788718-11	2016	Conclusion: Serum beta2-microglobulin, retinol binding protein, and cystatin C are more sensitive than eGFR in the monitoring of early renal dysfunction during the anti-HBV therapy with tenofovir or entecavir alone.	Tenofovir	186-195	cystatin C	Homo sapiens	68-78
26643107-5	2016	Our study investigated the differential regulation of miR-124a by nucleoside reverse transcriptase inhibitors (NRTIs): Zidovudine (AZT), Stavudine (d4T) and Tenofovir (TFV); at 24 h and 120 h treatments in HepG2 cells.	Tenofovir	157-166	microRNA 124-1	Homo sapiens	54-62
26643107-5	2016	Our study investigated the differential regulation of miR-124a by nucleoside reverse transcriptase inhibitors (NRTIs): Zidovudine (AZT), Stavudine (d4T) and Tenofovir (TFV); at 24 h and 120 h treatments in HepG2 cells.	Tenofovir	168-171	microRNA 124-1	Homo sapiens	54-62
27560968-2	2016	However, concerns for tenofovir disoproxil fumarate (TDF)-related nephrotoxicity persist with increased use.	Tenofovir	22-51	sex determining region Y	Homo sapiens	53-56
27124896-0	2016	Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV.	Tenofovir	78-87	GC vitamin D binding protein	Homo sapiens	25-50
27124896-1	2016	OBJECTIVE: To examine longitudinal change in vitamin D binding protein (DBP) levels during the first year after initiation of tenofovir disoproxil fumarate (TDF)/lamivudine/efavirenz and compare these findings with concurrent changes in markers of skeletal metabolism.	Tenofovir	126-155	GC vitamin D binding protein	Homo sapiens	45-70
27124896-1	2016	OBJECTIVE: To examine longitudinal change in vitamin D binding protein (DBP) levels during the first year after initiation of tenofovir disoproxil fumarate (TDF)/lamivudine/efavirenz and compare these findings with concurrent changes in markers of skeletal metabolism.	Tenofovir	126-155	D-box binding PAR bZIP transcription factor	Homo sapiens	72-75
27124896-1	2016	OBJECTIVE: To examine longitudinal change in vitamin D binding protein (DBP) levels during the first year after initiation of tenofovir disoproxil fumarate (TDF)/lamivudine/efavirenz and compare these findings with concurrent changes in markers of skeletal metabolism.	Tenofovir	157-160	GC vitamin D binding protein	Homo sapiens	45-70
27124896-1	2016	OBJECTIVE: To examine longitudinal change in vitamin D binding protein (DBP) levels during the first year after initiation of tenofovir disoproxil fumarate (TDF)/lamivudine/efavirenz and compare these findings with concurrent changes in markers of skeletal metabolism.	Tenofovir	157-160	D-box binding PAR bZIP transcription factor	Homo sapiens	72-75
26971407-9	2016	The combination of IL-1beta and already used therapies, i.e. IFNalpha or tenofovir, demonstrated a stronger or similar anti-HBV activity.	Tenofovir	73-82	interleukin 1 beta	Homo sapiens	19-27
26988401-3	2016	METHODS: In this prospective, observational study, we assessed outcomes of therapy with tenofovir (TDF), entecavir (ETV), and telbivudine (LdT) in 13 heart transplant recipients (HTR) with CHB.	Tenofovir	88-97	sex determining region Y	Homo sapiens	99-102
27196332-1	2016	OBJECTIVES: The objective of this analysis is to perform an indirect comparison of elvitegravir, cobicistat, emtricitabine and tenofovir DF (E/C/F/TDF) to abacavir/lamivudine and dolutegravir (ABC/3TC + DTG) by using 2 trials evaluating each of these regimens in comparison to efavirenz, emtricitabine and tenofovir DF (EFV/FTC/TDF).	Tenofovir	127-139	sex determining region Y	Homo sapiens	147-150
26307135-4	2016	Median intact FGF23 tended to increase with past use of both nonnucleoside reverse-transcriptase inhibitors and protease inhibitors, but tended to decrease with recent use of either tenofovir, efavirenz or lopinavir.	Tenofovir	182-191	fibroblast growth factor 23	Homo sapiens	14-19
27231099-7	2016	Failure in the tenofovir-only group was associated with lower CD4 values and advanced WHO stage.	Tenofovir	15-24	CD4 molecule	Homo sapiens	62-65
26636928-1	2016	OBJECTIVE: To assess if tenofovir (TFV) clearance is associated with urinary retinal-binding protein (RBP) in HIV-positive patients with normal estimated filtration rate.	Tenofovir	24-33	retinol binding protein 4	Homo sapiens	77-100
26952360-7	2016	In this review, we consider the evolution and development of tenofovir alafenamide (TAF), a novel prodrug of tenofovir which offers high antiviral efficacy at doses over ten times lower than that of tenofovir disoproxil fumarate (TDF).	Tenofovir	61-70	TATA-box binding protein associated factor 8	Homo sapiens	84-87
26952360-7	2016	In this review, we consider the evolution and development of tenofovir alafenamide (TAF), a novel prodrug of tenofovir which offers high antiviral efficacy at doses over ten times lower than that of tenofovir disoproxil fumarate (TDF).	Tenofovir	230-233	TATA-box binding protein associated factor 8	Homo sapiens	84-87
26952360-8	2016	Emerging clinical data suggest that elvitegravir, cobicistat, emtricitabine and TAF (E/C/F/TAF) as a single-tablet regimen offers highly effective viral suppression in treatment-naive and treatment-experienced patients with an improved renal and bone safety profile compared with TDF, this having been demonstrated in diverse groups including patients with existing renal impairment and adolescents.	Tenofovir	280-283	TATA-box binding protein associated factor 8	Homo sapiens	80-83
26952360-8	2016	Emerging clinical data suggest that elvitegravir, cobicistat, emtricitabine and TAF (E/C/F/TAF) as a single-tablet regimen offers highly effective viral suppression in treatment-naive and treatment-experienced patients with an improved renal and bone safety profile compared with TDF, this having been demonstrated in diverse groups including patients with existing renal impairment and adolescents.	Tenofovir	280-283	TATA-box binding protein associated factor 8	Homo sapiens	85-94
26813340-4	2016	There were significantly higher response rates to gp120 Env (P=0.03), p24 (P=0.002), and p66 (P=0.009) in plasma and GT in women assigned to tenofovir than placebo gel at multiple time points post infection.	Tenofovir	141-150	transmembrane p24 trafficking protein 2	Homo sapiens	70-73
26813340-4	2016	There were significantly higher response rates to gp120 Env (P=0.03), p24 (P=0.002), and p66 (P=0.009) in plasma and GT in women assigned to tenofovir than placebo gel at multiple time points post infection.	Tenofovir	141-150	DNA polymerase delta 3, accessory subunit	Homo sapiens	89-92
26813340-5	2016	Notably, p66 IgA titers in the GT and plasma were significantly higher in the tenofovir compared with the placebo arm (P&lt;0.05).	Tenofovir	78-87	DNA polymerase delta 3, accessory subunit	Homo sapiens	9-12
26906233-4	2016	He was receiving treatment with efavirenz, emtricitabine and tenofovir, his CD4 count was 580/mm3 and HIV viral load was undetectable.	Tenofovir	61-70	CD4 molecule	Homo sapiens	76-79
26307135-8	2016	Lower levels of intact FGF23 with recent use of tenofovir, efavirenz or lopinavir may reflect their adverse effects on bone and vitamin D metabolism relative to other drugs in their respective drug classes.	Tenofovir	48-57	fibroblast growth factor 23	Homo sapiens	23-28
26636928-1	2016	OBJECTIVE: To assess if tenofovir (TFV) clearance is associated with urinary retinal-binding protein (RBP) in HIV-positive patients with normal estimated filtration rate.	Tenofovir	24-33	retinol binding protein 4	Homo sapiens	102-105
26636928-1	2016	OBJECTIVE: To assess if tenofovir (TFV) clearance is associated with urinary retinal-binding protein (RBP) in HIV-positive patients with normal estimated filtration rate.	Tenofovir	35-38	retinol binding protein 4	Homo sapiens	77-100
26636928-1	2016	OBJECTIVE: To assess if tenofovir (TFV) clearance is associated with urinary retinal-binding protein (RBP) in HIV-positive patients with normal estimated filtration rate.	Tenofovir	35-38	retinol binding protein 4	Homo sapiens	102-105
26821801-11	2016	Functional OAT1 was directly responsible for cytotoxicity of adefovir, cidofovir, and tenofovir, while a drug interaction with zidovudine was not associated with decreased cell viability.	Tenofovir	86-95	solute carrier family 22 member 6	Homo sapiens	11-15
27032851-10	2016	Clinicians were more likely to stop tenofovir in patients with lower CrCl and CD4 count.	Tenofovir	36-45	CD4 molecule	Homo sapiens	78-81
26731175-0	2016	Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.	Tenofovir	0-9	cyclin dependent kinase inhibitor 2A	Homo sapiens	92-95
26431373-14	2016	All patients on tenofovir had normal HbA2.	Tenofovir	16-25	hemoglobin subunit alpha 2	Homo sapiens	37-41
26807589-0	2016	A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection.	Tenofovir	61-70	ATP binding cassette subfamily C member 4	Homo sapiens	36-41
26364263-1	2016	BACKGROUND: Randomised placebo-controlled trials have shown that daily oral pre-exposure prophylaxis (PrEP) with tenofovir-emtricitabine reduces the risk of HIV infection.	Tenofovir	113-122	prolyl endopeptidase	Homo sapiens	76-79
26364263-1	2016	BACKGROUND: Randomised placebo-controlled trials have shown that daily oral pre-exposure prophylaxis (PrEP) with tenofovir-emtricitabine reduces the risk of HIV infection.	Tenofovir	113-122	prolyl endopeptidase	Homo sapiens	102-106
27699068-8	2016	Independent factors for not achieving PTH objective were tenofovir (TDF) and protease inhibitors use.	Tenofovir	57-66	parathyroid hormone	Homo sapiens	38-41
26892863-1	2016	Tenofovir alafenamide (TAF), a novel prodrug of the NtRTI tenofovir (TFV), delivers TFV-diphosphate (TFV-DP) to target cells more efficiently than the current prodrug, tenofovir disoproxil fumarate (TDF), with a 90% reduction in TFV plasma exposure.	Tenofovir	69-72	TATA-box binding protein associated factor 8	Homo sapiens	23-26
26892863-1	2016	Tenofovir alafenamide (TAF), a novel prodrug of the NtRTI tenofovir (TFV), delivers TFV-diphosphate (TFV-DP) to target cells more efficiently than the current prodrug, tenofovir disoproxil fumarate (TDF), with a 90% reduction in TFV plasma exposure.	Tenofovir	69-72	sex determining region Y	Homo sapiens	199-202
26892863-1	2016	Tenofovir alafenamide (TAF), a novel prodrug of the NtRTI tenofovir (TFV), delivers TFV-diphosphate (TFV-DP) to target cells more efficiently than the current prodrug, tenofovir disoproxil fumarate (TDF), with a 90% reduction in TFV plasma exposure.	Tenofovir	168-197	TATA-box binding protein associated factor 8	Homo sapiens	23-26
26892863-1	2016	Tenofovir alafenamide (TAF), a novel prodrug of the NtRTI tenofovir (TFV), delivers TFV-diphosphate (TFV-DP) to target cells more efficiently than the current prodrug, tenofovir disoproxil fumarate (TDF), with a 90% reduction in TFV plasma exposure.	Tenofovir	84-87	TATA-box binding protein associated factor 8	Homo sapiens	23-26
26731175-0	2016	Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.	Tenofovir	0-9	cyclin dependent kinase inhibitor 2A	Homo sapiens	96-101
26531764-8	2016	CONCLUSION: In our study, naive patients starting tenofovir/emtricitabine or abacavir/lamivudine plus efavirenz showed after 48 weeks a significant and comparable decrease in serum concentrations of IL-6, TNF-alpha, ICAM-1, VCAM-1, Eselectin and P-selectin, while the mean level of hs-CRP did not change significantly in any group.	Tenofovir	50-59	interleukin 6	Homo sapiens	199-203
26055419-4	2016	The estimated glomerular filtration rate (eGFR) decreased significantly in the tenofovir group after a mean of 17 months treatment (from 92.2 to 85.6 mL/min/1.73 m(2), p &lt; 0.001), but increased in the telbivudine group after a mean of 32 months of treatment (from 86.1 to 95 mL/min/1.73 m(2), p &lt; 0.001).	Tenofovir	79-88	CD59 molecule (CD59 blood group)	Homo sapiens	153-158
26055419-4	2016	The estimated glomerular filtration rate (eGFR) decreased significantly in the tenofovir group after a mean of 17 months treatment (from 92.2 to 85.6 mL/min/1.73 m(2), p &lt; 0.001), but increased in the telbivudine group after a mean of 32 months of treatment (from 86.1 to 95 mL/min/1.73 m(2), p &lt; 0.001).	Tenofovir	79-88	CD59 molecule (CD59 blood group)	Homo sapiens	281-286
26531764-8	2016	CONCLUSION: In our study, naive patients starting tenofovir/emtricitabine or abacavir/lamivudine plus efavirenz showed after 48 weeks a significant and comparable decrease in serum concentrations of IL-6, TNF-alpha, ICAM-1, VCAM-1, Eselectin and P-selectin, while the mean level of hs-CRP did not change significantly in any group.	Tenofovir	50-59	tumor necrosis factor	Homo sapiens	205-214
26531764-8	2016	CONCLUSION: In our study, naive patients starting tenofovir/emtricitabine or abacavir/lamivudine plus efavirenz showed after 48 weeks a significant and comparable decrease in serum concentrations of IL-6, TNF-alpha, ICAM-1, VCAM-1, Eselectin and P-selectin, while the mean level of hs-CRP did not change significantly in any group.	Tenofovir	50-59	intercellular adhesion molecule 1	Homo sapiens	216-222
26531764-8	2016	CONCLUSION: In our study, naive patients starting tenofovir/emtricitabine or abacavir/lamivudine plus efavirenz showed after 48 weeks a significant and comparable decrease in serum concentrations of IL-6, TNF-alpha, ICAM-1, VCAM-1, Eselectin and P-selectin, while the mean level of hs-CRP did not change significantly in any group.	Tenofovir	50-59	vascular cell adhesion molecule 1	Homo sapiens	224-230
26531764-8	2016	CONCLUSION: In our study, naive patients starting tenofovir/emtricitabine or abacavir/lamivudine plus efavirenz showed after 48 weeks a significant and comparable decrease in serum concentrations of IL-6, TNF-alpha, ICAM-1, VCAM-1, Eselectin and P-selectin, while the mean level of hs-CRP did not change significantly in any group.	Tenofovir	50-59	selectin E	Homo sapiens	232-241
26531764-8	2016	CONCLUSION: In our study, naive patients starting tenofovir/emtricitabine or abacavir/lamivudine plus efavirenz showed after 48 weeks a significant and comparable decrease in serum concentrations of IL-6, TNF-alpha, ICAM-1, VCAM-1, Eselectin and P-selectin, while the mean level of hs-CRP did not change significantly in any group.	Tenofovir	50-59	selectin P	Homo sapiens	246-256
26727197-0	2016	Long-term administration of tenofovir or emtricitabine to pregnant rats; effect on Abcb1a, Abcb1b and Abcg2 expression in the placenta and in maternal and fetal organs.	Tenofovir	28-37	ATP binding cassette subfamily B member 1A	Rattus norvegicus	83-89
26690199-1	2015	At Week 96 of the Single-Tablet Regimen (STaR) study, more treatment-naive subjects that received rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF) developed resistance mutations compared to those treated with efavirenz (EFV)/FTC/TDF by population sequencing.	Tenofovir	124-136	sex determining region Y	Homo sapiens	146-149
26146764-1	2015	The kinetics of serum HBsAg and interferon-inducible protein 10 (IP10) levels in patients with chronic hepatitis B infection treated with tenofovir are unclear.	Tenofovir	138-147	C-X-C motif chemokine ligand 10	Homo sapiens	32-63
26146764-1	2015	The kinetics of serum HBsAg and interferon-inducible protein 10 (IP10) levels in patients with chronic hepatitis B infection treated with tenofovir are unclear.	Tenofovir	138-147	C-X-C motif chemokine ligand 10	Homo sapiens	65-69
26727197-2	2016	The aim of our study was to determine whether tenofovir or emtricitabine administered in long-term fashion affect expression of two widely described pharmacokinetic determinants, P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2), in maternal or fetal biological tissues.	Tenofovir	46-55	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	179-193
26727197-2	2016	The aim of our study was to determine whether tenofovir or emtricitabine administered in long-term fashion affect expression of two widely described pharmacokinetic determinants, P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2), in maternal or fetal biological tissues.	Tenofovir	46-55	ATP binding cassette subfamily B member 1A	Rattus norvegicus	195-200
26727197-2	2016	The aim of our study was to determine whether tenofovir or emtricitabine administered in long-term fashion affect expression of two widely described pharmacokinetic determinants, P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2), in maternal or fetal biological tissues.	Tenofovir	46-55	ATP binding cassette subfamily G member 2	Rattus norvegicus	240-245
26727197-0	2016	Long-term administration of tenofovir or emtricitabine to pregnant rats; effect on Abcb1a, Abcb1b and Abcg2 expression in the placenta and in maternal and fetal organs.	Tenofovir	28-37	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	91-97
26727197-0	2016	Long-term administration of tenofovir or emtricitabine to pregnant rats; effect on Abcb1a, Abcb1b and Abcg2 expression in the placenta and in maternal and fetal organs.	Tenofovir	28-37	ATP binding cassette subfamily G member 2	Rattus norvegicus	102-107
25856383-1	2015	BACKGROUND AND AIMS: Tenofovir (TDF)-associated renal dysfunction has been described in various studies of human immunodeficiency virus-infected patients.	Tenofovir	21-30	sex determining region Y	Homo sapiens	32-35
26559816-9	2015	Seventy-eight percent (n = 2772) of patients received a prescription for PEP, consisting of Tenofovir/Emtracitabine (TVD) + Lopinavir/Ritonavir (LPV) in 74% of cases, followed by Zidovudine/Lamivudine (CBV) + LPV (10%) and TVD + Raltegravir (RAL) (8%).	Tenofovir	92-101	prolyl endopeptidase	Homo sapiens	73-76
26598082-9	2015	After adjustment for variables with p&lt;0.2 in the univariate analysis using a Poisson regression model, tenofovir-containing regimens and a CD4 lymphocyte count below 200 cells/mm3 were significantly associated with pathological proteinuria.	Tenofovir	106-115	CD4 molecule	Homo sapiens	142-145
26395328-10	2015	Tenofovir disoproxil fumarate-based regimens are associated with a more favorable lipid profile, but with increased risk of reduced BMD and eGFR.	Tenofovir	0-29	epidermal growth factor receptor	Homo sapiens	140-144
25800974-1	2015	BACKGROUND &amp; AIMS: To evaluate the efficacy of tenofovir in chronic hepatitis B (CHB) patients with adefovir resistance (ADF-R) and suboptimal response to adefovir (ADF-S).	Tenofovir	51-60	destrin, actin depolymerizing factor	Homo sapiens	125-128
25973716-2	2015	Very limited data are available on the efficacy of tenofovir (TDF) rescue regimens in patients with multidrug resistance (MDR).	Tenofovir	51-60	sex determining region Y	Homo sapiens	62-65
26286337-1	2015	BACKGROUND: Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; Stribild( )) is a recommended integrase inhibitor-based regimen in treatment guidelines from the US Department of Health and Human Services and the British HIV Association.	Tenofovir	70-99	sex determining region Y	Homo sapiens	114-117
26347243-1	2015	INTRODUCTION: We present what we believe to be the first case in the literature of rhabdomyolysis-induced renal failure caused by a probable drug interaction between elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) and pravastatin/fenofibrate.	Tenofovir	204-233	sex determining region Y	Homo sapiens	248-251
25712973-8	2015	Women assigned to TFV gel demonstrated slower antibody avidity maturation, as determined by the Bio-Rad (P = .04) and gp120 Bio-Plex (P = .028) assays.	Tenofovir	18-21	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	Homo sapiens	100-103
25712973-8	2015	Women assigned to TFV gel demonstrated slower antibody avidity maturation, as determined by the Bio-Rad (P = .04) and gp120 Bio-Plex (P = .028) assays.	Tenofovir	18-21	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	118-123
26157126-12	2015	HIV acquisition by hCD4/R5/cT1 mice vaginally coinfected with HSV-2 could be completely prevented in almost half the mice by preexposure prophylaxis (PrEP) with a novel gel containing tenofovir disoproxil fumarate (TDF), the tenofovir prodrug, but not with the tenofovir microbicide gel utilized in CAPRISA-004, VOICE, and FACTS-001 clinical trials.	Tenofovir	184-213	CD4 molecule	Homo sapiens	19-23
26157126-12	2015	HIV acquisition by hCD4/R5/cT1 mice vaginally coinfected with HSV-2 could be completely prevented in almost half the mice by preexposure prophylaxis (PrEP) with a novel gel containing tenofovir disoproxil fumarate (TDF), the tenofovir prodrug, but not with the tenofovir microbicide gel utilized in CAPRISA-004, VOICE, and FACTS-001 clinical trials.	Tenofovir	184-213	cardiotrophin 1	Mus musculus	27-30
26157126-12	2015	HIV acquisition by hCD4/R5/cT1 mice vaginally coinfected with HSV-2 could be completely prevented in almost half the mice by preexposure prophylaxis (PrEP) with a novel gel containing tenofovir disoproxil fumarate (TDF), the tenofovir prodrug, but not with the tenofovir microbicide gel utilized in CAPRISA-004, VOICE, and FACTS-001 clinical trials.	Tenofovir	184-193	CD4 molecule	Homo sapiens	19-23
26157126-12	2015	HIV acquisition by hCD4/R5/cT1 mice vaginally coinfected with HSV-2 could be completely prevented in almost half the mice by preexposure prophylaxis (PrEP) with a novel gel containing tenofovir disoproxil fumarate (TDF), the tenofovir prodrug, but not with the tenofovir microbicide gel utilized in CAPRISA-004, VOICE, and FACTS-001 clinical trials.	Tenofovir	184-193	cardiotrophin 1	Mus musculus	27-30
26148204-10	2015	In genomewide analyses SLC17A1 rs12662869 was found to be associated with an increase in tenofovir clearance (P=7.1x10).	Tenofovir	89-98	solute carrier family 17 member 1	Homo sapiens	23-30
26148204-11	2015	In candidate gene analysis for tenofovir clearance, most polymorphisms evaluated were in ABCC4.	Tenofovir	31-40	ATP binding cassette subfamily C member 4	Homo sapiens	89-94
26148204-13	2015	Among African Americans, SLC22A2 rs3127573 was associated with a greater 6-month CrCl increase in the tenofovir arm after correcting for multiple comparisons (P=3.3x10).	Tenofovir	102-111	solute carrier family 22 member 2	Homo sapiens	25-32
26119851-6	2015	A higher frequency of beta2-microglobulin proteinuria (beta2-microglobulin-creatinine ratio &gt;0.68mg/g) was also observed in the tenofovir group (28.9%) compared to the non-tenofovir group (13.6%, p=0.024).	Tenofovir	131-140	beta-2-microglobulin	Homo sapiens	22-41
26045359-1	2015	BACKGROUND: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; Stribild( )) is a guideline-recommended regimen for HIV treatment-naive patients and a switch option for virologically suppressed patients.	Tenofovir	71-100	sex determining region Y	Homo sapiens	115-118
26183311-7	2015	In vitro the triple medication efavirenz, tenofovir and emtricitabine leads to a reduced survival fraction and an increased activation of the DNA repair proteins H2AX, Nbs, Atm and 53BP1 in combination with ionizing radiation.	Tenofovir	42-51	H2A.X variant histone	Homo sapiens	162-166
26183311-7	2015	In vitro the triple medication efavirenz, tenofovir and emtricitabine leads to a reduced survival fraction and an increased activation of the DNA repair proteins H2AX, Nbs, Atm and 53BP1 in combination with ionizing radiation.	Tenofovir	42-51	nibrin	Homo sapiens	168-171
26183311-7	2015	In vitro the triple medication efavirenz, tenofovir and emtricitabine leads to a reduced survival fraction and an increased activation of the DNA repair proteins H2AX, Nbs, Atm and 53BP1 in combination with ionizing radiation.	Tenofovir	42-51	ATM serine/threonine kinase	Homo sapiens	173-176
26183311-7	2015	In vitro the triple medication efavirenz, tenofovir and emtricitabine leads to a reduced survival fraction and an increased activation of the DNA repair proteins H2AX, Nbs, Atm and 53BP1 in combination with ionizing radiation.	Tenofovir	42-51	tumor protein p53 binding protein 1	Homo sapiens	181-186
26119851-6	2015	A higher frequency of beta2-microglobulin proteinuria (beta2-microglobulin-creatinine ratio &gt;0.68mg/g) was also observed in the tenofovir group (28.9%) compared to the non-tenofovir group (13.6%, p=0.024).	Tenofovir	131-140	beta-2-microglobulin	Homo sapiens	55-74
25782332-1	2015	OBJECTIVE: To compare virologic success between adult patients on tenofovir (TDF) and zidovudine (AZT)-containing first-line antiretroviral (ART) regimens in 10 rural clinics in Lesotho, Southern Africa.	Tenofovir	66-75	sex determining region Y	Homo sapiens	77-80
25956353-2	2015	We investigated the antiviral efficacy of tenofovir (TDF)/LAM combination therapy versus TDF monotherapy in LAM-resistant chronic hepatitis B (CHB) patients who failed to respond to LAM plus ADV rescue therapy.	Tenofovir	42-51	sex determining region Y	Homo sapiens	53-56
26102284-8	2015	Stimulation with darunavir and dapivirine upregulated MRP transporters, including MRP5 involved in transport of tenofovir.	Tenofovir	112-121	ATP binding cassette subfamily C member 5	Homo sapiens	82-86
26121361-1	2015	The efficacy of entecavir (ETV) and tenofovir (TDF) for the treatment of nucleos(t)ide analogue (NA)-experienced chronic hepatitis B (CHB) patients has been little studied.	Tenofovir	36-45	sex determining region Y	Homo sapiens	47-50
26102284-9	2015	Dapivirine also significantly downregulated tenofovir substrate MRP4 in cervical cell lines.	Tenofovir	44-53	ATP binding cassette subfamily C member 4	Homo sapiens	64-68
25919772-7	2015	Tenofovir was most effective at increasing efficacy in HBeAg-positive patients, ranking first for three outcomes and increased odds of undetectable levels of hepatitis B virus (HBV) DNA compared with seven other therapies (such as lamivudine: odds ratio 33.0; 95% credible interval 7.0-292.7).	Tenofovir	0-9	capsid protein;pre-capsid protein	Hepatitis B virus	55-60
25919772-8	2015	For HBeAg-negative patients, the large network (seven therapies) ranked entecavir alone or in combination with tenofovir highly for reduction in HBV DNA and histologic improvement.	Tenofovir	111-120	capsid protein;pre-capsid protein	Hepatitis B virus	4-9
25919772-11	2015	CONCLUSION: For HBeAg-positive patients tenofovir is the most effective at increasing efficacy, whereas for HBeAg-negative patients, either tenofovir or entecavir is most effective.	Tenofovir	40-49	capsid protein;pre-capsid protein	Hepatitis B virus	16-21
25919772-12	2015	Further research should focus on strengthening the network connections, in particular comparing tenofovir and entecavir in HBeAg-negative patients.	Tenofovir	96-105	capsid protein;pre-capsid protein	Hepatitis B virus	123-128
26021773-1	2015	BACKGROUND/AIMS: This study aimed to evaluate the antiviral response and safety of tenofovir (TDF) versus entecavir (ETV) in treatment-naive CHB patients.	Tenofovir	83-92	sex determining region Y	Homo sapiens	94-97
25583749-12	2015	CONCLUSIONS: In this population of mostly female HIV-1-infected African patients, tenofovir plasma overexposure was associated with PI/ritonavir and a time-dependent decrease in eGFR, probably via an inhibition of MRP2/MRP4 efflux transporters.	Tenofovir	82-91	ATP binding cassette subfamily C member 2	Homo sapiens	214-218
25583749-12	2015	CONCLUSIONS: In this population of mostly female HIV-1-infected African patients, tenofovir plasma overexposure was associated with PI/ritonavir and a time-dependent decrease in eGFR, probably via an inhibition of MRP2/MRP4 efflux transporters.	Tenofovir	82-91	ATP binding cassette subfamily C member 4	Homo sapiens	219-223
25914645-9	2015	Tetraethylammonium accumulation was higher in SLC22A1-expressing cells compared to mock-transfected cells (10.6 +- 0.8 muM vs. 0.3 +- 0.004 muM, p = 0.009) and was significantly reduced in SLC22A1-expressing cells when co-incubated with all antiretrovirals tested except atazanavir, lamivudine, tenofovir, zidovudine, and raltegravir.	Tenofovir	295-304	solute carrier family 22 member 1	Homo sapiens	46-53
25554586-2	2015	Substrates transported by ABCC2 include antiepileptics, statins, tenofovir, cisplatin, irinotecan, and carbamazepine.	Tenofovir	65-74	ATP binding cassette subfamily C member 2	Homo sapiens	26-31
25442109-9	2015	On average, estimated glomerular function improved over the first year on tenofovir [1.10 ml/min/1.73 m(2) average increase over 12 months (95% CI: 0.80; 1.40)].	Tenofovir	74-83	CD59 molecule (CD59 blood group)	Homo sapiens	93-98
25490043-0	2015	Study on the interaction of antiviral drug "Tenofovir" with human serum albumin by spectral and molecular modeling methods.	Tenofovir	44-53	albumin	Homo sapiens	66-79
25490043-1	2015	This study was designed to examine the interaction of Tenofovir (Ten) with human serum albumin (HSA) under physiological conditions.	Tenofovir	54-63	albumin	Homo sapiens	81-94
25247433-9	2015	Overall mean CD4 counts were 463 and 514 cells per microliter in women assigned to tenofovir and placebo (P = 0.290).	Tenofovir	83-92	CD4 molecule	Homo sapiens	13-16
25070158-1	2015	Due to the differences between bioavailability of efavirenz (EFV) and tenofovir (TDF), the single-tablet regimen of EFV/emtricitabine (FTC)/TDF is not approved as initial antiretroviral therapy (ART) in Europe by the European Medical Agency.	Tenofovir	70-79	sex determining region Y	Homo sapiens	81-84
25448811-3	2015	We show here that three antiviral drugs, adefovir, cidofovir and tenofovir exhibit significantly increased cytotoxicity in HEK293 cells transfected with organic anion transporter (OAT) 1 and 3 compared to a lack of cytotoxicity in HEK293 wildtype cells.	Tenofovir	65-74	solute carrier family 22 member 6	Homo sapiens	153-192
25801567-0	2015	Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients.	Tenofovir	46-55	ATP binding cassette subfamily C member 2	Homo sapiens	13-18
25801567-0	2015	Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients.	Tenofovir	46-55	ATP binding cassette subfamily C member 4	Homo sapiens	23-28
25801567-1	2015	Tenofovir (TFV) is eliminated by renal excretion, which is mediated through multidrug-resistant protein 2 (MRP2) and MRP4, encoded by ABCC2 and ABCC4, respectively.	Tenofovir	0-9	ATP binding cassette subfamily C member 2	Homo sapiens	76-105
25801567-1	2015	Tenofovir (TFV) is eliminated by renal excretion, which is mediated through multidrug-resistant protein 2 (MRP2) and MRP4, encoded by ABCC2 and ABCC4, respectively.	Tenofovir	0-9	ATP binding cassette subfamily C member 2	Homo sapiens	107-111
25801567-1	2015	Tenofovir (TFV) is eliminated by renal excretion, which is mediated through multidrug-resistant protein 2 (MRP2) and MRP4, encoded by ABCC2 and ABCC4, respectively.	Tenofovir	0-9	ATP binding cassette subfamily C member 4	Homo sapiens	117-121
25801567-1	2015	Tenofovir (TFV) is eliminated by renal excretion, which is mediated through multidrug-resistant protein 2 (MRP2) and MRP4, encoded by ABCC2 and ABCC4, respectively.	Tenofovir	0-9	ATP binding cassette subfamily C member 2	Homo sapiens	134-139
25801567-1	2015	Tenofovir (TFV) is eliminated by renal excretion, which is mediated through multidrug-resistant protein 2 (MRP2) and MRP4, encoded by ABCC2 and ABCC4, respectively.	Tenofovir	0-9	ATP binding cassette subfamily C member 4	Homo sapiens	144-149
25801567-1	2015	Tenofovir (TFV) is eliminated by renal excretion, which is mediated through multidrug-resistant protein 2 (MRP2) and MRP4, encoded by ABCC2 and ABCC4, respectively.	Tenofovir	11-14	ATP binding cassette subfamily C member 2	Homo sapiens	76-105
25801567-1	2015	Tenofovir (TFV) is eliminated by renal excretion, which is mediated through multidrug-resistant protein 2 (MRP2) and MRP4, encoded by ABCC2 and ABCC4, respectively.	Tenofovir	11-14	ATP binding cassette subfamily C member 2	Homo sapiens	107-111
25801567-1	2015	Tenofovir (TFV) is eliminated by renal excretion, which is mediated through multidrug-resistant protein 2 (MRP2) and MRP4, encoded by ABCC2 and ABCC4, respectively.	Tenofovir	11-14	ATP binding cassette subfamily C member 4	Homo sapiens	117-121
25801567-1	2015	Tenofovir (TFV) is eliminated by renal excretion, which is mediated through multidrug-resistant protein 2 (MRP2) and MRP4, encoded by ABCC2 and ABCC4, respectively.	Tenofovir	11-14	ATP binding cassette subfamily C member 2	Homo sapiens	134-139
25801567-1	2015	Tenofovir (TFV) is eliminated by renal excretion, which is mediated through multidrug-resistant protein 2 (MRP2) and MRP4, encoded by ABCC2 and ABCC4, respectively.	Tenofovir	11-14	ATP binding cassette subfamily C member 4	Homo sapiens	144-149
25801567-10	2015	In multivariate analysis, a low body weight, a low eGFR, the concomitant use of ritonavir-boosted protease inhibitors, and the ABCC4 4131T   G variation (genotype TG or GG) were independently associated with higher tenofovir plasma concentrations.	Tenofovir	215-224	ATP binding cassette subfamily C member 4	Homo sapiens	127-132
25801567-11	2015	After adjusting for weight, eGFR, and the concomitant use of ritonavir-boosted protease inhibitors, a 30% increase in the mean tenofovir plasma concentration was observed in patients having the ABCC4 4131 TG or GG genotype.	Tenofovir	127-136	ATP binding cassette subfamily C member 4	Homo sapiens	194-199
25740950-1	2015	BACKGROUND: The combination of tenofovir and efavirenz with either lamivudine or emtricitabine (TELE) has proved to be highly effective in clinical trials for first-line treatment of HIV-1 infection.	Tenofovir	31-40	titin-cap	Homo sapiens	96-100
25394078-1	2014	INTRODUCTION: In clinical trials, toxicity leading to discontinuation of tenofovir (TDF) is a rare occurrence (3% by two years)[1, 2]; however, in clinical practice it seems to be higher.	Tenofovir	73-82	sex determining region Y	Homo sapiens	84-87
25136003-11	2014	Our findings indicate that TFV modulates proinflammatory cytokines, nucleotidase gene expression, and nucleotidase biological activity in epithelial cells, fibroblasts, CD4(+) T cells, and CD14(+) cells at distinct sites within the FRT.	Tenofovir	27-30	CD14 molecule	Homo sapiens	189-193
24740633-1	2014	BACKGROUND: The iPrEx study demonstrated that combination oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as preexposure prophylaxis (PrEP) protects against HIV acquisition in men who have sex with men and transgender women.	Tenofovir	81-110	sex determining region Y	Homo sapiens	116-119
25394057-1	2014	INTRODUCTION: Previous studies have described improvements on lipid parameters when switching from other antiretroviral drugs to tenofovir (TDF) and impairments in lipid profile when discontinuing TDF.	Tenofovir	129-138	sex determining region Y	Homo sapiens	140-143
25394059-1	2014	INTRODUCTION: Due to its side effects stavudine (D4T) has been replaced by zidovudine (AZT) and tenofovir (TDF) in most low- and middle-income countries (LMICs).	Tenofovir	96-105	sex determining region Y	Homo sapiens	107-110
25350130-8	2014	The EC50 for CD4+MMC was within the single topical treatment range, providing evidence that a 1% topical, vaginally-formulated TFV gel provided in-vivo doses predicted to provide for 50% efficacy in the ex vivo assay.	Tenofovir	127-130	CD4 molecule	Homo sapiens	13-16
25350130-9	2014	The 7-daily topical TFV gel treatment provided TFVdp concentrations that reached EC90 biopsy efficacy for CD4-MMC, CD4+MMC and TotalMMC compartments.	Tenofovir	20-23	CD4 molecule	Homo sapiens	106-109
25350130-9	2014	The 7-daily topical TFV gel treatment provided TFVdp concentrations that reached EC90 biopsy efficacy for CD4-MMC, CD4+MMC and TotalMMC compartments.	Tenofovir	20-23	CD4 molecule	Homo sapiens	115-118
25350130-10	2014	CONCLUSION: The TFVdp MMC compartment (CD4+, CD4- and Total) provided the best surrogate for biopsy infectibility and the 7-daily topical TFV gel treatment provided the strongest PK profile for HIV suppression.	Tenofovir	16-19	CD4 molecule	Homo sapiens	39-42
25091927-4	2014	The phosphonate was shown to be a moderate but selective substrate of the mitochondrial human AK2, better than well-known antiviral acyclic phosphonates 9-(2-phosphonomethoxyethyl)adenine (PMEA, Adefovir) and (R)-9-(2-phosphonomethoxypropyl)adenine (PMPA, Tenofovir).	Tenofovir	209-248	adenylate kinase 2	Homo sapiens	94-97
25091927-4	2014	The phosphonate was shown to be a moderate but selective substrate of the mitochondrial human AK2, better than well-known antiviral acyclic phosphonates 9-(2-phosphonomethoxyethyl)adenine (PMEA, Adefovir) and (R)-9-(2-phosphonomethoxypropyl)adenine (PMPA, Tenofovir).	Tenofovir	250-254	adenylate kinase 2	Homo sapiens	94-97
25091927-4	2014	The phosphonate was shown to be a moderate but selective substrate of the mitochondrial human AK2, better than well-known antiviral acyclic phosphonates 9-(2-phosphonomethoxyethyl)adenine (PMEA, Adefovir) and (R)-9-(2-phosphonomethoxypropyl)adenine (PMPA, Tenofovir).	Tenofovir	256-265	adenylate kinase 2	Homo sapiens	94-97
24641488-7	2014	The estimated linear rate of decline in eGFR on tenofovir was -1.1 (95% CI -1.5 to -0.8) mL/min/1.73 m(2) per year and its recovery after discontinuing tenofovir was 2.1 (95% CI 1.3 to 2.9) mL/min/1.73 m(2) per year.	Tenofovir	48-57	CD59 molecule (CD59 blood group)	Homo sapiens	92-97
25075941-0	2014	The Use of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase.	Tenofovir	11-40	glutamic--pyruvic transaminase	Homo sapiens	106-130
24641488-7	2014	The estimated linear rate of decline in eGFR on tenofovir was -1.1 (95% CI -1.5 to -0.8) mL/min/1.73 m(2) per year and its recovery after discontinuing tenofovir was 2.1 (95% CI 1.3 to 2.9) mL/min/1.73 m(2) per year.	Tenofovir	48-57	CD59 molecule (CD59 blood group)	Homo sapiens	193-198
24861361-1	2014	Tenofovir disoproxil fumarate (TDF) is recommended as treatment for chronic hepatitis B patients harboring lamivudine-associated resistance mutations (LAM-R, rtM204V/I +- rtL180M).	Tenofovir	0-29	ribosomal protein SA	Homo sapiens	151-156
25350960-1	2014	OBJECTIVE: To describe baseline and emergent HIV-1 resistance to elvitegravir/ cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF) in HIV-1-infected, treatment-naive subjects through 144 weeks.	Tenofovir	104-113	sex determining region Y	Homo sapiens	131-134
23818285-3	2013	We investigated urine and plasma NGAL in patients on long-term treatment with nevirapine associated with either tenofovir/emtricitabine or abacavir/lamivudine.	Tenofovir	112-121	lipocalin 2	Homo sapiens	33-37
24729492-7	2014	With emtricitabine/tenofovir, levels of HDL-C were increased, TC and LDL-C were unchanged, and triglycerides were decreased.	Tenofovir	19-28	component of oligomeric golgi complex 2	Homo sapiens	69-74
24884881-6	2014	RESULTS: Both ART regimens present pronounced effect on inflammatory mediators, resulting in decreased PAF levels and Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity for tenofovir-containing regimen and same as baseline PAF levels with a peak though at the 3rd month as well as elevated Lp-PLA2 activity for abacavir-containing regimen.	Tenofovir	181-190	phospholipase A2 group VII	Homo sapiens	118-157
24884881-6	2014	RESULTS: Both ART regimens present pronounced effect on inflammatory mediators, resulting in decreased PAF levels and Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity for tenofovir-containing regimen and same as baseline PAF levels with a peak though at the 3rd month as well as elevated Lp-PLA2 activity for abacavir-containing regimen.	Tenofovir	181-190	phospholipase A2 group VII	Homo sapiens	159-166
24500175-1	2014	BACKGROUND: Despite widespread use in HIV and hepatitis B virus (HBV) infection, the effectiveness of tenofovir (TDF) has not been studied extensively outside of small cohorts of coinfected patients with HBV-HIV.	Tenofovir	102-111	sex determining region Y	Homo sapiens	113-116
24508897-5	2014	There were higher intracellular tenofovir concentrations within peripheral blood mononuclear cells with both 40 mg of tenofovir alafenamide (8.2 muM) and 120 mg of tenofovir alafenamide (16.9 muM) compared with 300 mg of tenofovir disoproxil fumarate (0.9 muM).	Tenofovir	32-41	latexin	Homo sapiens	145-148
24508897-5	2014	There were higher intracellular tenofovir concentrations within peripheral blood mononuclear cells with both 40 mg of tenofovir alafenamide (8.2 muM) and 120 mg of tenofovir alafenamide (16.9 muM) compared with 300 mg of tenofovir disoproxil fumarate (0.9 muM).	Tenofovir	32-41	latexin	Homo sapiens	192-195
24508897-5	2014	There were higher intracellular tenofovir concentrations within peripheral blood mononuclear cells with both 40 mg of tenofovir alafenamide (8.2 muM) and 120 mg of tenofovir alafenamide (16.9 muM) compared with 300 mg of tenofovir disoproxil fumarate (0.9 muM).	Tenofovir	32-41	latexin	Homo sapiens	192-195
24343710-2	2014	We hypothesized drug transporter expression in vaginal, cervical, and colorectal tissues is a contributing factor and selected 3 efflux (ABCB1/MDR1, ABCC2/MRP2, ABCC4/MRP4) and 3 uptake (SLC22A6/OAT1, SLC22A8/OAT3, SLCO1B1/OATP1B1) transporters to further investigate based on their affinity for 2 ARVs central to prevention (tenofovir, maraviroc).	Tenofovir	326-335	ATP binding cassette subfamily B member 1	Homo sapiens	137-142
24343710-2	2014	We hypothesized drug transporter expression in vaginal, cervical, and colorectal tissues is a contributing factor and selected 3 efflux (ABCB1/MDR1, ABCC2/MRP2, ABCC4/MRP4) and 3 uptake (SLC22A6/OAT1, SLC22A8/OAT3, SLCO1B1/OATP1B1) transporters to further investigate based on their affinity for 2 ARVs central to prevention (tenofovir, maraviroc).	Tenofovir	326-335	ATP binding cassette subfamily C member 4	Homo sapiens	161-166
24343710-2	2014	We hypothesized drug transporter expression in vaginal, cervical, and colorectal tissues is a contributing factor and selected 3 efflux (ABCB1/MDR1, ABCC2/MRP2, ABCC4/MRP4) and 3 uptake (SLC22A6/OAT1, SLC22A8/OAT3, SLCO1B1/OATP1B1) transporters to further investigate based on their affinity for 2 ARVs central to prevention (tenofovir, maraviroc).	Tenofovir	326-335	solute carrier family 22 member 6	Homo sapiens	187-194
24343710-2	2014	We hypothesized drug transporter expression in vaginal, cervical, and colorectal tissues is a contributing factor and selected 3 efflux (ABCB1/MDR1, ABCC2/MRP2, ABCC4/MRP4) and 3 uptake (SLC22A6/OAT1, SLC22A8/OAT3, SLCO1B1/OATP1B1) transporters to further investigate based on their affinity for 2 ARVs central to prevention (tenofovir, maraviroc).	Tenofovir	326-335	solute carrier family 22 member 6	Homo sapiens	195-199
24343710-2	2014	We hypothesized drug transporter expression in vaginal, cervical, and colorectal tissues is a contributing factor and selected 3 efflux (ABCB1/MDR1, ABCC2/MRP2, ABCC4/MRP4) and 3 uptake (SLC22A6/OAT1, SLC22A8/OAT3, SLCO1B1/OATP1B1) transporters to further investigate based on their affinity for 2 ARVs central to prevention (tenofovir, maraviroc).	Tenofovir	326-335	solute carrier family 22 member 8	Homo sapiens	201-208
24343710-2	2014	We hypothesized drug transporter expression in vaginal, cervical, and colorectal tissues is a contributing factor and selected 3 efflux (ABCB1/MDR1, ABCC2/MRP2, ABCC4/MRP4) and 3 uptake (SLC22A6/OAT1, SLC22A8/OAT3, SLCO1B1/OATP1B1) transporters to further investigate based on their affinity for 2 ARVs central to prevention (tenofovir, maraviroc).	Tenofovir	326-335	solute carrier family 22 member 8	Homo sapiens	209-213
24343710-2	2014	We hypothesized drug transporter expression in vaginal, cervical, and colorectal tissues is a contributing factor and selected 3 efflux (ABCB1/MDR1, ABCC2/MRP2, ABCC4/MRP4) and 3 uptake (SLC22A6/OAT1, SLC22A8/OAT3, SLCO1B1/OATP1B1) transporters to further investigate based on their affinity for 2 ARVs central to prevention (tenofovir, maraviroc).	Tenofovir	326-335	solute carrier organic anion transporter family member 1B1	Homo sapiens	215-222
24343710-2	2014	We hypothesized drug transporter expression in vaginal, cervical, and colorectal tissues is a contributing factor and selected 3 efflux (ABCB1/MDR1, ABCC2/MRP2, ABCC4/MRP4) and 3 uptake (SLC22A6/OAT1, SLC22A8/OAT3, SLCO1B1/OATP1B1) transporters to further investigate based on their affinity for 2 ARVs central to prevention (tenofovir, maraviroc).	Tenofovir	326-335	solute carrier organic anion transporter family member 1B1	Homo sapiens	223-230
24164392-0	2014	Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.	Tenofovir	151-160	fatty acid binding protein 1	Homo sapiens	6-43
24275255-10	2014	CONCLUSION: Concomitant ritonavir use, increasing age, decreasing BMI, and lower GFR prior to tenofovir initiation as estimated by cystatin C were all associated with elevated tenofovir exposure in a diverse cohort of HIV-infected women.	Tenofovir	176-185	cystatin C	Homo sapiens	131-141
24413260-0	2014	Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.	Tenofovir	16-25	ATP binding cassette subfamily B member 1	Homo sapiens	90-95
24413260-0	2014	Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.	Tenofovir	16-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	97-102
24413260-0	2014	Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.	Tenofovir	16-25	ATP binding cassette subfamily C member 2	Homo sapiens	108-113
24413260-0	2014	Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.	Tenofovir	30-59	ATP binding cassette subfamily B member 1	Homo sapiens	90-95
24413260-0	2014	Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.	Tenofovir	30-59	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	97-102
24413260-0	2014	Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.	Tenofovir	30-59	ATP binding cassette subfamily C member 2	Homo sapiens	108-113
24413260-2	2014	We aimed to detect whether TFV and/or its prodrug, tenofovir disoproxil fumarate (TDF), are substrates of ATP-binding cassette (ABC) transporters that are functionally expressed in the placenta, namely P-glycoprotein (ABCB1/MDR1), Breast Cancer Resistance Protein (ABCG2/BCRP) and Multidrug Resistance-Associated Protein 2 (ABCC2/MRP2).	Tenofovir	51-80	ATP binding cassette subfamily B member 1	Homo sapiens	218-223
24413260-2	2014	We aimed to detect whether TFV and/or its prodrug, tenofovir disoproxil fumarate (TDF), are substrates of ATP-binding cassette (ABC) transporters that are functionally expressed in the placenta, namely P-glycoprotein (ABCB1/MDR1), Breast Cancer Resistance Protein (ABCG2/BCRP) and Multidrug Resistance-Associated Protein 2 (ABCC2/MRP2).	Tenofovir	51-80	ATP binding cassette subfamily B member 1	Homo sapiens	224-228
24413260-2	2014	We aimed to detect whether TFV and/or its prodrug, tenofovir disoproxil fumarate (TDF), are substrates of ATP-binding cassette (ABC) transporters that are functionally expressed in the placenta, namely P-glycoprotein (ABCB1/MDR1), Breast Cancer Resistance Protein (ABCG2/BCRP) and Multidrug Resistance-Associated Protein 2 (ABCC2/MRP2).	Tenofovir	51-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	231-263
24413260-2	2014	We aimed to detect whether TFV and/or its prodrug, tenofovir disoproxil fumarate (TDF), are substrates of ATP-binding cassette (ABC) transporters that are functionally expressed in the placenta, namely P-glycoprotein (ABCB1/MDR1), Breast Cancer Resistance Protein (ABCG2/BCRP) and Multidrug Resistance-Associated Protein 2 (ABCC2/MRP2).	Tenofovir	51-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	265-270
24413260-2	2014	We aimed to detect whether TFV and/or its prodrug, tenofovir disoproxil fumarate (TDF), are substrates of ATP-binding cassette (ABC) transporters that are functionally expressed in the placenta, namely P-glycoprotein (ABCB1/MDR1), Breast Cancer Resistance Protein (ABCG2/BCRP) and Multidrug Resistance-Associated Protein 2 (ABCC2/MRP2).	Tenofovir	51-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	271-275
24413260-2	2014	We aimed to detect whether TFV and/or its prodrug, tenofovir disoproxil fumarate (TDF), are substrates of ATP-binding cassette (ABC) transporters that are functionally expressed in the placenta, namely P-glycoprotein (ABCB1/MDR1), Breast Cancer Resistance Protein (ABCG2/BCRP) and Multidrug Resistance-Associated Protein 2 (ABCC2/MRP2).	Tenofovir	51-80	ATP binding cassette subfamily C member 2	Homo sapiens	281-322
24413260-2	2014	We aimed to detect whether TFV and/or its prodrug, tenofovir disoproxil fumarate (TDF), are substrates of ATP-binding cassette (ABC) transporters that are functionally expressed in the placenta, namely P-glycoprotein (ABCB1/MDR1), Breast Cancer Resistance Protein (ABCG2/BCRP) and Multidrug Resistance-Associated Protein 2 (ABCC2/MRP2).	Tenofovir	51-80	ATP binding cassette subfamily C member 2	Homo sapiens	324-329
24413260-2	2014	We aimed to detect whether TFV and/or its prodrug, tenofovir disoproxil fumarate (TDF), are substrates of ATP-binding cassette (ABC) transporters that are functionally expressed in the placenta, namely P-glycoprotein (ABCB1/MDR1), Breast Cancer Resistance Protein (ABCG2/BCRP) and Multidrug Resistance-Associated Protein 2 (ABCC2/MRP2).	Tenofovir	51-80	ATP binding cassette subfamily C member 2	Homo sapiens	330-334
24296645-8	2014	Patients on tenofovir were more likely to have switched to second-line ART in recent years, spent more time on first-line ART (33 versus 24 months) and had lower CD4(+) T-cell counts (172 versus 341 cells/mul) at initiation of second-line ART.	Tenofovir	12-21	CD4 molecule	Homo sapiens	162-165
24535626-2	2014	Fibroblast growth factor 23 (FGF23) causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D-binding protein (VDBP) binds to 1,25-OH(2)D, decreasing its biological activity, and is elevated in individuals with higher plasma tenofovir concentrations.	Tenofovir	248-257	fibroblast growth factor 23	Homo sapiens	0-27
24535626-2	2014	Fibroblast growth factor 23 (FGF23) causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D-binding protein (VDBP) binds to 1,25-OH(2)D, decreasing its biological activity, and is elevated in individuals with higher plasma tenofovir concentrations.	Tenofovir	248-257	fibroblast growth factor 23	Homo sapiens	29-34
24535626-2	2014	Fibroblast growth factor 23 (FGF23) causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D-binding protein (VDBP) binds to 1,25-OH(2)D, decreasing its biological activity, and is elevated in individuals with higher plasma tenofovir concentrations.	Tenofovir	248-257	GC vitamin D binding protein	Homo sapiens	107-132
24535626-2	2014	Fibroblast growth factor 23 (FGF23) causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D-binding protein (VDBP) binds to 1,25-OH(2)D, decreasing its biological activity, and is elevated in individuals with higher plasma tenofovir concentrations.	Tenofovir	248-257	GC vitamin D binding protein	Homo sapiens	134-138
24699134-2	2014	Tenofovir released from TDF undergoes active renal secretion via organic anion transporters (OAT1 and OAT3), leading to higher exposure of renal proximal tubules to tenofovir and a potential for renal adverse effects in a small subset of TDF-treated patients.	Tenofovir	0-9	solute carrier family 22 member 6	Homo sapiens	93-97
24699134-2	2014	Tenofovir released from TDF undergoes active renal secretion via organic anion transporters (OAT1 and OAT3), leading to higher exposure of renal proximal tubules to tenofovir and a potential for renal adverse effects in a small subset of TDF-treated patients.	Tenofovir	0-9	solute carrier family 22 member 8	Homo sapiens	102-106
24699134-2	2014	Tenofovir released from TDF undergoes active renal secretion via organic anion transporters (OAT1 and OAT3), leading to higher exposure of renal proximal tubules to tenofovir and a potential for renal adverse effects in a small subset of TDF-treated patients.	Tenofovir	165-174	solute carrier family 22 member 6	Homo sapiens	93-97
24699134-2	2014	Tenofovir released from TDF undergoes active renal secretion via organic anion transporters (OAT1 and OAT3), leading to higher exposure of renal proximal tubules to tenofovir and a potential for renal adverse effects in a small subset of TDF-treated patients.	Tenofovir	165-174	solute carrier family 22 member 8	Homo sapiens	102-106
24699134-2	2014	Tenofovir released from TDF undergoes active renal secretion via organic anion transporters (OAT1 and OAT3), leading to higher exposure of renal proximal tubules to tenofovir and a potential for renal adverse effects in a small subset of TDF-treated patients.	Tenofovir	24-27	solute carrier family 22 member 6	Homo sapiens	93-97
24699134-2	2014	Tenofovir released from TDF undergoes active renal secretion via organic anion transporters (OAT1 and OAT3), leading to higher exposure of renal proximal tubules to tenofovir and a potential for renal adverse effects in a small subset of TDF-treated patients.	Tenofovir	24-27	solute carrier family 22 member 8	Homo sapiens	102-106
24699134-5	2014	RESULTS: While OAT1 and OAT3 expression increased tenofovir cellular uptake by &gt;70-fold and 8.2-fold, respectively, the expression of either OAT did not significantly change TAF intracellular accumulation under identical conditions.	Tenofovir	50-59	solute carrier family 22 member 6	Homo sapiens	15-19
24699134-5	2014	RESULTS: While OAT1 and OAT3 expression increased tenofovir cellular uptake by &gt;70-fold and 8.2-fold, respectively, the expression of either OAT did not significantly change TAF intracellular accumulation under identical conditions.	Tenofovir	50-59	solute carrier family 22 member 8	Homo sapiens	24-28
24699134-6	2014	In addition, although tenofovir was significantly more cytotoxic in OAT1- and OAT3-expressing cells (&gt;21 and &gt;3.6 fold change in CC50 values, respectively), TAF in vitro cytotoxicity showed little to no change upon overexpression of either renal transporter (0.5-3.5 fold change in CC50).	Tenofovir	22-31	solute carrier family 22 member 6	Homo sapiens	68-72
24699134-6	2014	In addition, although tenofovir was significantly more cytotoxic in OAT1- and OAT3-expressing cells (&gt;21 and &gt;3.6 fold change in CC50 values, respectively), TAF in vitro cytotoxicity showed little to no change upon overexpression of either renal transporter (0.5-3.5 fold change in CC50).	Tenofovir	22-31	solute carrier family 22 member 8	Homo sapiens	78-82
25030944-1	2014	Elvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment.	Tenofovir	38-49	sex determining region Y	Homo sapiens	64-67
23972039-1	2013	The effect of tenofovir (TDF) alone or in combination with interferon on hepatitis D virus (HDV) replication is poorly characterized in patients infected with human immunodeficiency virus (HIV), hepatitis B virus (HBV), and HDV.	Tenofovir	14-23	sex determining region Y	Homo sapiens	25-28
24788661-0	2014	ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.	Tenofovir	123-132	ATP binding cassette subfamily C member 2	Homo sapiens	0-5
24788661-11	2014	Mean +- SD tenofovir concentration in ABCC2*1C genotype CC versus CT/TT was 113 +- 47 versus 93 +- 44 ng/mL, respectively (P = 0.018).	Tenofovir	11-20	ATP binding cassette subfamily C member 2	Homo sapiens	38-43
24788661-14	2014	CONCLUSIONS: HIV-infected patients who carry ABCC2*1C genotype CC at position -24 or have high plasma tenofovir concentration are at risk of decreased glomerular filtration rate.	Tenofovir	102-111	ATP binding cassette subfamily C member 2	Homo sapiens	45-50
25672029-1	2014	OBJECTIVE: To describe the i ncidence a nd cha racteristics of Tenofovir (TDF) induced nephrotoxicity among people living with HIV AIDS (PLHA) receiving TDF based anti-retroviral therapy (ART) at Christian Medical College, Vellore.	Tenofovir	63-72	sex determining region Y	Homo sapiens	74-77
25672029-1	2014	OBJECTIVE: To describe the i ncidence a nd cha racteristics of Tenofovir (TDF) induced nephrotoxicity among people living with HIV AIDS (PLHA) receiving TDF based anti-retroviral therapy (ART) at Christian Medical College, Vellore.	Tenofovir	63-72	sex determining region Y	Homo sapiens	153-156
24706031-0	2014	Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia.	Tenofovir	43-52	fibroblast growth factor 23	Homo sapiens	0-27
24695108-8	2014	Zidovudine (AZT) and tenofovir (TDF) use had a reduced risk for modification (aHR; 0.60 95%CI: 0.38-0.96 and aHR; 0.51 95%CI: 0.29-0.91 respectively).	Tenofovir	21-30	aryl hydrocarbon receptor	Homo sapiens	78-81
24695108-8	2014	Zidovudine (AZT) and tenofovir (TDF) use had a reduced risk for modification (aHR; 0.60 95%CI: 0.38-0.96 and aHR; 0.51 95%CI: 0.29-0.91 respectively).	Tenofovir	21-30	aryl hydrocarbon receptor	Homo sapiens	109-112
24695108-8	2014	Zidovudine (AZT) and tenofovir (TDF) use had a reduced risk for modification (aHR; 0.60 95%CI: 0.38-0.96 and aHR; 0.51 95%CI: 0.29-0.91 respectively).	Tenofovir	32-35	aryl hydrocarbon receptor	Homo sapiens	78-81
24695108-8	2014	Zidovudine (AZT) and tenofovir (TDF) use had a reduced risk for modification (aHR; 0.60 95%CI: 0.38-0.96 and aHR; 0.51 95%CI: 0.29-0.91 respectively).	Tenofovir	32-35	aryl hydrocarbon receptor	Homo sapiens	109-112
23701022-8	2013	Our data suggest that concomitant tenofovir (TDF) use may be a risk factor for the development of hypophosphatemia in HIV/HCV-coinfected patients treated with IFN/RBV.	Tenofovir	34-43	interferon alpha 1	Homo sapiens	159-166
24002093-7	2013	The highest quintile of plasma tenofovir concentrations was associated with higher vitamin D binding protein, lower free 1,25-OH(2)D, higher 25-OH vitamin D, and higher serum calcium.	Tenofovir	31-40	GC vitamin D binding protein	Homo sapiens	83-108
24002093-9	2013	Higher plasma tenofovir concentrations were associated with higher vitamin D binding protein and lower free 1,25-OH(2)D, suggesting a functional vitamin D deficiency explaining TDF-associated increased parathyroid hormone.	Tenofovir	14-23	GC vitamin D binding protein	Homo sapiens	67-92
23896476-2	2013	COBI and TFV have been reported to interact with distinct transporters in renal proximal tubules; while TFV is renally eliminated by a combination of glomerular filtration and tubular secretion via anion transporters OAT1, OAT3, and MRP4, COBI inhibits renal cation transporters, particularly MATE1, resulting in a measurable decrease in the tubular secretion of creatinine.	Tenofovir	104-107	solute carrier family 22 member 6	Homo sapiens	217-221
23896476-2	2013	COBI and TFV have been reported to interact with distinct transporters in renal proximal tubules; while TFV is renally eliminated by a combination of glomerular filtration and tubular secretion via anion transporters OAT1, OAT3, and MRP4, COBI inhibits renal cation transporters, particularly MATE1, resulting in a measurable decrease in the tubular secretion of creatinine.	Tenofovir	104-107	solute carrier family 22 member 8	Homo sapiens	223-227
23896476-2	2013	COBI and TFV have been reported to interact with distinct transporters in renal proximal tubules; while TFV is renally eliminated by a combination of glomerular filtration and tubular secretion via anion transporters OAT1, OAT3, and MRP4, COBI inhibits renal cation transporters, particularly MATE1, resulting in a measurable decrease in the tubular secretion of creatinine.	Tenofovir	104-107	ATP binding cassette subfamily C member 4	Homo sapiens	233-237
23896476-2	2013	COBI and TFV have been reported to interact with distinct transporters in renal proximal tubules; while TFV is renally eliminated by a combination of glomerular filtration and tubular secretion via anion transporters OAT1, OAT3, and MRP4, COBI inhibits renal cation transporters, particularly MATE1, resulting in a measurable decrease in the tubular secretion of creatinine.	Tenofovir	104-107	solute carrier family 47 member 1	Homo sapiens	293-298
23742912-2	2013	Our aim was to compare viral kinetics, nucleos(t)ide analog resistance mutations, and quasispecies (QS) evolution during therapy with tenofovir disoproxil fumarate (TDF) or emtricitabine + TDF (FTC/TDF) in selected patients with incomplete ADV responses.	Tenofovir	134-163	sex determining region Y	Homo sapiens	165-168
24067562-0	2013	Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes.	Tenofovir	0-9	ATP binding cassette subfamily C member 2	Homo sapiens	113-118
24067562-0	2013	Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes.	Tenofovir	0-9	ATP binding cassette subfamily C member 4	Homo sapiens	120-125
24067562-0	2013	Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes.	Tenofovir	0-9	ATP binding cassette subfamily C member 10	Homo sapiens	130-136
24086333-6	2013	DESIGN: Seventy two HIV-uninfected volunteers in HIV serodiscordant couple relationships in Uganda were randomly assigned to receive daily oral Tenofovir/Emtricitabine (TDF/FTC-Truvada) or placebo, or intermittent (Monday, Friday and within 2 hours after sex, not to exceed one dose per day) oral TDF/FTC or placebo in a 2:1:2:1 ratio.	Tenofovir	144-153	sex determining region Y	Homo sapiens	169-172
23937548-1	2013	The fixed-dose combination efavirenz, emtricitabine, and tenofovir (EFV/FTC/TDF) is a first-line agent for the treatment of HIV.	Tenofovir	57-66	sex determining region Y	Homo sapiens	76-79
24002093-0	2013	Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?	Tenofovir	93-122	GC vitamin D binding protein	Homo sapiens	29-54
24085784-7	2013	Total and percent of CD5 + B cells gradually decreased following the diminution of the HBV DNA load after tenofovir and adefovir treatment.	Tenofovir	106-115	CD5 molecule	Homo sapiens	21-24
24085784-8	2013	Upon tenofovir treatment, the percent of memory CD27 + B cells was increased but the absolute number declined, whereas naive CD27- B cells declined in both percent and absolute number.	Tenofovir	5-14	CD27 molecule	Homo sapiens	48-52
24334181-0	2013	Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.	Tenofovir	52-61	actin gamma 1	Homo sapiens	83-87
24334181-1	2013	BACKGROUND: ACTG A5202 randomized treatment-naive individuals to tenofovir-emtricitabine (TDF/FTC) or abacavir-lamivudine (ABC/3TC) combined with efavirenz (EFV) or atazanavir/ritonavir (ATV/r).	Tenofovir	65-74	actin gamma 1	Homo sapiens	12-16
24205323-6	2013	We found that TFV increases 5"-ecto-nucleotidase (NT5E) and inhibits mitochondrial nucleotidase (NT5M) gene expression and increases 5" nucleotidase activity in macrophages.	Tenofovir	14-17	5'-nucleotidase ecto	Homo sapiens	50-54
24205323-6	2013	We found that TFV increases 5"-ecto-nucleotidase (NT5E) and inhibits mitochondrial nucleotidase (NT5M) gene expression and increases 5" nucleotidase activity in macrophages.	Tenofovir	14-17	5',3'-nucleotidase, mitochondrial	Homo sapiens	97-101
24124383-8	2013	RESULTS: The tenofovir (TDF)/emtricitabine (FTC)/rilpivirine (RPV) single-tablet regimen (STR) ($7,417.00) revealed the lowest mean treatment cost.	Tenofovir	13-22	sex determining region Y	Homo sapiens	24-27
24093809-1	2013	In 2010, the iPrEx study demonstrated efficacy of daily emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) pre-exposure prophylaxis (PrEP) in reducing HIV acquisition among men who have sex with men.	Tenofovir	70-99	sex determining region Y	Homo sapiens	105-108
23892239-6	2013	The estimated CD4 recovery on cART was similar between HIV monoinfection and HIV-HBV coinfection groups and between lamivudine- and tenofovir-treated participants.	Tenofovir	132-141	CD4 molecule	Homo sapiens	14-17
23467792-0	2013	Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study.	Tenofovir	88-97	beta-2-microglobulin	Homo sapiens	8-28
23957306-12	2013	CONCLUSION: Tenofovir- induced mitochondrial damage and increased oxidative stress in the rat kidneys may be due to depletion of the antioxidant system particularly, the glutathione dependent system and MnSOD.	Tenofovir	12-21	superoxide dismutase 2	Rattus norvegicus	203-208
23886803-8	2013	Pericoital treatment of females with either 2",3"-dideoxcytidine (ddC) or tenofovir largely prevented their EcoHIV/NDK infection by mating (P&lt;0.05 and P&lt;0.003, respectively).	Tenofovir	74-83	NME/NM23 nucleoside diphosphate kinase 4	Mus musculus	115-118
23660583-2	2013	Nevirapine (NVP), tenofovir (TDF) and lamivudine (3TC) are antiretroviral (ARV) drugs used worldwide for treatment of HIV infection and prevention of mother-to-child-transmission.	Tenofovir	18-27	sex determining region Y	Homo sapiens	29-32
23633402-2	2013	We investigated in macaques whether FTC/TDF prevents transmission of a tenofovir-resistant simian/human immunodeficiency virus (SHIV) containing the K65R mutation.	Tenofovir	71-80	sex determining region Y	Homo sapiens	40-43
23840622-1	2013	OBJECTIVES: South Africa"s national antiretroviral (ARV) treatment program expanded in 2010 to include the nucleoside reverse transcriptase (RT) inhibitors (NRTI) tenofovir (TDF) for adults and abacavir (ABC) for children.	Tenofovir	163-172	sex determining region Y	Homo sapiens	174-177
23053505-1	2013	We report a case in which the atazanavir (ATV) concentration in the plasma decreased after unilateral nephrectomy in a patient receiving tenofovir (TDF).	Tenofovir	137-146	sex determining region Y	Homo sapiens	148-151
23814462-1	2013	The combination rilpivirine (RPV)/emtricitabine (FTC)/tenofovir (TDF) is a once-daily, single-tablet regimen (STR) containing one nonnucleoside reverse-transcriptase inhibitor associated with two nucleos(t)ide reverse transcriptase inhibitors.	Tenofovir	54-63	sex determining region Y	Homo sapiens	65-68
23691224-1	2013	BACKGROUND: Tenofovir (TDF) is part of the WHO recommended first-line antiretroviral therapy (ART); however, there are limited data comparing TDF to other nucleoside reverse transcriptase inhibitors in resource-limited-settings.	Tenofovir	12-21	sex determining region Y	Homo sapiens	23-26
23691224-1	2013	BACKGROUND: Tenofovir (TDF) is part of the WHO recommended first-line antiretroviral therapy (ART); however, there are limited data comparing TDF to other nucleoside reverse transcriptase inhibitors in resource-limited-settings.	Tenofovir	12-21	sex determining region Y	Homo sapiens	142-145
23874527-3	2013	The most potent and the one with the lowest risk of resistance appears to be tenofovir (TDF).	Tenofovir	77-86	sex determining region Y	Homo sapiens	88-91
23970775-1	2013	Hypophosphataemia with tenofovir (TDF) treatment has been well described.	Tenofovir	23-32	sex determining region Y	Homo sapiens	34-37
23776637-12	2013	A higher risk of CKD was found when tenofovir exposure was &gt;12 months [IRR = 3.0 with joint PIs vs 1.3 without (p&lt;0.001)].	Tenofovir	36-45	insulin receptor related receptor	Homo sapiens	74-77
23362296-1	2013	BACKGROUND: In the United States, emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is a preferred nucleoside reverse transcriptase inhibitor (NRTI) backbone with lamivudine/abacavir (3TC/ABC) as a commonly used alternative.	Tenofovir	48-77	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	192-195
22462533-0	2012	Fibroblast growth factor 23 in hypophosphataemic HIV-positive adults on tenofovir.	Tenofovir	72-81	fibroblast growth factor 23	Homo sapiens	0-27
23475910-6	2013	Within two months, concomitantly with initiation of raltegravir, etravirine and emcitricabine/tenofovir, the patient recovered, gained weight, resumed walking and his CD4 counts rose from 270 to 450 cells/mm(3).	Tenofovir	94-103	CD4 molecule	Homo sapiens	167-170
23079810-9	2013	In multivariate analysis tenofovir-based regimens were less likely to have at least three nucleoside reverse transcriptase inhibitor (NRTI) mutations after adjusting for subtype, previous ART, CD4, and HIV viral load [P &lt; 0.001, odds ratio (OR) 0.04].	Tenofovir	25-34	CD4 molecule	Homo sapiens	193-196
23196129-5	2013	Because many antiviral medications are Oat substrates, including those crucial in the treatment of HIV infections, the interaction of the antivirals zidovudine, acyclovir, tenofovir, lamivudine, and stavudine, with Oat1 and Oat3 in CP, was investigated by determining the inhibition of 6CF uptake.	Tenofovir	172-181	solute carrier family 22 (organic anion transporter), member 6	Mus musculus	215-219
22894916-1	2013	BACKGROUND: Ubiquitous mitochondrial creatine kinase (uMtCK) accumulates as macroenzyme creatine kinase type 2 (macro CK2) in the serum of HIV-infected patients under a tenofovir disoproxil fumarate (TDF)-containing antiretroviral regimen.	Tenofovir	169-198	creatine kinase, mitochondrial 1B	Homo sapiens	12-52
22894916-1	2013	BACKGROUND: Ubiquitous mitochondrial creatine kinase (uMtCK) accumulates as macroenzyme creatine kinase type 2 (macro CK2) in the serum of HIV-infected patients under a tenofovir disoproxil fumarate (TDF)-containing antiretroviral regimen.	Tenofovir	169-198	creatine kinase, mitochondrial 1B	Homo sapiens	54-59
22894916-1	2013	BACKGROUND: Ubiquitous mitochondrial creatine kinase (uMtCK) accumulates as macroenzyme creatine kinase type 2 (macro CK2) in the serum of HIV-infected patients under a tenofovir disoproxil fumarate (TDF)-containing antiretroviral regimen.	Tenofovir	200-203	creatine kinase, mitochondrial 1B	Homo sapiens	12-52
22894916-1	2013	BACKGROUND: Ubiquitous mitochondrial creatine kinase (uMtCK) accumulates as macroenzyme creatine kinase type 2 (macro CK2) in the serum of HIV-infected patients under a tenofovir disoproxil fumarate (TDF)-containing antiretroviral regimen.	Tenofovir	200-203	creatine kinase, mitochondrial 1B	Homo sapiens	54-59
22894916-4	2013	In addition, tenofovir (TFV), its prodrug TDF and its active, intracellular derivative TFV diphosphate (TDP) were tested in vitro for their effects on different key properties of uMtCK to clarify possible interactions of uMtCK with TFV compounds.	Tenofovir	13-22	creatine kinase, mitochondrial 1B	Homo sapiens	179-184
22894916-4	2013	In addition, tenofovir (TFV), its prodrug TDF and its active, intracellular derivative TFV diphosphate (TDP) were tested in vitro for their effects on different key properties of uMtCK to clarify possible interactions of uMtCK with TFV compounds.	Tenofovir	24-27	creatine kinase, mitochondrial 1B	Homo sapiens	179-184
22955427-0	2012	Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study.	Tenofovir	56-65	ATP binding cassette subfamily C member 2	Homo sapiens	35-40
22955427-3	2012	METHODS: The association between tenofovir-induced KTD and 14 single nucleotide polymorphisms (SNPs) in the ABCC2, ABCC4, ABCC10, SCL22A6, and ABCB1 genes was investigated in 190 Japanese patients.	Tenofovir	33-42	ATP binding cassette subfamily C member 2	Homo sapiens	108-113
22955427-3	2012	METHODS: The association between tenofovir-induced KTD and 14 single nucleotide polymorphisms (SNPs) in the ABCC2, ABCC4, ABCC10, SCL22A6, and ABCB1 genes was investigated in 190 Japanese patients.	Tenofovir	33-42	ATP binding cassette subfamily C member 4	Homo sapiens	115-120
22955427-3	2012	METHODS: The association between tenofovir-induced KTD and 14 single nucleotide polymorphisms (SNPs) in the ABCC2, ABCC4, ABCC10, SCL22A6, and ABCB1 genes was investigated in 190 Japanese patients.	Tenofovir	33-42	ATP binding cassette subfamily C member 10	Homo sapiens	122-128
22955427-3	2012	METHODS: The association between tenofovir-induced KTD and 14 single nucleotide polymorphisms (SNPs) in the ABCC2, ABCC4, ABCC10, SCL22A6, and ABCB1 genes was investigated in 190 Japanese patients.	Tenofovir	33-42	ATP binding cassette subfamily B member 1	Homo sapiens	143-148
22955427-10	2012	ABCC2 haplotype -24T and 1249G was a protective haplotype for KTD (OR, 0.098; 95% CI, .002-.603; P= .003 CONCLUSIONS: This is the first study of our knowledge to identify the association between SNPs in ABCC2 and tenofovir-induced KTD in an Asian population.	Tenofovir	213-222	ATP binding cassette subfamily C member 2	Homo sapiens	0-5
22951630-5	2012	We used marginal structural Cox models to estimate hazard ratios for the association of current tenofovir use and time to first incident pregnancy.	Tenofovir	96-105	cytochrome c oxidase subunit 8A	Homo sapiens	28-31
23373554-1	2012	A single pill daily fixed dose combination of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) provides a potent and convenient treatment option for HIV/AIDS.	Tenofovir	76-105	sex determining region Y	Homo sapiens	115-118
23412015-13	2013	CONCLUSIONS: In this exploratory analysis of combination therapy with tenofovir/emtricitabine in treatment-naive patients at week 240, vRNA suppression rates and increases in baseline CD4 counts were significantly higher in raltegravir than efavirenz recipients.	Tenofovir	70-79	vault RNA 1-1	Homo sapiens	135-139
23436922-1	2013	CONTEXT: In virologically suppressed, antiretroviral-treated patients, the effect of switching to tenofovir (TDF) on bone biomarkers compared to patients remaining on stable antiretroviral therapy is unknown.	Tenofovir	98-107	sex determining region Y	Homo sapiens	109-112
23691697-5	2013	The mean change of eGFR from the baseline to the six months of follow-up was +/-1.32 and +/- 5.88 mL/minute in the TDF and AZT groups.	Tenofovir	115-118	epidermal growth factor receptor	Homo sapiens	19-23
22544804-9	2012	Among patients with an alanine aminotransferase (ALT) level greater than the upper limit of normal at baseline, normalization of ALT occurred in 74% of patients receiving tenofovir DF and 31% of patients receiving placebo (P &lt; 0.001).	Tenofovir	171-183	glutamic--pyruvic transaminase	Homo sapiens	23-47
23000496-4	2012	When formulated in an aqueous-based HEC gel, high flux values across an HEC-1A cell layer were reached by tenofovir, as a result of its high aqueous solubility.	Tenofovir	106-115	NDC80 kinetochore complex component	Homo sapiens	72-77
22462533-4	2012	The aim of the study was to investigate whether FGF-23 might be involved in the aetiology of hypophosphataemia in HIV-positive patients on tenofovir.	Tenofovir	139-148	fibroblast growth factor 23	Homo sapiens	48-54
22889300-8	2012	Virological studies showed that the combination of R284K with TAM1 mutations confers a fitness advantage in the presence of zidovudine or tenofovir.	Tenofovir	138-147	stromal interaction molecule 1	Homo sapiens	62-66
26204593-0	2012	Tenofovir/FTC approved for PrEP...but issues remain regarding implementation.	Tenofovir	0-9	prolyl endopeptidase	Homo sapiens	27-31
22680981-5	2012	Treatment with tenofovir and indinavir was associated with lower eGFR in both strata: tenofovir - 2.00 (95% CI - 3.45, - 0.56) and - 1.94 (95% CI - 3.43, - 0.44) ml/min per 1.73 m(2) and indinavir - 2.14 (95% CI - 3.63, - 0.64) and - 3.29 (95% CI - 5.25, - 1.32) ml/min per 1.73 m(2).	Tenofovir	15-24	epidermal growth factor receptor	Homo sapiens	65-69
22680981-5	2012	Treatment with tenofovir and indinavir was associated with lower eGFR in both strata: tenofovir - 2.00 (95% CI - 3.45, - 0.56) and - 1.94 (95% CI - 3.43, - 0.44) ml/min per 1.73 m(2) and indinavir - 2.14 (95% CI - 3.63, - 0.64) and - 3.29 (95% CI - 5.25, - 1.32) ml/min per 1.73 m(2).	Tenofovir	86-95	epidermal growth factor receptor	Homo sapiens	65-69
22680981-6	2012	Nevirapine, atazanavir, and the combination of tenofovir and atazanavir were associated with lower eGFR in patients with eGFR(B) &lt; 90 ml/min per 1.73 m(2).	Tenofovir	47-56	epidermal growth factor receptor	Homo sapiens	99-103
22680981-6	2012	Nevirapine, atazanavir, and the combination of tenofovir and atazanavir were associated with lower eGFR in patients with eGFR(B) &lt; 90 ml/min per 1.73 m(2).	Tenofovir	47-56	epidermal growth factor receptor	Homo sapiens	121-128
22680981-7	2012	Highly active antiretroviral therapy (HAART) and exposure to tenofovir and atazanavir in combination were associated with CKD in patients with eGFR(B) &lt; 90 ml/min per 1.73 m(2) (adjusted IRRs 6.08 (95% CI 2.76-13.41) and 26.75 (95% CI 9.54-75.05)).	Tenofovir	61-70	epidermal growth factor receptor	Homo sapiens	143-150
22680981-8	2012	CONCLUSION: Tenofovir and indinavir reduce eGFR, while time with HIV only has a modest effect on this parameter.	Tenofovir	12-21	epidermal growth factor receptor	Homo sapiens	43-47
22680981-9	2012	Low eGFR(B) is associated with an increased risk of CKD, especially when receiving HAART regimens containing the combination tenofovir/atazanavir.	Tenofovir	125-134	epidermal growth factor receptor	Homo sapiens	4-8
22889300-12	2012	CONCLUSIONS: Our study shows the association of R284K and TAM1 mutations in individuals failing therapy with tenofovir/emtricitabine, and unveils a novel mechanism by which secondary mutations are selected in the context of drug-resistance mutations.	Tenofovir	109-118	stromal interaction molecule 1	Homo sapiens	58-62
22883485-3	2012	Markedly elevated urinary concentrations of retinal-binding protein (RBP) have been reported in patients with severe renal tubular disease, and low-molecular-weight proteins (LMWP) such as RBP may be useful in clinical practice to assess renal tubular function in patients receiving TFV.	Tenofovir	283-286	retinol binding protein 4	Homo sapiens	189-192
22193343-9	2012	CONCLUSIONS: We found that both viral load and CD4+CD25+FOXP3+ nTreg percentages decreased significantly in patients with chronic hepatitis B virus infection during 1 year course of tenofovir treatment.	Tenofovir	182-191	CD4 molecule	Homo sapiens	47-50
22050695-3	2012	In this study, we examined in naive HIV-infected patients the in vivo effects of a highly active antiretroviral therapy (HAART) regimen, containing tenofovir-DF/emtricitabine/efavirenz, on PAF metabolism.	Tenofovir	148-160	PCNA clamp associated factor	Homo sapiens	189-192
22050695-11	2012	Apart from its classical antiretroviral activities the tenofovir-DF/emtricitabine/efavirenz regimen also exhibited favorable effects on PAF metabolism and therefore may also display beneficial effects in some HIV-related conditions, such as cardiovascular disease (CVD), in which PAF is implicated.	Tenofovir	55-67	PCNA clamp associated factor	Homo sapiens	136-139
22050695-11	2012	Apart from its classical antiretroviral activities the tenofovir-DF/emtricitabine/efavirenz regimen also exhibited favorable effects on PAF metabolism and therefore may also display beneficial effects in some HIV-related conditions, such as cardiovascular disease (CVD), in which PAF is implicated.	Tenofovir	55-67	PCNA clamp associated factor	Homo sapiens	280-283
21713384-3	2012	Phosphorylation of the DNA repair enzyme H2AX by emtricitabine/tenofovir indicated that it interfered with the integrity of the DNA and replication machinery in human cancer cells.	Tenofovir	63-72	H2A.X variant histone	Homo sapiens	41-45
22759796-8	2012	Genetic polymorphisms affecting the activity and/or the expression of cytochromes P450 or UGT isozymes and membrane drug transport proteins are highlighted and include such examples as the association of neurotoxicity with efavirenz, nephrotoxicity with tenofovir, hepatotoxicity with nevirapine, and hyperbilirubinemia with indinavir and atazanavir.	Tenofovir	254-263	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	90-93
22612469-1	2012	Most patients (80-90%) newly diagnosed with HIV are started on the antiretroviral regimen efavirenz, emtricitabine, and tenofovir (EFV/FTC/TDF).	Tenofovir	120-129	sex determining region Y	Homo sapiens	139-142
22193343-9	2012	CONCLUSIONS: We found that both viral load and CD4+CD25+FOXP3+ nTreg percentages decreased significantly in patients with chronic hepatitis B virus infection during 1 year course of tenofovir treatment.	Tenofovir	182-191	interleukin 2 receptor subunit alpha	Homo sapiens	51-55
22193343-9	2012	CONCLUSIONS: We found that both viral load and CD4+CD25+FOXP3+ nTreg percentages decreased significantly in patients with chronic hepatitis B virus infection during 1 year course of tenofovir treatment.	Tenofovir	182-191	forkhead box P3	Homo sapiens	56-61
22301411-1	2012	BACKGROUND: Whereas tenofovir (TDF) exposure has been associated with decreased bone density, it remains unclear whether it is associated with increased risk of osteoporotic fractures.	Tenofovir	20-29	sex determining region Y	Homo sapiens	31-34
22568150-2	2012	In this paper, the reported data of new four drugs(tenofovir disoproxil fumarate [TDF], telbivudine, emtricitabine [FTC], clevudine) were described.	Tenofovir	51-80	sex determining region Y	Homo sapiens	82-85
21639815-0	2012	Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir.	Tenofovir	116-125	parathyroid hormone	Homo sapiens	17-36
21639815-3	2012	Cross-sectional data have linked tenofovir with higher parathyroid hormone (PTH) concentrations in patients with vitamin D deficiency.	Tenofovir	33-42	parathyroid hormone	Homo sapiens	55-74
22245017-6	2012	eGFR and serum phosphorus at baseline and during treatment should be carefully assessed in patients receiving tenofovir.	Tenofovir	110-119	epidermal growth factor receptor	Homo sapiens	0-4
22321026-7	2012	Trials investigating the efficacy of once-daily co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/COBI/FTC/TDF) demonstrate a high rate of virologic suppression with fewer CNS and psychiatric adverse events compared with co-formulated efavirenz/emtricitabine/tenofovir.	Tenofovir	100-109	sex determining region Y	Homo sapiens	124-127
22321026-7	2012	Trials investigating the efficacy of once-daily co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/COBI/FTC/TDF) demonstrate a high rate of virologic suppression with fewer CNS and psychiatric adverse events compared with co-formulated efavirenz/emtricitabine/tenofovir.	Tenofovir	276-285	sex determining region Y	Homo sapiens	124-127
22984574-1	2012	BACKGROUND: Tenofovir has been associated with renal phosphate wasting, reduced bone mineral density, and higher parathyroid hormone levels.	Tenofovir	12-21	parathyroid hormone	Homo sapiens	113-132
23304062-4	2012	In tenofovir group, the frequency of NK cells increased during the treatment accompanied by downregulated expression of NKG2A and KIR2DL3.	Tenofovir	3-12	killer cell lectin like receptor C1	Homo sapiens	120-125
23304062-4	2012	In tenofovir group, the frequency of NK cells increased during the treatment accompanied by downregulated expression of NKG2A and KIR2DL3.	Tenofovir	3-12	killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3	Homo sapiens	130-137
21480819-9	2012	Factors associated with elevated cystatin C included hepatitis C coinfection, hypertension, current smoking, older age, current tenofovir use, detectable plasma HIV RNA, and elevated microalbuminuria.	Tenofovir	128-137	cystatin C	Homo sapiens	33-43
22132702-4	2012	Using presteady state kinetic techniques, we have measured the substrate specificity values for human DNA polymerases beta, lambda, eta, iota, kappa, and Rev1 incorporating the active forms of the following anti-HBV nucleoside analogues approved for clinical use: adefovir, tenofovir, lamivudine, telbivudine, and entecavir.	Tenofovir	274-283	endothelin receptor type A	Homo sapiens	119-122
22132702-4	2012	Using presteady state kinetic techniques, we have measured the substrate specificity values for human DNA polymerases beta, lambda, eta, iota, kappa, and Rev1 incorporating the active forms of the following anti-HBV nucleoside analogues approved for clinical use: adefovir, tenofovir, lamivudine, telbivudine, and entecavir.	Tenofovir	274-283	REV1 DNA directed polymerase	Homo sapiens	154-158
23075703-11	2012	Baseline genotypic sensitivity scores &gt;=2 and TAM-2 were associated with better virological control in subjects treated with the TDF-containing regimen.	Tenofovir	132-135	ORAI calcium release-activated calcium modulator 1	Homo sapiens	49-54
22264046-2	2012	Here, we discuss the combination of tenofovir with various other antiretrovirals (ARV) highlighting the large class of carbohydrate-binding agents (CBAs) targeting the glycans on the viral envelope gp120 for their anti-HIV activity and their favorable combinatory potential.	Tenofovir	36-45	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	198-203
23037894-0	2012	Increased time exposure to tenofovir is associated with a greater decrease in estimated glomerular filtration rate in HIV patients with kidney function of less than 60 ml/min/1.73 m2.	Tenofovir	27-36	CD59 molecule (CD59 blood group)	Homo sapiens	171-176
22984574-6	2012	Stratification of the analysis by age and ethnicity revealed that non-white men but not women, on tenofovir had higher PTH levels than non-white men not on tenofovir (mean difference 3.1 pmol/L, 95% CI 5.3 to 0.9; p = 0.007).	Tenofovir	98-107	parathyroid hormone	Homo sapiens	119-122
22984574-8	2012	CONCLUSIONS: The effects of tenofovir on PTH levels were modified by sex and ethnicity in this cohort.	Tenofovir	28-37	parathyroid hormone	Homo sapiens	41-44
22905175-1	2012	BACKGROUND: The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy.	Tenofovir	143-152	sex determining region Y	Homo sapiens	154-157
22158861-3	2011	Here, we evaluated two drugs that are preferentially used for PrEP: tenofovir (TFV) disoproxil fumarate (TDF) and emtricitabine (FTC).	Tenofovir	68-77	sex determining region Y	Homo sapiens	105-108
21471820-12	2011	CONCLUSIONS: Our data suggest divergent effects of tenofovir and AZT on proinflammatory responses in monocytes (CCL3 and IL-8) and PBMCs (CCL3).	Tenofovir	51-60	C-C motif chemokine ligand 3	Homo sapiens	112-116
21471820-0	2011	Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells.	Tenofovir	0-9	interleukin 10	Homo sapiens	90-95
21471820-8	2011	Similarly, tenofovir decreased CCL3 levels in human PBMCs.	Tenofovir	11-20	C-C motif chemokine ligand 3	Homo sapiens	31-35
21471820-9	2011	Furthermore, tenofovir strongly decreased induction of IL-10 but increased levels of IL-12.	Tenofovir	13-22	interleukin 10	Homo sapiens	55-60
21628669-3	2011	METHODS: TFV accumulation was assessed in parental and ABCC10-transfected HEK293 cells (HEK293-ABCC10), CD4(+) cells and monocyte-derived macrophages (MDMs).	Tenofovir	9-12	ATP binding cassette subfamily C member 10	Homo sapiens	55-61
21628669-3	2011	METHODS: TFV accumulation was assessed in parental and ABCC10-transfected HEK293 cells (HEK293-ABCC10), CD4(+) cells and monocyte-derived macrophages (MDMs).	Tenofovir	9-12	ATP binding cassette subfamily C member 10	Homo sapiens	95-101
21628669-3	2011	METHODS: TFV accumulation was assessed in parental and ABCC10-transfected HEK293 cells (HEK293-ABCC10), CD4(+) cells and monocyte-derived macrophages (MDMs).	Tenofovir	9-12	CD4 molecule	Homo sapiens	104-107
21628669-7	2011	RESULTS: TFV accumulation was significantly lower in HEK293-ABCC10 cell lines than in parental HEK293 cells (35% lower; P = .02); this was reversed by cepharanthine.	Tenofovir	9-12	ATP binding cassette subfamily C member 10	Homo sapiens	60-66
21471820-12	2011	CONCLUSIONS: Our data suggest divergent effects of tenofovir and AZT on proinflammatory responses in monocytes (CCL3 and IL-8) and PBMCs (CCL3).	Tenofovir	51-60	C-X-C motif chemokine ligand 8	Homo sapiens	121-125
21471820-12	2011	CONCLUSIONS: Our data suggest divergent effects of tenofovir and AZT on proinflammatory responses in monocytes (CCL3 and IL-8) and PBMCs (CCL3).	Tenofovir	51-60	C-C motif chemokine ligand 3	Homo sapiens	138-142
21471820-13	2011	Moreover, tenofovir shifts the IL-10/IL-12 balance after cell stimulation with TLR ligands or infection with live bacteria, thus suggesting that the choice of nucleoside reverse transcriptase inhibitor affects overall inflammation and early immune responses against secondary pathogens.	Tenofovir	10-19	interleukin 10	Homo sapiens	31-36
21403643-5	2011	In this study, the role(s) of organic anion transporter type 1 (OAT1) and multidrug-resistant protein type 4 (MRP4) in transport and regulation of tenofovir in proximal tubules were assessed.	Tenofovir	147-156	solute carrier family 22 member 6	Homo sapiens	30-62
24310499-1	2011	Certain triple nucleoside/tide reverse transcriptase inhibitor (NRTI) regimens containing tenofovir (TDF) have been associated with rapid early treatment failure.	Tenofovir	90-99	sex determining region Y	Homo sapiens	101-104
21501631-2	2011	Here, we evaluated the combination of tenofovir with various members of the class of carbohydrate-binding agents (CBAs) targeting the glycans on the viral envelope gp120 for their anti-HIV efficacy.	Tenofovir	38-47	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	164-169
21403643-5	2011	In this study, the role(s) of organic anion transporter type 1 (OAT1) and multidrug-resistant protein type 4 (MRP4) in transport and regulation of tenofovir in proximal tubules were assessed.	Tenofovir	147-156	solute carrier family 22 member 6	Homo sapiens	64-68
21403643-5	2011	In this study, the role(s) of organic anion transporter type 1 (OAT1) and multidrug-resistant protein type 4 (MRP4) in transport and regulation of tenofovir in proximal tubules were assessed.	Tenofovir	147-156	ATP binding cassette subfamily C member 4	Homo sapiens	74-108
21403643-5	2011	In this study, the role(s) of organic anion transporter type 1 (OAT1) and multidrug-resistant protein type 4 (MRP4) in transport and regulation of tenofovir in proximal tubules were assessed.	Tenofovir	147-156	ATP binding cassette subfamily C member 4	Homo sapiens	110-114
21403643-14	2011	Both OAT1 and MRP4 have a direct role in transport and efflux of tenofovir, regulating levels of tenofovir in proximal tubules.	Tenofovir	65-74	solute carrier family 22 member 6	Homo sapiens	5-9
21403643-14	2011	Both OAT1 and MRP4 have a direct role in transport and efflux of tenofovir, regulating levels of tenofovir in proximal tubules.	Tenofovir	65-74	ATP binding cassette subfamily C member 4	Homo sapiens	14-18
21403643-14	2011	Both OAT1 and MRP4 have a direct role in transport and efflux of tenofovir, regulating levels of tenofovir in proximal tubules.	Tenofovir	97-106	solute carrier family 22 member 6	Homo sapiens	5-9
21403643-14	2011	Both OAT1 and MRP4 have a direct role in transport and efflux of tenofovir, regulating levels of tenofovir in proximal tubules.	Tenofovir	97-106	ATP binding cassette subfamily C member 4	Homo sapiens	14-18
21403643-15	2011	Disruption of OAT1 activity prevents tenofovir toxicity but loss of MRP4 can lead to increased renal proximal tubular toxicity.	Tenofovir	37-46	solute carrier family 22 member 6	Homo sapiens	14-18
21235431-2	2011	Many studies have been performed replacing AZT or d4T with newer nucleoside analogs reverse transcriptase inhibitors (NRTIs) with less toxicity, such as tenofovir (TDF) or abacavir (ABC), maintaining virological efficacy.	Tenofovir	153-162	sex determining region Y	Homo sapiens	164-167
21435764-1	2011	Tenofovir (TDF) is an effective and widely used treatment for both human immunodeficiency virus (HIV) and hepatitis B virus infection.	Tenofovir	0-9	sex determining region Y	Homo sapiens	11-14
20600036-6	2010	RESULTS: In HBeAg-positive patients, tenofovir was most effective in inducing undetectable levels of HBV DNA (predicted probability, 88%), normalization of alanine aminotransferase (ALT) levels (66%), HBeAg seroconversion (20%), and hepatitis B surface antigen loss (5%); it ranked third in histologic improvement of the liver (53%).	Tenofovir	37-46	glutamic--pyruvic transaminase	Homo sapiens	156-180
21685533-0	2011	Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.	Tenofovir	123-132	phospholipase A2 group VII	Homo sapiens	33-72
21685533-1	2011	BACKGROUND: The aim of this study was to assess changes in the size and cholesterol content of low-density lipoproteins (LDL) and changes in lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in HIV-infected patients switching to tenofovir + emtricitabine (TDF+FTC) or abacavir + lamivudine (ABC+3TC).	Tenofovir	238-247	phospholipase A2 group VII	Homo sapiens	182-189
21185214-0	2011	Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease.	Tenofovir	38-47	fibroblast growth factor 23	Homo sapiens	14-19
21185214-3	2011	We evaluated FGF23 plasma concentrations in an HIV-positive patient with neurofibromatosis in whom hypophosphatemia developed during tenofovir therapy.	Tenofovir	133-142	fibroblast growth factor 23	Homo sapiens	13-18
21294867-10	2011	The procoagulant biomarker PAI-1 plasma levels increased from baseline at week 12 (+57%; p = 0.017), week 24 (+72%; p = 0.008), and week 48 (+149%; p &lt; 0.001) in patients on tenofovir, but differences between groups were not statistically significant.	Tenofovir	177-186	serpin family E member 1	Homo sapiens	27-32
21078936-0	2011	Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir.	Tenofovir	105-114	solute carrier family 22 member 6	Homo sapiens	31-38
21078936-9	2011	Tenofovir and raltegravir competed for SLC22A6 transport in a concentration-dependent manner.	Tenofovir	0-9	solute carrier family 22 member 6	Homo sapiens	39-46
21078936-10	2011	Raltegravir inhibited 1 muM tenofovir with a 50% inhibitory concentration (IC(50)) of 14.0 muM, and tenofovir inhibited 1 muM raltegravir with an IC(50) of 27.3 muM.	Tenofovir	28-37	latexin	Homo sapiens	24-27
21078936-10	2011	Raltegravir inhibited 1 muM tenofovir with a 50% inhibitory concentration (IC(50)) of 14.0 muM, and tenofovir inhibited 1 muM raltegravir with an IC(50) of 27.3 muM.	Tenofovir	28-37	latexin	Homo sapiens	91-94
21078936-10	2011	Raltegravir inhibited 1 muM tenofovir with a 50% inhibitory concentration (IC(50)) of 14.0 muM, and tenofovir inhibited 1 muM raltegravir with an IC(50) of 27.3 muM.	Tenofovir	28-37	latexin	Homo sapiens	91-94
21078936-10	2011	Raltegravir inhibited 1 muM tenofovir with a 50% inhibitory concentration (IC(50)) of 14.0 muM, and tenofovir inhibited 1 muM raltegravir with an IC(50) of 27.3 muM.	Tenofovir	28-37	latexin	Homo sapiens	91-94
21078938-6	2011	Using pre-steady-state kinetic techniques, we measured the substrate specificity constants for human DNA polymerases beta, lambda, eta, iota, kappa, and Rev1 incorporating the active, 5"-phosphorylated forms of tenofovir, lamivudine, emtricitabine, and zidovudine.	Tenofovir	211-220	endothelin receptor type A	Homo sapiens	118-121
21078938-6	2011	Using pre-steady-state kinetic techniques, we measured the substrate specificity constants for human DNA polymerases beta, lambda, eta, iota, kappa, and Rev1 incorporating the active, 5"-phosphorylated forms of tenofovir, lamivudine, emtricitabine, and zidovudine.	Tenofovir	211-220	REV1 DNA directed polymerase	Homo sapiens	153-157
21045636-1	2010	BACKGROUND: Although, single-tablet regimen (STR) efavirenz, emtricibine, and tenofovir disoproxil fumarate (EFV/FTC/TDF) may be appealing in HIV-infected persons who are at high risk for nonadherence, the degree to which this simplified formulation affects adherence is not known.	Tenofovir	78-107	sex determining region Y	Homo sapiens	117-120
21086562-5	2010	In one patient with an alanine aminotransferase (ALT) flare, tenofovir was added after 3 mo of treatment.	Tenofovir	61-70	glutamic--pyruvic transaminase	Homo sapiens	23-47
20585260-3	2010	TDF 300 mg once daily was then administered for 7 days (period 2).	Tenofovir	0-3	period circadian regulator 2	Homo sapiens	56-64
20970638-1	2010	AIMS: To establish the efficacy and safety of entecavir (ETV) and/or tenofovir (TDF) in the treatment and prevention of hepatitis B virus (HBV) recurrence after liver transplantation.	Tenofovir	69-78	sex determining region Y	Homo sapiens	80-83
20671544-9	2010	In the selected model, duration of tenofovir use was associated with lower common cIMT (-0.0094 mm/year of use; 95% confidence interval: -0.0177 to -0.0010).	Tenofovir	35-44	CIMT	Homo sapiens	82-86
20671544-11	2010	CONCLUSION: We observed an inverse association between duration of tenofovir use and common carotid cIMT.	Tenofovir	67-76	CIMT	Homo sapiens	100-104
20173649-1	2010	BACKGROUND: Significant nephrotoxicity develops in 1%-2% of HIV-infected adults receiving tenofovir (TDF).	Tenofovir	90-99	sex determining region Y	Homo sapiens	101-104
20515419-9	2010	Among tenofovir users, factors associated with a reduction in GFR included female gender (p &lt; 0.001), African American ethnicity (p = 0.003), and lower CD4 nadir (p = 0.002).	Tenofovir	6-15	CD4 molecule	Homo sapiens	155-158
20672993-0	2010	Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users.	Tenofovir	88-97	parathyroid hormone	Homo sapiens	54-73
20672993-2	2010	We aimed to examine the impact of vitamin D status and tenofovir (TDF) use on PTH levels among HIV-infected patients receiving combination antiretroviral therapy (cART).	Tenofovir	55-64	sex determining region Y	Homo sapiens	66-69
20672993-2	2010	We aimed to examine the impact of vitamin D status and tenofovir (TDF) use on PTH levels among HIV-infected patients receiving combination antiretroviral therapy (cART).	Tenofovir	55-64	parathyroid hormone	Homo sapiens	78-81
20495438-0	2010	A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.	Tenofovir	64-73	actin gamma 1	Homo sapiens	119-123
20431394-6	2010	Urinary excretion of retinol-binding protein and beta-2 microglobulin increased significantly more in the tenofovir/emtricitabine arm (+50%; +24%) compared with the abacavir/lamivudine arm (no change; -47%) (P &lt; 0.0001).	Tenofovir	106-115	beta-2-microglobulin	Homo sapiens	49-69
20648600-1	2010	This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV).	Tenofovir	84-93	sex determining region Y	Homo sapiens	95-98
20672448-9	2010	Tenofovir use was not associated with serum creatinine or eGFR overall but interacted with vitamin D status (P = 0.05 and P = 0.08, respectively), being linked to somewhat higher creatinine and lower eGFR among patients without VDD but higher eGFR in VDD patients.	Tenofovir	0-9	epidermal growth factor receptor	Homo sapiens	200-204
20672448-9	2010	Tenofovir use was not associated with serum creatinine or eGFR overall but interacted with vitamin D status (P = 0.05 and P = 0.08, respectively), being linked to somewhat higher creatinine and lower eGFR among patients without VDD but higher eGFR in VDD patients.	Tenofovir	0-9	epidermal growth factor receptor	Homo sapiens	200-204
20588161-10	2010	CONCLUSION: Efavirenz was associated with severe VDD, a condition associated with multiple adverse health outcomes, and efavirenz and tenofovir with increased ALP.	Tenofovir	134-143	alkaline phosphatase, placental	Homo sapiens	159-162
20515419-12	2010	Factors associated with renal loss among tenofovir users included female gender, African American ethnicity, and CD4 nadir &lt;200 cells/mm(3).	Tenofovir	41-50	CD4 molecule	Homo sapiens	113-116
20517472-3	2010	METHODS: Patients chronically treated with emtricitabine (FTC) + tenofovir (TDF) + efavirenz (EFV) or lamivudine (3TC) +TDF +EFV and with a HIV-RNA &lt; 50 copies/mL were switched to the single-pill fixed-dose regimen (FDR) of FTC +TDF +EFV.	Tenofovir	65-74	sex determining region Y	Homo sapiens	76-79
20452889-4	2010	Introduction of an integrase-inhibitor regimen based on raltegravir, tenofovir, and emtricitabine allowed a prompt achievement of undetectable viral load and a substantial rise of CD4 count to high levels, with no subsequent episodes of hepatic toxicity, and no other side effects.	Tenofovir	69-78	CD4 molecule	Homo sapiens	180-183
20233398-6	2010	When emtricitabine (FTC) and tenofovir (PMPA) were added to treatment, undetectable viral load was reached in two weeks, and a parallel increase in CD4 counts was observed.	Tenofovir	29-38	CD4 molecule	Homo sapiens	148-151
20233398-6	2010	When emtricitabine (FTC) and tenofovir (PMPA) were added to treatment, undetectable viral load was reached in two weeks, and a parallel increase in CD4 counts was observed.	Tenofovir	40-44	CD4 molecule	Homo sapiens	148-151
20026012-0	2010	Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts.	Tenofovir	52-61	GNAS complex locus	Homo sapiens	18-22
20026012-0	2010	Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts.	Tenofovir	52-61	glutamic-oxaloacetic transaminase 2	Homo sapiens	24-28
20026012-0	2010	Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts.	Tenofovir	52-61	small nucleolar RNA, C/D box 32A	Homo sapiens	33-41
20026012-5	2010	Specific downregulation of Gnas, Got2 and Snord32a were observed in the TDF-treated cells.	Tenofovir	72-75	GNAS complex locus	Homo sapiens	27-31
20026012-5	2010	Specific downregulation of Gnas, Got2 and Snord32a were observed in the TDF-treated cells.	Tenofovir	72-75	glutamic-oxaloacetic transaminase 2	Homo sapiens	33-37
20026012-5	2010	Specific downregulation of Gnas, Got2 and Snord32a were observed in the TDF-treated cells.	Tenofovir	72-75	small nucleolar RNA, C/D box 32A	Homo sapiens	42-50
19490182-11	2009	In multivariate analyses, significant predictors of eGFR decline were diagnoses of hypertension, hyperlipidaemia, proteinuria, use of tenofovir or stavudine, and lower viral load.	Tenofovir	134-143	epidermal growth factor receptor	Homo sapiens	52-56
19737231-8	2009	The proportion of CD4(+)CD45RA(+) T cells and of functionally inhibited killer immunoglobulin-like receptor T cell receptor alphabeta(+) cells, the proliferation to recall antigens as well as NK cell phenotype and function as determined by interferon-gamma production in patients treated with tenofovir-didanosine were comparable to those treated with a different regimen.	Tenofovir	293-302	CD4 molecule	Homo sapiens	18-21
20386078-0	2010	The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers.	Tenofovir	14-43	insulin	Homo sapiens	58-65
20386078-2	2010	The aim of this study was to assess the effect on insulin sensitivity (determined by peripheral glucose uptake using a hyperinsulinaemic euglycaemic clamp) of tenofovir disoproxil fumarate (TDF) administration compared with placebo for 2 weeks in HIV-1-seronegative healthy male volunteers.	Tenofovir	159-188	insulin	Homo sapiens	50-57
20386078-2	2010	The aim of this study was to assess the effect on insulin sensitivity (determined by peripheral glucose uptake using a hyperinsulinaemic euglycaemic clamp) of tenofovir disoproxil fumarate (TDF) administration compared with placebo for 2 weeks in HIV-1-seronegative healthy male volunteers.	Tenofovir	190-193	insulin	Homo sapiens	50-57
19626612-1	2009	The K65R mutation in HIV-1 reverse transcriptase (RT) can be selected by the RT inhibitors tenofovir (TDF), abacavir (ABC), and didanosine (DDI).	Tenofovir	91-100	sex determining region Y	Homo sapiens	102-105
20183617-0	2009	Nucleoside diphosphate kinase and the activation of antiviral phosphonate analogs of nucleotides: binding mode and phosphorylation of tenofovir derivatives.	Tenofovir	134-143	cytidine/uridine monophosphate kinase 2	Homo sapiens	0-29
19542866-1	2009	BACKGROUND: Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for initial HIV-1 treatment.	Tenofovir	54-66	sex determining region Y	Homo sapiens	82-85
19457140-1	2009	Reports have described a decrease in glomerular filtration rate (eGFR) associated with tenofovir disoproxil fumarate (TDF) use in HIV positive individuals.	Tenofovir	87-116	epidermal growth factor receptor	Homo sapiens	65-69
19398921-9	2009	CD4 counts and plasma lipids showed higher increments in the abacavir/lamivudine group than in the tenofovir/emtricitabine group.	Tenofovir	99-108	CD4 molecule	Homo sapiens	0-3
19457140-1	2009	Reports have described a decrease in glomerular filtration rate (eGFR) associated with tenofovir disoproxil fumarate (TDF) use in HIV positive individuals.	Tenofovir	118-121	epidermal growth factor receptor	Homo sapiens	65-69
19432547-3	2009	We evaluated 4 patients with a history of CD4(+) T cell decline despite successfully suppressive ART, from a median of 719 cells/mm(3) (range, 360-1141 cells/mm(3)) to 227 cells/mm(3) (range, 174-311 cells/mm(3)) over a period of 18-24 months; 3 of the patients were receiving tenofovir and didanosine, which may have contributed to this decrease.	Tenofovir	277-286	CD4 molecule	Homo sapiens	42-45
19178592-1	2009	OBJECTIVES: The aim of the study was to identify and characterize hepatitis B virus (HBV) polymerase gene mutations associated with ongoing HBV replication in HIV/HBV-coinfected individuals receiving tenofovir (TDF).	Tenofovir	200-209	sex determining region Y	Homo sapiens	211-214
19262355-1	2009	BACKGROUND: Tenofovir (TDF) is the most widely prescribed antiretroviral drug.	Tenofovir	12-21	sex determining region Y	Homo sapiens	23-26
19183077-1	2009	We report two cases of tenofovir (TDF)-associated nephrotoxicity in perinatally HIV-infected adolescents.	Tenofovir	23-32	sex determining region Y	Homo sapiens	34-37
19098496-0	2009	Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients.	Tenofovir	61-70	cystatin C	Homo sapiens	8-18
19098496-1	2009	A receiver operating curve analysis was performed to assess the predictive value of the urinary cystatin C to urinary creatinine ratio for the renal monitoring of tenofovir.	Tenofovir	163-172	cystatin C	Homo sapiens	96-106
19098496-2	2009	Urinary cystatin C to urinary creatinine ratio was measured in 37 samples from patients referred for suspected tenofovir-induced Fanconi syndrome.	Tenofovir	111-120	cystatin C	Homo sapiens	8-18
19008174-3	2008	In this retrospective analysis of 22 patients during therapy with tipranavir/ritonavir (TPV) 500 mg/200 mg bid, we found significantly decreased TPV-trough levels in combination with tenofovir (15.32+/-5.22 microg/ml) in comparison to TPV trough levels without tenofovir (20.21+/-14.87 microg/ml).	Tenofovir	183-192	BH3 interacting domain death agonist	Homo sapiens	107-110
19008174-3	2008	In this retrospective analysis of 22 patients during therapy with tipranavir/ritonavir (TPV) 500 mg/200 mg bid, we found significantly decreased TPV-trough levels in combination with tenofovir (15.32+/-5.22 microg/ml) in comparison to TPV trough levels without tenofovir (20.21+/-14.87 microg/ml).	Tenofovir	261-270	BH3 interacting domain death agonist	Homo sapiens	107-110
18620493-7	2008	Several of these drugs have also inhibited in vitro microsomal PAF-CPT activity, and concentrations of lopinavir-r or tenofovir-DF (similar to their IC(50) against PAF-induced platelet aggregation) exhibited the same effect against PAF-CPT and Lyso-PAF-AT when added in the cell medium of cultured HMC.	Tenofovir	118-130	lysophosphatidylcholine acyltransferase 1	Homo sapiens	244-255
19825144-1	2008	OBJECTIVE: To assess effectiveness and safety of a generic fixed-dose combination of tenofovir (TDF)/emtricitabine (FTC)/efavirenz (EFV) among HIV-1-infected patients in Western India.	Tenofovir	85-94	sex determining region Y	Homo sapiens	96-99
18620493-5	2008	Among the drugs tested, several inhibited PAF-induced platelet aggregation in a concentration-depended manner, with tenofovir, efavirenz, and ritonavir exhibiting the higher inhibitory effect.	Tenofovir	116-125	PCNA clamp associated factor	Homo sapiens	42-45
18770899-0	2008	CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral load.	Tenofovir	32-41	CD4 molecule	Homo sapiens	0-3
18784465-13	2008	CONCLUSION: Pharmacogenetic testing for HLA-B*5701 is cost-effective only if abacavir-based treatment is as effective and costs less than tenofovir-based treatment.	Tenofovir	138-147	major histocompatibility complex, class I, B	Homo sapiens	40-45
18620493-8	2008	In addition, in naive patients treated with one of the most potent anti-PAF HAART regimens (efavirenz/emtricitabine/tenofovir-DF) for a period of 1 month, a significant reduction of the specific activity of PAF-CPT of washed human leukocytes of these patients was also observed, compared with its levels before the HAART treatment.	Tenofovir	116-128	PCNA clamp associated factor	Homo sapiens	72-75
18620493-8	2008	In addition, in naive patients treated with one of the most potent anti-PAF HAART regimens (efavirenz/emtricitabine/tenofovir-DF) for a period of 1 month, a significant reduction of the specific activity of PAF-CPT of washed human leukocytes of these patients was also observed, compared with its levels before the HAART treatment.	Tenofovir	116-128	PCNA clamp associated factor	Homo sapiens	207-210
19195432-4	2008	Tenofovir disoproxil fumarate(TDF) is a nucleoside monophosphate (nucleotide) analogue that inhibits reverse trascriptase enzyme.	Tenofovir	0-29	sex determining region Y	Homo sapiens	30-33
19338072-3	2008	The "gold standard" in patients initiating ART is tenofovir (TDF)/emtricitabine (FTC)/efavirenz.	Tenofovir	50-59	sex determining region Y	Homo sapiens	61-64
19372981-6	2008	Some other important advances in our knowledge have also been made, such as the association of TA repeats in the UGT1A1 regulatory region (UGT1A1 28) with atazanavir-related hyperbilirubinaemia and the association of ABCC2 and ABCC4 single nucleotide polymorphisms with tenofovir-associated renal toxicity.	Tenofovir	270-279	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	113-119
19372981-6	2008	Some other important advances in our knowledge have also been made, such as the association of TA repeats in the UGT1A1 regulatory region (UGT1A1 28) with atazanavir-related hyperbilirubinaemia and the association of ABCC2 and ABCC4 single nucleotide polymorphisms with tenofovir-associated renal toxicity.	Tenofovir	270-279	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	139-145